

CITATION REPORT

List of articles citing

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis

DOI: 10.1002/ana.1032

Annals of Neurology, 2001, 50, 121-7.

Source: <https://exaly.com/paper-pdf/33073406/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2332	Immune diseases. 102-112		
2331	Problems with diagnostic criteria for multiple sclerosis. 2001 , 358, 1746-7		20
2330	Multiple sclerosis: How practice nurses can help. 2001 , 12, 449-452		
2329	Primary progressive multiple sclerosis. 2001 , 22 Suppl 2, S41-8		7
2328	Is it multiple sclerosis or not?. 2001 , 57, 1357-8		8
2327	An examination of the association between beta2 adrenergic receptor polymorphisms and multiple sclerosis. 2002 , 8, 475-8		5
2326	Update on the diagnosis of multiple sclerosis. 2002 , 2, 319-28		2
2325	A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. 2002 , 346, 158-64		694
2324	Minimal neuropsychological assessment of MS patients: a consensus approach. 2002 , 16, 381-97		459
2323	Gender prevalence in childhood multiple sclerosis and myasthenia gravis. 2002 , 17, 390-2		31
2322	Hideyo Noguchi (1876-1928). 2002 , 73, 147-147		78
2321	International consensus statement on the use of disease-modifying agents in multiple sclerosis. 2002 , 8, 19-23		7
2320	Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. 2002 , 125, 2202-12		528
2319	The emerging role of MRI in multiple sclerosis and the new diagnostic criteria. 2002 , 8, 71-2		2
2318	Magnetic Resonance Imaging in Multiple Sclerosis. 2002 , 2, 103-112		3
2317	International consensus statement on the use of disease-modifying agents in multiple sclerosis. 2002 , 8, 19-23		31
2316	A comparative study of Japanese multiple sclerosis patients with and without oligoclonal IgG bands. 2002 , 8, 459-62		17

2315	HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. 2002 , 72, 184-7	114
2314	A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. 2002 , 125, 1337-47	95
2313	MRI techniques to monitor MS evolution: the present and the future. 2002 , 58, 1147-53	138
2312	Pure optic-spinal form of multiple sclerosis in Japan. 2002 , 125, 2460-8	91
2311	The lesions of multiple sclerosis. 2002 , 346, 199-200	16
2310	Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis. 2002 , 22, 17-25	3
2309	Entz^ädliche und toxische Erkrankungender wei^ën Hirnsubstanz beim Erwachsenen. 2002 , 2, 169-183	
2308	Neurologische Manifestationen beim Sj^ögren-Syndrom. 2002 , 29, 321-326	1
2307	Therapie der multiplen Sklerose - Wann beginnen?. 2002 , 29, 258-262	
2306	Correlates of disability in multiple sclerosis detected by transcranial magnetic stimulation. 2002 , 59, 1218-24	66
2305	Course and prognosis in early-onset MS: comparison with adult-onset forms. 2002 , 59, 1922-8	263
2304	MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. 2002 , 59, 998-1005	79
2303	Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study. 2002 , 8, 330-8	22
2302	The prevalence of Sj^ögren syndrome in patients with primary progressive multiple sclerosis. 2002 , 58, 1576; author reply 1576	0
2301	Cortical motor reorganization after a single clinical attack of multiple sclerosis. 2002 , 125, 1607-15	134
2300	Current immunotherapy for demyelinating diseases. 2002 , 59, 726-31	12
2299	Workshop on primary progressive multiple sclerosis: meeting summary. 2002 , 8, 177-8	5
2298	Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. 2002 , 59, 1224-31	529

2297	Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. 2002 , 73, 141-7	104
2296	Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. 2002 , 58, 666-7; author reply 666-7	3
2295	Primary antiphospholipid syndrome presenting with a branch retinal artery occlusion in a 15-year-old boy. 2002 , 17, 392-4	9
2294	Headache characteristics in patients after migrainous stroke. 2002 , 58, 668-9; author reply 669	0
2293	Effects of internal globus pallidus stimulation on motor cortex excitability. 2002 , 58, 669-70; author reply 670	2
2292	The diagnosis and management of multiple sclerosis. 2002 , 1620-1632	
2291	Approved and future pharmacotherapy for multiple sclerosis. 2002 , 8, 290-301	10
2290	The diagnosis of multiple sclerosis. 2002 , 15, 253-6	11
2289	Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. 2002 , 15, 247-51	44
2288	The clinico-radiological paradox in multiple sclerosis revisited. 2002 , 15, 239-45	443
2287	Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. 2002 , 15, 361-70	18
2286	Concurrent syrinx and inflammatory central nervous system disease detected by magnetic resonance imaging: an illustrative case and review of the literature. 2002 , 81, 41-50	13
2285	Spontaneous resolution of idiopathic syringomyelia. 2002 , 58, 1576-7; author reply 1577	5
2284	Mitochondrial myopathy, parkinsonism and multiple mtDNA deletions in a Sephardic Jewish family. 2002 , 58, 670; author reply 670	
2283	Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. 2002 , 58, 671-2; author reply 671-2	2
2282	Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. 2002 , 197, 57-61	153
2281	Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. 2002 , 199, 1-15	31
2280	Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. 2002 , 200, 53-5	27

2279	An assessment of the association between IL-2 gene polymorphisms and Japanese patients with multiple sclerosis. 2002 , 205, 47-50	12
2278	Interferon beta treatment in relapsing-remitting multiple sclerosis. A review. 2002 , 104, 251-8	16
2277	Multiple sclerosis. 2002 , 53, 285-302	311
2276	Vestibular evoked myogenic potentials in multiple sclerosis patients. 2002 , 113, 1464-9	73
2275	Management of Relapsing-Remitting Multiple Sclerosis. 2002 , 10, 307-325	4
2274	Multiple sclerosis. 2002 , 359, 1221-31	1618
2273	Management of acute optic neuritis. 2002 , 360, 1953-62	184
2272	Contribution of corticospinal tract damage to cortical motor reorganization after a single clinical attack of multiple sclerosis. 2002 , 17, 1837-43	92
2271	Hughes syndrome crosses boundaries. 2002 , 1, 43-8	24
2270	[Neurologic manifestations of Behcet's disease: analysis of a series of 27 patients]. 2002 , 23, 592-606	23
2269	Comparison of Methods for the Detection of Oligoclonal IgG Bands in Cerebrospinal Fluid and Serum: Results of the Dutch Quality Control Survey. 2002 , 48, 1578-1580	12
2268	The emerging role of MRI in multiple sclerosis and the new diagnostic criteria. 2002 , 8, 71-72	5
2267	Genetic association studies: genes in search of diseases. 2002 , 58, 1577	2
2266	Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: III. Diretrizes baseadas em evidências e recomendações. 2002 , 60, 881-886	4
2265	An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. 2002 , 2, 8	14
2264	Immunological disturbances in the central nervous system linked to MRI findings in multiple sclerosis. 2002 , 125, 149-54	19
2263	Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. 2002 , 127, 59-68	190
2262	No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. 2002 , 127, 177-9	38

2261	Estrogen receptor gene polymorphism and multiple sclerosis in Japanese patients: interaction with HLA-DRB1*1501 and disease modulation. 2002 , 128, 77-81	34
2260	The expression of apoptosis-regulatory proteins in B lymphocytes from patients with multiple sclerosis. 2002 , 130, 202-10	13
2259	Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis. 2002 , 133, 184-92	17
2258	Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. 2002 , 133, 205-10	22
2257	Predictive value of MRI findings in multiple sclerosis. 2002 , 1, 9	11
2256	An expert system for the evaluation of EDSS in multiple sclerosis. 2002 , 25, 187-210	20
2255	Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. 2002 , 70, 149-53	22
2254	Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Annals of Neurology</i> , 2002 , 52, 47-53	9-4 212
2253	Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. 2002 , 15, 499-504	62
2252	Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies. 2002 , 2, 267-76	6
2251	[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. 2002 , 73, 556-63	25
2250	[DRGs as future reimbursement system for hospital services exemplified by multiple sclerosis]. 2002 , 73, 785-91	
2249	A case of Sjögren's syndrome or multiple sclerosis? A diagnostic and therapeutic dilemma. 2002 , 22, 256-8	6
2248	The role of magnetic resonance imaging in the assessment of patients with established multiple sclerosis. 2002 , 23, 89-90	1
2247	De novo aphasic status epilepticus as presenting symptom of multiple sclerosis. 2002 , 249, 782-3	19
2246	Recurrent optic neuromyelitis with multiple endocrinopathies and autoimmune disorders. 2002 , 249, 784-5	11
2245	T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. 2002 , 129, 510-8	109
2244	A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. 2002 , 20, 383-8	77

2243	Tumefactive demyelinating lesions by combined perfusion-weighted and diffusion weighted imaging. 2002 , 26, 343-6	26
2242	Magnetic resonance imaging of multiple sclerosis. 2002 , 12, 289-301	23
2241	Proposed diagnostic criteria and nosology of acute transverse myelitis. 2002 , 59, 499-505	597
2240	Evaluation of Gd-enhancement in brain MR of multiple sclerosis: image subtraction with and without magnetization transfer. 2002 , 12, 2077-82	14
2239	Reversible MRI changes of hypothalamus in a multiple sclerosis patient with homeostatic disturbances. 2002 , 12 Suppl 3, S28-31	8
2238	Transient splenic lesion of the corpus callosum associated with antiepileptic drugs: evaluation by diffusion-weighted MR imaging. 2003 , 13, 1902-6	65
2237	Disease-modifying Therapies for Multiple Sclerosis. 2003 , 5, 35-54	27
2236	Postinfectious encephalomyelitis. 2003 , 3, 256-64	51
2235	HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. 2003 , 250, 1099-106	36
2234	Prospective study of patients presenting with acute partial transverse myelopathy. 2003 , 250, 1447-52	54
2233	Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. 2003 , 250, 1407-19	195
2232	Nitric oxide as an activity marker in multiple sclerosis. 2003 , 250, 588-92	63
2231	Clinically definite multiple sclerosis after radiological Schilder-like onset. 2003 , 250, 871-3	5
2230	Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. 2003 , 24, 130-3	22
2229	Risk factors of multiple sclerosis: a case-control study. 2003 , 24, 242-7	91
2228	Epileptic seizures in multiple sclerosis: clinical and EEG correlations. 2003 , 24, 322-8	32
2227	Spinal-cord MRI in multiple sclerosis. 2003 , 2, 555-62	181
2226	New and emerging treatment options for multiple sclerosis. 2003 , 2, 563-6	49

2225	Multiple sclerosis in children. 2003 , 25, 229-32		57
2224	A whole genome screen for association in Polish multiple sclerosis patients. 2003 , 143, 107-11		12
2223	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. 2003 , 143, 124-8		33
2222	C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. 2003 , 145, 135-8		37
2221	Sclérose en plaques chez l'enfant. 2003 , 16, 401-405		
2220	Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. 2003 , 100, 49-62		27
2219	Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. 2003 , 135, 154-60		70
2218	Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. 2003 , 136, 125-9		57
2217	Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. 2003 , 136, 46-53		134
2216	CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. 2003 , 137, 210-7		74
2215	Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. 2003 , 139, 150-4		82
2214	Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. 2003 , 20, 51-8		201
2213	Pelvic movements as rhythmic motor manifestation associated with restless legs syndrome. 2003 , 18, 110-3		29
2212	Parkinsonism as a manifestation of multiple sclerosis. 2003 , 18, 108-10		36
2211	Subthalamic lesion and paroxysmal tonic spasms. 2003 , 18, 1401-3		2
2210	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. <i>Annals of Neurology</i> , 2003 , 53, 718-24	9.4	96
2209	Weight loss in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 53, 676-9	9.4	195
2208	New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Annals of Neurology</i> , 2003 , 53, 673-6	9.4	68

2207	A biased Valpha24+ T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. 2003 , 90, 223-8	34
2206	Delivering the diagnosis of MS--results of a survey among patients and neurologists. 2003 , 107, 363-8	52
2205	Acute disseminated encephalomyelitis: a review of 18 cases in childhood. 2003 , 39, 336-42	67
2204	Multiple sclerosis is more prevalent in northern New Zealand than previously reported. 2003 , 33, 79-83	15
2203	Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. 2003 , 83, 1081-8	86
2202	Protocolo diagnóstico de la paraplej ^a y tetraplej ^a . 2003 , 8, 5359-5361	
2201	20. Immunologic neuromuscular disorders. 2003 , 111, S659-68	15
2200	How different MR imaging criteria relate to the diagnosis of multiple sclerosis and its outcome. 2003 , 13, 265-72, xi	1
2199	Multiple sclerosis. 2003 , 87, 867-97, viii-ix	59
2198	Caso clínico Var ^{ón} de 30 años con paraparesia y déficit sensitivo en miembros inferiores de aparición aguda. 2003 , 8, 5369-5372	
2197	Protocolo diagnóstico del paciente con sospecha de enfermedad desmielinizante. 2003 , 8, 5213-5214	
2196	Chapter 1 The Diagnosis of Multiple Sclerosis. 2003 , 27, 1-11	1
2195	The diagnosis of primary progressive multiple sclerosis. 2003 , 206, 145-52	54
2194	Myelitis with atopic diathesis: a nationwide survey of 79 cases in Japan. 2003 , 209, 5-11	40
2193	Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. 2003 , 210, 73-6	72
2192	Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis. 2003 , 212, 11-20	31
2191	Cortical silent period and motor evoked potentials in patients with multiple sclerosis. 2003 , 105, 105-10	20
2190	Sensitivity of laser-evoked potentials versus somatosensory evoked potentials in patients with multiple sclerosis. 2003 , 114, 992-1002	43

2189	Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. 2003 , 18, 847-55	122
2188	Functional cortical changes in patients with multiple sclerosis and nonspecific findings on conventional magnetic resonance imaging scans of the brain. 2003 , 19, 826-36	57
2187	The same TCR (N)Dbeta(N)Jbeta junctional region is associated with several different vbeta13 subtypes in a multiple sclerosis patient at the onset of the disease. 2003 , 14, 470-82	8
2186	Multimodal magnetic resonance imaging of the central nervous system. 2003 , 85, 905-14	15
2185	Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. 2003 , 139, 109-18	68
2184	The role of MRI in the diagnosis of MS. 2003 , 58, 434-48	31
2183	[Relationship between gait speed and strength parameters in multiple sclerosis]. 2003 , 46, 85-90	18
2182	The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. 2003 , 25, 2865-74	36
2181	Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. 2003 , 60, 634-9	160
2180	Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. 2003 , 10, 63-6	53
2179	Esclerosis múltiple. concepto. etiopatogenia. fisiopatología. manifestaciones clínicas. Diagnóstico. historia natural. pronóstico. 2003 , 8, 5185-5195	
2178	Childhood autoimmune neurologic diseases of the central nervous system. 2003 , 21, 745-64	22
2177	The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. 2003 , 61, 602-11	146
2176	D: The Diffusion of Water. 203-256	9
2175	Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients. 2003 , 9, 440-5	21
2174	Gender issues in multiple sclerosis. 2003 , 3, 649-60	2
2173	Chapter 18 Multiple Sclerosis with Early and Late Disease Onset. 2003 , 27, 285-302	2
2172	Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. 2003 , 349, 139-45	492

2171	Spinal cord MRI in clinically isolated optic neuritis. 2003 , 74, 1577-80	43
2170	Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. 2003 , 9, 108-10	30
2169	Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years. 2003 , 9, 204-9	33
2168	MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. 2003 , 9, 554-65	47
2167	Optic neuritis and multiple sclerosis. 2003 , 121, 1039-40	6
2166	Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis. 2003 , 9, 382-6	22
2165	Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. 2003 , 9, 481-5	15
2164	Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?. 2003 , 9, 210-2	10
2163	Multiple sclerosis: it's not the disease you thought it was. 2003 , 1, 57-60	51
2162	Epilepsia partialis continua as a first symptom of multiple sclerosis: electrophysiological study of one case. 2003 , 9, 199-203	18
2161	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. 2003 , 73, 584-90	140
2160	Complementarity-determining region 3 spectratyping analysis of the TCR repertoire in multiple sclerosis. 2003 , 170, 4846-53	43
2159	Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. 2003 , 60, 1082-8	150
2158	Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. 2003 , 9, 39-43	42
2157	Vaccinations and risk of central nervous system demyelinating diseases in adults. 2003 , 60, 504-9	165
2156	Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. 2003 , 9, 393-6	244
2155	Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. 2003 , 12, 689-712	23
2154	Cognitive presentation of multiple sclerosis: evidence for a cortical variant. 2003 , 74, 872-7	80

2153	Acute disseminated encephalomyelitis: recognition in the hands of general paediatricians. 2003 , 88, 122-4	62
2152	Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. 2003 , 74, 495-7	13
2151	Family shares a new nystagmus locus. 2003 , 74, 1580-1580	78
2150	Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. 2003 , 9, 550-3	39
2149	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. 2003 , 9, 521-5	103
2148	CD24 is a genetic modifier for risk and progression of multiple sclerosis. 2003 , 100, 15041-6	92
2147	Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. 2003 , 126, 2738-49	254
2146	The immune response against herpesvirus is more prominent in the early stages of MS. 2003 , 60, 1944-8	47
2145	Cord damage elicits brain functional reorganization after a single episode of myelitis. 2003 , 61, 1078-85	37
2144	Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. 2003 , 9, 235-8	49
2143	Is multiple sclerosis still a clinical diagnosis?. 2003 , 61, 596-7	7
2142	Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. 2003 , 61, 1720-5	239
2141	New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. 2003 , 60, 27-30	180
2140	HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Human leukocyte antigen. 2003 , 60, 647-51	61
2139	Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. 2003 , 9, 621-6	83
2138	Chapter 2 Clinical Features and Subtypes of Multiple Sclerosis. 2003 , 27, 13-20	1
2137	Emerging disease modifying therapies for multiple sclerosis. 2003 , 8, 145-61	3
2136	Changes in neuropsychological test performance over the workday in multiple sclerosis. 2003 , 17, 551-60	32

2135	Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. 2003 , 126, 2323-32	86
2134	Acute ischemic cerebrovascular syndrome: diagnostic criteria. 2003 , 34, 2995-8	135
2133	Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. 2003 , 126, 433-7	260
2132	Confounding Issues in the Diagnosis of Multiple Sclerosis: Lyme Disease Testing. 2003 , 34, 467-475	
2131	Die neuen Diagnosekriterien der Multiplen Sklerose. 2003 , 29, 332-335	
2130	Therapieoptionen bei Multipler Sklerose. 2003 , 29, 336-343	
2129	Hirnstammdiagnostik mittels somatosensibel evozierter Potenziale nach Nervus-medianus-Stimulation. 2003 , 34, 2-7	
2128	Current disease-modifying therapies in multiple sclerosis. 2003 , 23, 133-46	54
2127	Practical consultations: multiple sclerosis. 2003 , 23, 253-64	5
2126	Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. 2003 , 34, 120-6	94
2125	Immunmodulierende Therapiestrategien bei der multiplen Sklerose: ^ Bersicht und aktueller Stand klinischer Studien. 2003 , 30, 433-441	
2124	[Multiple sclerosis: imaging, diagnostic criteria and differential diagnosis]. 2003 , 175, 613-22	2
2123	Confounding Issues in the Diagnosis of Multiple Sclerosis: Lyme Disease Testing. 2003 , 34, 467-475	
2122	Age-related brain parenchymal fraction is significantly decreased in young multiple sclerosis patients: a quantitative MRI study. 2003 , 14, 427-30	23
2121	Magnetic resonance-based techniques for the study and management of multiple sclerosis. 2003 , 65, 133-44	11
2120	Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. 2003 , 16, 275-282	38
2119	. 2003 , 38, 423-427	19
2118	Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?. 2003 , 26, 28-37	7

2117	Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. 2003 , 16, 299-305	19
2116	MRI contributes to the differentiation between MS and HTLV-I associated myelopathy in British Columbian coastal natives. 2003 , 30, 41-8	25
2115	Temporal lobe epilepsy as a unique manifestation of multiple sclerosis. 2003 , 30, 228-32	28
2114	. 2003 , 16, 349-367	1
2113	Current World Literature. 2003 , 16, 419-442	
2112	Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. 2003 , 38, 423-7	97
2111	Bibliography Current World Literature. 2003 , 16, 349-367	
2110	Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. 2003 , 36, 133-41	42
2109	Anticholinergics for urinary symptoms in multiple sclerosis. 2003 ,	2
2108	Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. 2003 , 42, 743-5	49
2107	Chapter 10 Magnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis. 2003 , 27, 139-167	1
2106	Amantadine for fatigue in multiple sclerosis. 2003 , CD002818	20
2105	Chapter 11 Treatment of Relapses and Relapsing-Remitting Multiple Sclerosis. 2003 , 27, 169-191	2
2104	Dietary interventions for multiple sclerosis. 2003 ,	2
2103	CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. 2003 , 101, 4775-82	136
2102	Autoimmune neutropenia associated with multiple sclerosis. 2003 , 42, 102-4	5
2101	Patients with clinically isolated syndromes suggestive of MS: does MRI allow earlier diagnosis?. 2003 , 60, 6-7	7
2100	Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. 2003 , 16, 299-305	9

2099	Molecular analysis of HLA class II-associated susceptibility to neuroinflammatory diseases in Korean children. 2004 , 19, 426-30	28
2098	4.6 Multiple Sklerose. 2004 ,	
2097	Multiple sclerosis. 2004 , 113, 788-94	280
2096	Role of MRI in multiple sclerosis I: inflammation and lesions. 2004 , 9, 665-83	67
2095	Primär chronisch progrediente multiple Sklerose (MS): Das Einhalten der neuen diagnostischen Kriterien verhindert Fehldiagnosen. 2004 , 31, 407-410	1
2094	Neue Therapieansätze bei der Multiplen Sklerose. 2004 , 30, 375-379	
2093	Diagnostische Kriterien der Multiplen Sklerose - Aktuelle Aspekte. 2004 , 30, 370-374	
2092	Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. 2004 , 61, 1515-20	92
2091	The natural history of recurrent optic neuritis. 2004 , 61, 1401-5	91
2090	Multiple sclerosis -- a coordinated immune attack across the blood brain barrier. 2004 , 1, 141-50	32
2089	Formale MRT-Kriterien in der Diagnose der Multiplen Sklerose. 2004 , 4, 107-122	
2088	CSF characteristics in early-onset multiple sclerosis. 2004 , 63, 1966-7	126
2087	Audiovestibular evolution in a patient with multiple sclerosis. 2004 , 113, 726-9	14
2086	Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. 2004 , 10, 330-1	31
2085	Primary progressive multiple sclerosis: cerebrospinal fluid considerations. 2004 , 10, S31-S35	3
2084	Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test. 2004 , 10, 686-9	11
2083	Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. 2004 , 61, 226-30	304
2082	Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization. 2004 , 10, 705-7	24

2081	Cotugno and cerebrospinal fluid. 2004 , 75, 1299	6
2080	Thoracic syringomyelia and suspected multiple sclerosis: cause and effect or coincidence?. 2004 , 63, 185-6	2
2079	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. 2004 , 10, 413-6	22
2078	Congenital adrenal hyperplasia and multiple sclerosis: is there an increased risk of multiple sclerosis in individuals with congenital adrenal hyperplasia?. 2004 , 61, 1953-5	6
2077	Bias in parental transmission of the HLA-DR3 allele in Sardinian multiple sclerosis. 2004 , 63, 1084-6	18
2076	Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. 2004 , 63, 2381-3	63
2075	Optic neuritis: chemokine receptor CXCR3 and its ligands. 2004 , 88, 1146-8	10
2074	Mitochondrial haplogroups in Basque multiple sclerosis patients. 2004 , 10, 532-5	24
2073	Primary progressive multiple sclerosis: cerebrospinal fluid considerations. 2004 , 10 Suppl 1, S31-4; discussion S34-5	1
2072	Reliable screening for neuropsychological impairment in multiple sclerosis. 2004 , 10, 675-8	194
2071	High frequency of primary Sjögren's syndrome in Taiwanese patients presenting as relapsing-remitting multiple sclerosis. 2004 , 51, 21-5	11
2070	Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse. 2004 , 52, 237-41	13
2069	Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. 2004 , 75, 308-10	41
2068	Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. 2004 , 127, 1101-7	277
2067	Validation of diagnostic imaging based on repeat examinations. An image interpretation model. 2004 , 45, 540-6	2
2066	Frontal parenchymal atrophy measures in multiple sclerosis. 2004 , 10, 562-8	34
2065	The PRO MiSe trial: baseline data review and progress report. 2004 , 10, S65-S72	23
2064	Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. 2004 , 10, 266-71	44

2063	Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. 2004 , 127, 616-27	230
2062	Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. 2004 , 101, 2428-33	276
2061	An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. 2004 , 63, 584-5	39
2060	Challenges in addressing community concerns regarding clusters of multiple sclerosis and potential environmental exposures. 2004 , 23, 211-6	9
2059	Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. 2004 , 61, 1538-41	17
2058	Effects of an Aquatics Exercise Program on Quality of Life Measures for Individuals with Progressive Multiple Sclerosis. 2004 , 28, 63-71	39
2057	Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. 2004 , 127, 259-68	57
2056	Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. 2004 , 127, 1361-9	159
2055	Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. 2004 , 172, 3893-904	186
2054	Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. 2004 , 50, 1809-13	49
2053	Quality versus quantity: which is better for cerebrospinal fluid IgG?. 2004 , 50, 1721-2	6
2052	Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. 2004 , 127, 111-9	157
2051	Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. 2004 , 75, 1294-9	48
2050	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 2004 , 101, 11064-9	280
2049	Training-dependent plasticity in patients with multiple sclerosis. 2004 , 127, 2506-17	85
2048	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. 2004 , 63, 2039-45	214
2047	T1 relaxation maps allow differentiation between pathologic tissue subsets in relapsing-remitting and secondary progressive multiple sclerosis. 2004 , 10, 556-61	17
2046	Visual evoked potential is superior to triple dose magnetic resonance imaging in the diagnosis of optic nerve involvement. 2004 , 114, 1025-33	9

2045	MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort. 2004 , 62, 806-8	96
2044	Plasma exchange for severe optic neuritis: treatment of 10 patients. 2004 , 63, 1081-3	143
2043	Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. 2004 , 10, 2-4	89
2042	Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. 2004 , 10, S2-S7	17
2041	Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. 2004 , 61, 222-4	27
2040	The PROMiSe trial: baseline data review and progress report. 2004 , 10 Suppl 1, S65-71; discussion S71-2	33
2039	The MS Co-Operative REsearch (MS-CORE) group: an alternate approach to fostering multicenter studies. 2004 , 10, 332-3	4
2038	Acute aphasia in multiple sclerosis: A multicenter study of 22 patients. 2004 , 62, 974-7	45
2037	Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. 2004 , 30, 106-17	55
2036	Patients with multiple sclerosis prefer early diagnosis. 2004 , 11, 335-7	17
2035	Primary progressive multiple sclerosis: clinical and paraclinical characteristics with application of the new diagnostic criteria. 2004 , 11, 439-44	10
2034	CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. 2004 , 11, 525-9	56
2033	Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. 2004 , 109, 385-9	32
2032	Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. 2004 , 110, 386-92	7
2031	Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone. 2004 , 14, 58-62	35
2030	Measurement of Spinal Cord Atrophy in Multiple Sclerosis. 2004 , 14, 20S-26S	59
2029	Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. 2004 , 14, 27S-35S	53
2028	Magnetic Resonance Imaging Surrogates of Multiple Sclerosis Pathology and Their Relationship to Central Nervous System Atrophy. 2004 , 14, 46S-53S	11

2027	An ultrasensitive method for the detection of oligoclonal IgG bands. 2004 , 284, 141-5	37
2026	Immunomonitoring measures in relapsing-remitting multiple sclerosis. 2004 , 148, 192-9	10
2025	CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. 2004 , 149, 182-6	62
2024	CD4 T cell activation and disease activity at onset of multiple sclerosis. 2004 , 149, 202-9	43
2023	Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis. 2004 , 150, 150-6	11
2022	The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. 2004 , 156, 171-7	7
2021	Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. 2004 , 156, 195-203	44
2020	Environmental risk factors in multiple sclerosis aetiology. 2004 , 3, 709-18	241
2019	What is acute disseminated encephalomyelitis (ADEM)?. 2004 , 8, 239-42	30
2018	Dystonia in a 13-year-old boy with secondary progressive multiple sclerosis. 2004 , 26, 539-41	4
2017	Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients. 2004 , 24, 287-93	25
2016	Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. 2004 , 63, 838-42	188
2015	Increased 14-3-3 immunoreactivity in glial elements in patients with multiple sclerosis. 2004 , 107, 137-43	16
2014	Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. 2004 , 251, 165-70	17
2013	Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study. 2004 , 251, 284-93	297
2012	Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. 2004 , 251, 542-7	25
2011	Multiple sclerosis-like illness in a HIV-1 patient. 2004 , 251, 1142-4	12
2010	PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. 2004 , 251, 1085-8	10

2009	Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. 2004 , 251, 1133-7	138
2008	CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. 2004 , 251, 1278-9	24
2007	Escalating immunotherapy of multiple sclerosis--new aspects and practical application. 2004 , 251, 1329-39	100
2006	Cervical dystonia as first manifestation of multiple sclerosis. 2004 , 251, 1408-10	16
2005	Unexpected aggravation of Parkinson's disease by a mesencephalic multiple sclerosis lesion. 2004 , 251, 1526-7	9
2004	The pros and cons of early treatment of relapsing forms of multiple sclerosis. 2004 , 251 Suppl 4, IV30-4	4
2003	MRI: role in optimising treatment. 2004 , 251 Suppl 5, v36-v41	1
2002	Improving MS patient care. 2004 , 251 Suppl 5, v69-v73	34
2001	Seasonal variation of multiple sclerosis exacerbations in Japan. 2004 , 24, 417-9	33
2000	Headache and inflammatory disorders of the central nervous system. 2004 , 25 Suppl 3, S148-53	15
1999	Multiple sclerosis in children under 10 years of age. 2004 , 25 Suppl 4, S326-35	69
1998	Diffusion tensor and magnetization transfer MR imaging of early-onset multiple sclerosis. 2004 , 25 Suppl 4, S344-5	4
1997	Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. 2004 , 25 Suppl 4, S350-5	47
1996	Multiple sclerosis: pseudotumoral forms. 2004 , 25 Suppl 4, S374-9	33
1995	Italian studies on early-onset multiple sclerosis: the present and the future. 2004 , 25 Suppl 4, S346-9	17
1994	Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. 2004 , 94, 183-9	23
1993	The effect of contrast reduction on pattern-reversal VEPs in suspected multiple sclerosis and optic neuritis. 2004 , 109, 157-61	4
1992	[Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters]. 2004 , 75, 945-52	6

1991	Differenzierte MRT-Befundung zur Diagnosestellung der Multiplen Sklerose. 2004 , 14, 233-243		1
1990	Pediatric multiple sclerosis. 2004 , 4, 245-52		20
1989	Treatment optimization in multiple sclerosis: report of an international consensus meeting. 2004 , 11, 43-7		23
1988	More transgenic mouse models of dopamine deficiency. <i>Annals of Neurology</i> , 2004 , 55, 297-8	9.4	
1987	Disease penetrance in amyotrophic lateral sclerosis associated with mutations in the SOD1 gene. <i>Annals of Neurology</i> , 2004 , 55, 298-9; author reply 299	9.4	13
1986	Reply. <i>Annals of Neurology</i> , 2004 , 55, 299-299	9.4	1
1985	Herpes simplex virus type 1 and Alzheimer's disease. <i>Annals of Neurology</i> , 2004 , 55, 299-300; author reply 300-1	9.4	16
1984	Reply. <i>Annals of Neurology</i> , 2004 , 55, 300-301	9.4	1
1983	Multiple sclerosis: should MR criteria for dissemination in time be less stringent. <i>Annals of Neurology</i> , 2004 , 55, 297	9.4	2
1982	Expression of CCR7 in multiple sclerosis: implications for CNS immunity. <i>Annals of Neurology</i> , 2004 , 55, 627-38	9.4	201
1981	Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. <i>Annals of Neurology</i> , 2004 , 56, 273-8	9.4	60
1980	Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. <i>Annals of Neurology</i> , 2004 , 56, 407-15	9.4	579
1979	Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. <i>Annals of Neurology</i> , 2004 , 56, 778-86	9.4	35
1978	Altered decision-making in multiple sclerosis: a sign of impaired emotional reactivity?. <i>Annals of Neurology</i> , 2004 , 56, 787-95	9.4	58
1977	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. 2004 , 21, 108-17		85
1976	Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. 2004 , 20, 765-71		68
1975	Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. 2004 , 10 Suppl 1, S2-7		38
1974	T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. 2004 , 172, 7169-76		185

1973	Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. 2004 , 4, 571-80	134
1972	MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. 2004 , 127, 1942-7	180
1971	Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. 2004 , 62, 226-33	234
1970	A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. 2004 , 10, 636-42	22
1969	Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. 2004 , 75, 478-85	70
1968	Multiple sclerosis. 2004 , 177-201	5
1967	Diagn�stico y tratamiento de la esclerosis m�ltiple. 2004 , 123, 743-748	
1966	Auto-antibodies in multiple sclerosis: an hypothesis. 2004 , 58, 282-282	
1965	Multiple sclerosis. 2004 , 31, 201-26	5
1964	Immunomonitoring measures in relapsing-remitting multiple sclerosis. 2004 ,	
1963	[Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response]. 2004 , 160, 659-65	3
1962	Suivi immunobiologique de malades atteints de scl�rose en plaques. 2004 ,	
1961	Motor Behavior. 2004 , 22, e1201-e1392	
1960	Aspects cliniques, physiopathologiques, et th�rapeutiques de la scl�rose en plaques. 2004 , 1, 415-457	2
1959	Demyelinating Diseases. 2004 , 44-49	
1958	Multiple sclerosis: a short review of the disease and its differences between men and women. 2004 , 1, 334-340	19
1957	Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. 2004 , 217, 217-23	47
1956	Functional imaging during covert auditory attention in multiple sclerosis. 2004 , 218, 9-15	14

1955	Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. 2004 , 222, 65-73	19
1954	Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. 2004 , 224, 23-7	22
1953	Attack-related severity: a key factor in understanding the spectrum of idiopathic inflammatory demyelinating disorders. 2004 , 225, 71-8	17
1952	Effect of immunotherapy in myelitis with atopic diathesis. 2004 , 227, 39-47	14
1951	Early-stage multiple sclerosis : what are the treatment options?. 2004 , 64, 2021-9	
1950	Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. 2004 , 24, 409-20	21
1949	Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. 2004 , 1, 284-94	99
1948	Evidence from biomarkers and surrogate endpoints. 2004 , 1, 323-30	16
1947	Multiple Sclerosis Classification and Overview. 2004 , 691-699	
1946	Multiple Sclerosis: Therapy. 2004 , 791-806	
1945	[Multiple sclerosis with sensory disturbances and hyperhidrosis of the hand]. 2004 , 160, 830-2	
1944	Treatment for ataxia in multiple sclerosis. 2004 ,	
1943	Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. 2004 , 127, 1370-8	126
1942	Multiple sclerosis and pregnancy. 2004 , 22, 757-69	21
1941	[The contribution of automatic anatomical matching of sequential brain MRI scans in the monitoring of multiple sclerosis lesions]. 2004 , 160, 805-10	0
1940	Effect of cryopreservation on expression of Th1 and Th2 cytokines in blood mononuclear cells from patients with different cytokine profiles, analysed with three common assays: an overall decrease of interleukin-4. 2004 , 49, 157-68	34
1939	Auto-antibodies in multiple sclerosis: an hypothesis. 2004 , 58, 282-5	2
1938	Intracranial pathology of the visual pathway. 2004 , 49, 143-78	11

1937	Suivi immunobiologique de malades atteints de sclérose en plaques. 2004 , 19, 138-147	10
1936	Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study. 2004 , 34, 147-51	9
1935	Analysis of the threshold liability model provides new understanding of causation in autoimmune diseases. 2004 , 63, 257-61	6
1934	The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?. 2004 , 11, 689-92	29
1933	First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. 2004 , 144, 246-52	252
1932	Orientational contrast sensitivity and chromatic contrast thresholds in multiple sclerosis. 2004 , 137, 283-6	6
1931	[Can multiple sclerosis be diagnosed on a first demyelinating event?]. 2004 , 33, 174-9; discussion 192	
1930	[Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?]. 2004 , 33, 180-6; discussion 192	
1929	[The significance and treatment of antiphospholipid antibodies]. 2004 , 33, 944-52	2
1928	The regulatory role of natural killer cells in multiple sclerosis. 2004 , 127, 1917-27	103
1927	Stroke and neurodegenerative disorders. 4. Neurodegenerative disorders. 2004 , 85, S21-33	89
1926	Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. 2004 , 74, 1321-2	31
1925	Diagnostic criteria for multiple sclerosis: an historical review. 2004 , 106, 147-58	48
1924	The multiple sclerosis trait: a disease waiting to happen?. 2004 , 106, 172-4	6
1923	Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation. 2004 , 115, 956-65	88
1922	Dynamics of MRI lesion development in an animal model of viral-induced acute progressive CNS demyelination. 2004 , 21, 576-82	30
1921	Pyramidal tract lesions and movement-associated cortical recruitment in patients with MS. 2004 , 23, 141-7	47
1920	Neuroretinitis in patients with multiple sclerosis. 2004 , 111, 335-40; discussion 340-1	13

1919	A 16-year-old boy with progressive central vision loss in his left eye. 2004 , 170, 1228	1
1918	MULTIPLE SCLEROSIS CLINICAL VARIANTS AND DIFFERENTIAL DIAGNOSIS. 2004 , 10, 102-119	1
1917	Pathological aging of the brain: an overview. 2004 , 15, 369-89	48
1916	Can better disease definition lead to cure?. 2004 , 16, 615-6	
1915	Toward the definition of acute disseminated encephalitis of childhood. 2004 , 16, 637-40	18
1914	MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS. 2004 , 10, 74-101	
1913	QUINTEssentials. 2004 , 10, 197-217	
1912	An update on neuroimaging of multiple sclerosis. 2004 , 17, 453-8	10
1911	CLINICAL FEATURES OF MULTIPLE SCLEROSIS. 2004 , 10, 38-73	1
1910	Neuroimaging of Visual Pathway Pathology. 2004 , 17, 427-433	
1909	Familial multiple sclerosis and other inherited disorders of the white matter. 2004 , 10, 201-15	12
1908	Construct validity and frequency of euphoria sclerotica in multiple sclerosis. 2004 , 16, 350-6	32
1907	Anticipation of age at onset in multiple sclerosis: a Sardinian cohort study. 2004 , 62, 1794-8	33
1906	Aspects cliniques, physiopathologiques, et th�rapeutiques de la scl�rose en plaques. 2004 , 1, 1-27	1
1905	Cognitive impairment in relapsing and primary progressive multiple sclerosis: mostly a matter of speed. 2004 , 10, 948-56	80
1904	The vibration quantitation scale (VQS): a simple, reproducible bedside measure of sensory function in multiple sclerosis. 2004 , 31, 490-3	1
1903	Treatment optimization in multiple sclerosis. 2004 , 31, 157-68	93
1902	Cortical relay time for long latency reflexes in patients with definite multiple sclerosis. 2004 , 31, 229-34	17

1901	A Guide to the Interpretation of CSF Indices. 2005 , 36, 558-562	5
1900	Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. 2005 , 18, 267-71	24
1899	Clinicoradiological review: dural arteriovenous fistula and cervical spondylosis mimicking multiple sclerosis. 2005 , 56, 1325-9; discussion 1329	
1898	MR as a Measure of Axonal Injury in Brain Diseases. 2005 , 18, 455-467	
1897	Primary progressive multiple sclerosis. 2005 , 18, 261-6	27
1896	Pregnancy and multiple sclerosis. 2005 , 48, 38-47	22
1895	Dysphagia in aging. 2005 , 39, 357-71	138
1894	Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002. 2005 , 44, 560-6	11
1893	Comparison of the clinical courses of the opticospinal and conventional forms of multiple sclerosis in Japan. 2005 , 44, 934-8	10
1892	Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. 2005 , 62, 803-8	97
1891	Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. 2005 , 11, 727-36	99
1890	Announcements. 2005 , 1329	
1889	Role of return migration in the emergence of multiple sclerosis in the French West Indies. 2005 , 128, 2899-910	106
1888	Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. 2005 , 62, 585-90	59
1887	Vestibular evoked myogenic potential: new perspectives in multiple sclerosis. 2005 , 71, 48-54	4
1886	FLAIR lesion volume in multiple sclerosis: relation to processing speed and verbal memory. 2005 , 11, 205-9	23
1885	Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. 2005 , 11, 574-83	78
1884	Memory interference in multiple sclerosis. 2005 , 11, 737-46	8

1883	Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. 2005 , 32, 37-42	34
1882	Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis. 2005 , 97, 55-62	8
1881	Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity. 2005 , 1051, 111-20	6
1880	Spinal cord imaging in multiple sclerosis. 2005 , 15, 94S-102S	37
1879	Magnetic resonance imaging advances in multiple sclerosis. 2005 , 15, 5S-9S	17
1878	A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis: detection of three biomarkers. 2005 , 25, 119-25	18
1877	Analysis of the human brain in primary progressive multiple sclerosis with mapping of the spatial distributions using 1H MR spectroscopy and diffusion tensor imaging. 2005 , 15, 1686-93	26
1876	CSF from MS patients can induce acute conduction block in the isolated optic nerve. 2005 , 12, 45-8	4
1875	Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of demyelinating diseases. 2005 , 12, 527-30	22
1874	EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. 2005 , 12, 939-46	106
1873	Anti-heat shock protein 90beta antibodies decrease pre-oligodendrocyte population in perinatal and adult cell cultures. Implications for remyelination in multiple sclerosis. 2005 , 95, 349-60	20
1872	The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis. 2005 , 45, 670-7	87
1871	Severe impulsiveness as the primary manifestation of multiple sclerosis in a young female. 2005 , 59, 739-42	14
1870	Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. 2005 , 35, 382-7	10
1869	Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. 2005 , 62, 176-82	59
1868	MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. 2005 , 37, 486-94	254
1867	A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. 2005 , 37, 1113-8	220
1866	Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. 2005 , 36, 1053-63	35

1865	Association of haplotypes in the beta-chemokine locus with multiple sclerosis. 2005 , 13, 240-7	20
1864	Clinical characteristics, course and prognosis of spinal multiple sclerosis. 2005 , 43, 731-4	16
1863	Letter to the Editor. 2005 , 15, 206-206	
1862	Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system--value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. 2005 , 112, 207-13	48
1861	The diagnosis and management of multiple sclerosis. 2005 , 112, 199-201	13
1860	Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta. 2005 , 112, 194-6	13
1859	Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan. 2005 , 27, 224-7	31
1858	Dystonia and multiple sclerosis. 2005 , 27, 602; author reply 602	
1857	Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. 2005 , 4, 32-41	199
1856	The neuro-ophthalmology of multiple sclerosis. 2005 , 4, 111-21	216
1855	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. 2005 , 4, 281-8	436
1854	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. 2005 , 4, 341-8	112
1853	CSF testing for multiple sclerosis. 2005 , 4, 522-3	2
1852	Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. 2005 , 4, 618-26	205
1851	Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. 2005 , 158, 195-203	51
1850	CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha. 2005 , 159, 177-82	28
1849	CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. 2005 , 159, 225-9	20
1848	Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis. 2005 , 161, 195-8	12

1847	Systemic T-cell activation in acute clinically isolated optic neuritis. 2005 , 162, 165-72		18
1846	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. 2005 , 163, 172-8		54
1845	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. 2005 , 165, 192-200		36
1844	E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. 2005 , 165, 201-5		15
1843	Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis. 2005 , 167, 143-9		61
1842	TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. 2005 , 167, 170-4		37
1841	Homozygosity for the 168His variant of the minor histocompatibility antigen HA-1 is associated with reduced risk of primary Sjögren's syndrome. 2005 , 35, 305-17		15
1840	Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. 2005 , 24, 216-28		140
1839	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005 , 57, 210-5	9.4	93
1838	How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. <i>Annals of Neurology</i> , 2005 , 57, 606-7	9.4	10
1837	Upbeat nystagmus as the initial clinical sign of Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 2005 , 57, 607-8	9.4	7
1836	Sparse multifocal stimuli for the detection of multiple sclerosis. <i>Annals of Neurology</i> , 2005 , 57, 904-13	9.4	36
1835	Defective ATM-p53-mediated apoptotic pathway in multiple sclerosis. <i>Annals of Neurology</i> , 2005 , 58, 577-84	9.4	26
1834	Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. <i>Annals of Neurology</i> , 2005 , 58, 470-3	9.4	42
1833	Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. <i>Annals of Neurology</i> , 2005 , 58, 781-3	9.4	53
1832	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005 , 58, 840-6	9.4	4020
1831	Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. 2005 , 21, 669-75		38
1830	Scientific Sessions. 2005 , 47, S15-S85		

1829	[Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature]. 2005 , 76, 748-55	4
1828	[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients]. 2005 , 76, 740-7	14
1827	[Neuroradiology of the intracranial visual pathway. Part II]. 2005 , 45, 1043-55	
1826	Akute disseminierte Enzephalomyelitis (ADEM). 2005 , 42, 496-509	
1825	Intrathecal sICAM-1 production in multiple sclerosis--correlation with triple dose Gd-DTPA MRI enhancement and IgG index. 2005 , 252, 146-50	15
1824	Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. 2005 , 252, 396-402	76
1823	Neurology training in the United Kingdom: a diagnostic analysis of over 5000 patients. 2005 , 252, 605-7	11
1822	Discriminant analysis of the cognitive performance profile of MS patients differentiates their clinical course. 2005 , 252, 808-13	21
1821	CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria. 2005 , 252, 824-9	8
1820	Proton magnetic resonance spectroscopy of normal appearing white matter in familial and sporadic multiple sclerosis. 2005 , 252, 830-2	10
1819	Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis. 2005 , 252, 908-15	14
1818	Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. 2005 , 252, 968-71	60
1817	The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. 2005 , 252, 1255-61	27
1816	Fifteenth Meeting of the European Neurological Society, 18-22 June 2005, Vienna, Austria. Abstracts. 2005 , 252 Suppl 2, 3-159	0
1815	Genomics and proteomics: role in the management of multiple sclerosis. 2005 , 252 Suppl 3, iii21-iii27	6
1814	Early treatment and dose optimisation BENEFIT and BEYOND. 2005 , 252 Suppl 3, iii44-iii50	14
1813	MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. 2005 , 252 Suppl 5, v16-24	91
1812	Multiple sclerosis trial designs for the 21st century: building on recent lessons. 2005 , 252 Suppl 5, v46-53	17

1811	Haplotypes within genes of beta-chemokines in 17q11 are associated with multiple sclerosis: a second phase study. 2005 , 118, 67-75	18
1810	Immunological markers in multiple sclerosis: tackling the missing elements. 2005 , 26 Suppl 4, S215-7	5
1809	Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. 2005 , 112, 797-803	23
1808	Increased accumulations of N-isopropyl-p-[123I]-iodoamphetamine related to tumefactive multiple sclerosis. 2005 , 19, 603-6	6
1807	Treatment of Pediatric Multiple Sclerosis. 2005 , 7, 191-199	11
1806	Post-infectious encephalomyelitis. 2005 , 5, 440-5	20
1805	Recent advances in the neuroimaging of multiple sclerosis. 2005 , 5, 217-24	5
1804	Role of microglia in multiple sclerosis. 2005 , 5, 239-44	18
1803	Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. 2005 , 25, 338-45	44
1802	Adenosine deaminase and 5' nucleotidase activities in peripheral blood T cells of multiple sclerosis patients. 2005 , 30, 453-6	8
1801	Clinical Add-on: Multiple sclerosis [Clinical picture and therapeutic strategies. 2005 , 5, 266-272	
1800	Demyelination-like syndrome in Crohn's disease after infliximab therapy. 2005 , 19, 313-6	34
1799	Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. 2005 , 21, 49-55	18
1798	Visual phenotype of multiple sclerosis in the Afro-Caribbean population and the influence of migration to metropolitan France. 2005 , 15, 392-9	6
1797	[Multiple sclerosis--update]. 2005 , 94, 1167-70	
1796	Potencial evocado miogênico vestibular: novas perspectivas diagnósticas em esclerose múltipla. 2005 , 71, 48-54	
1795	The use of interferon beta-1b (Betaferon) in multiple sclerosis and the MS nurse's role. 2005 , 1, 132-138	2
1794	Autoimmunity [Multiple Sclerosis. 2005 , 515-524	1

1793	Die Wertigkeit der evozierten Potenziale in der Diagnostik der multiplen Sklerose. 2005 , 433-445	1
1792	[Guidelines for the treatment of multiple sclerosis with immunomodulatory drugs]. 2005 , 63, 892-5	3
1791	Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis. 2005 , 11, 69-75	64
1790	Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. 2005 , 65, 1626-30	45
1789	Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. 2005 , 24, 70-5	31
1788	Imaging in Drug Discovery and Early Clinical Trials. 2005 ,	
1787	Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. 2005 , 11, 227-31	24
1786	Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. 2005 , 64, 987-91	211
1785	Changes in the ascertainment of multiple sclerosis. 2005 , 65, 1066-70	67
1784	A longitudinal fMRI study on motor activity in patients with multiple sclerosis. 2005 , 128, 2146-53	75
1783	Recent use of oral contraceptives and the risk of multiple sclerosis. 2005 , 62, 1362-5	114
1782	Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. 2005 , 65, 1479-82	249
1781	Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. 2005 , 62, 865-70	348
1780	Visual Evoked Potentials in Clinical Neurology. 2005 , 453-471	2
1779	Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. 2005 , 11, 127-34	99
1778	Brain atrophy and lesion load in a large population of patients with multiple sclerosis. 2005 , 65, 280-5	126
1777	No evidence for MSRV viraemia and glial cell death in acute optic neuritis. 2005 , 11, 495-6	3
1776	Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?. 2005 , 44, 434-42	91

1775	Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. 2005 , 102, 5150-5	244
1774	Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease. 2005 , 25, 570-3	8
1773	Robert B^ m ny 1876-1936. 2005 , 76, 662	
1772	Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. 2005 , 102, 3070-5	83
1771	The clinical role of evoked potentials. 2005 , 76 Suppl 2, ii16-22	78
1770	Multiple sclerosis: diagnosis and the management of acute relapses. 2005 , 81, 302-8	65
1769	Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase. 2005 , 11, 395-7	13
1768	Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. 2005 , 11, 542-51	28
1767	Acute disseminated encephalomyelitis: an update. 2005 , 62, 1673-80	285
1766	Cognitive functioning in children and adolescents with multiple sclerosis. 2005 , 64, 1422-5	185
1765	The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis. 2005 , 76, 656-62	23
1764	Relevance of clinical findings for multiple sclerosis diagnosis in the MRI era: a case report. 2005 , 11, 93	1
1763	Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. 2005 , 11, 390-4	19
1762	Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. 2005 , 116, 431-6	99
1761	Prognostic factors in multidisciplinary rehabilitation treatment in multiple sclerosis: an outcome study. 2005 , 11, 719-24	44
1760	Central nervous system involvement in hereditary neuropathy with liability to pressure palsies: description of a large family with this association. 2005 , 62, 1911-4	22
1759	[Recent advances in pathogenesis and therapy of multiple sclerosis]. 2005 , 73, 715-27	
1758	Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. 2005 , 62, 33-6	14

1757	Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. 2005 , 353, 1744-6; author reply 1744-6	16
1756	[Differential influence of immune therapy on relapses and progression in multiple sclerosis: interpretation and therapeutic consequences]. 2005 , 73, 143-9	1
1755	Differenzialdiagnose von L ¹ sionen der wei ¹ ßen Hirnsubstanz in der Magnetresonanztomographie. 2005 , 32, 402-417	2
1754	Transkranielle Magnetstimulation bei multipler Sklerose. 2005 , 36, 155-160	
1753	Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. 2005 , 62, 1620-3	99
1752	Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. 2005 , 62, 1519-30	22
1751	Interferon-beta1a treatment for multiple sclerosis. 2005 , 5, 25-34	
1750	Interferon-beta1b for multiple sclerosis. 2005 , 5, 153-64	26
1749	Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. 2005 , 5, 403-11	15
1748	Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. 2005 , 11, 485-91	144
1747	Assessment of multiple sclerosis lesions with spherical harmonics: comparison of MR imaging and pathologic findings. 2005 , 235, 1036-44	8
1746	Visuell evozierte Potenziale und Elektroretinogramm. 2005 , 253-368	
1745	Lipoic acid in multiple sclerosis: a pilot study. 2005 , 11, 159-65	115
1744	Interferon beta for secondary progressive multiple sclerosis. 2005 ,	1
1743	Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. 2005 , 56, 273-302	15
1742	Intrathecal activation of the IL-17/IL-8 axis in optico-spinal multiple sclerosis. 2005 , 128, 988-1002	286
1741	Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis?. 2005 , 90, 636-9	75
1740	Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. 2005 , 76, 206-11	99

1739	Between-laboratory variability in oligoclonal IgG band numbering. 2005 , 51, 270-2	10
1738	Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. 2005 , 19, 1902-4	62
1737	Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. 2005 , 27, 591-7	19
1736	Reappraisal of Lhermitte's sign in multiple sclerosis. 2005 , 11, 398-402	65
1735	Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. 2005 , 236, 254-60	400
1734	Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. 2005 , 11, 492-4	77
1733	Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. 2005 , 20, 822-5	28
1732	Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. 2006 , 77, 345-50	26
1731	MRI as a marker for disease heterogeneity in multiple sclerosis. 2005 , 65, 1071-6	59
1730	False-negative serum protein electrophoresis in a sample with an IgM monoclonal protein by semiautomated gel electrophoresis. 2005 , 51, 270	16
1729	Multiple sclerosis with idiopathic dilated cardiomyopathy: a case report. 2005 , 53, 214-5	5
1728	Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. 2005 , 54, 28-33	31
1727	Acute disseminated myelitis associated with 5-fluorouracil and l-leucovorin treatment. 2005 , 54, 214-6	2
1726	Imaging in multiple sclerosis. 2005 , 76 Suppl 3, iii11-iii18	20
1725	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. 2005 , 11, 420-4	90
1724	A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. 2005 , 11, 552-61	51
1723	A case of ophthalmoplegic migraine mimicking ocular myasthenia gravis. 2005 , 53, 215-7	8
1722	Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. 2005 , 76, 1693-7	49

1721	Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. 2005 , 128, 1016-25	358
1720	Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. 2005 , 11, 658-68	11
1719	Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients. 2005 , 11, 282-5	59
1718	Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. 2005 , 175, 1974-82	141
1717	Chapter 26 Multiple sclerosis and other demyelinating disorders. 2005 , 5, 491-516	1
1716	Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. 2005 , 62, 574-7	46
1715	Acute Disseminated Encephalomyelitis. 2005 , 147-162	
1714	Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. 2005 , 128, 1667-76	280
1713	Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. 2005 , 128, 2689-704	137
1712	¹ H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. 2005 , 128, 2483-506	88
1711	Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. 2005 , 128, 2911-25	94
1710	Center of pressure measures during standing tasks in minimally impaired persons with multiple sclerosis. 2005 , 29, 170-80	97
1709	25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. 2005 , 11, 266-71	190
1708	Hereditary Melkersson-Rosenthal syndrome and multiple sclerosis. 2005 , 11, 364-6	6
1707	[Prevention of the impact on health of the heat wave]. 2005 , 125, 758-9	
1706	[Multiple sclerosis after treatment with anti-TNF-alpha antibodies]. 2005 , 125, 759	2
1705	A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. 2005 , 26, 258-65	168
1704	Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. 2005 , 26, 822-8	108

1703	A high-density screen for linkage in multiple sclerosis. 2005 , 77, 454-67	235
1702	Translational research in central nervous system drug discovery. 2005 , 2, 671-82	80
1701	Neuroimaging in multiple sclerosis. 2005 , 23, 131-48, vii	13
1700	[Immunofixation compared to isoelectric focusing in the detection of oligoclonal bands in cerebrospinal fluid of multiple sclerosis patients]. 2005 , 161, 1183-90	2
1699	Natural history of multiple sclerosis. 2005 , 23, 17-38, v	93
1698	[Cystic fibrosis and uveitis in childhood and multiple sclerosis at adulthood]. 2005 , 28, 850-3	1
1697	Diagnosing multiple sclerosis and its imitators. 2005 , 16, 359-81	2
1696	[Relapsing remitting multiple sclerosis or multiphasic disseminated encephalomyelitis?]. 2005 , 161, 228-33	2
1695	Clinical features and diagnosis of multiple sclerosis. 2005 , 23, 1-15, v	72
1694	A practical approach to immunomodulatory therapy for multiple sclerosis. 2005 , 16, 449-66, ix	6
1693	Chapter 12 Role of clinical neurophysiology in assessing both normal and pathological processing of visual information. 2005 , 5, 231-248	
1692	Acute Optic Neuritis in Multiple Sclerosis: Evaluation of Hemodynamics in the Ophthalmic Artery with Colour Doppler Imaging. 2005 , 29, 161-164	3
1691	A randomized crossover study of bee sting therapy for multiple sclerosis. 2005 , 65, 1764-8	45
1690	Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis. 2005 , 19, 55-61; discussion 63-4	2
1689	Primary progressive multiple sclerosis : current and future treatment options. 2005 , 19, 369-76	33
1688	Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. 2005 , 11, 373-7	59
1687	Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. 2005 , 11, 261-5	48
1686	Multiple sclerosis diagnostic criteria: three years later. 2005 , 11, 5-12	69

1685	Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. 2005 , 18, 537-50	102
1684	P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. 2005 , 388, 149-52	13
1683	Acute tinnitus and hearing loss as the initial symptom of multiple sclerosis in a child. 2005 , 69, 123-6	17
1682	Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis. 2005 , 65, 232-7	2
1681	How frequently do patients with multiple sclerosis use complementary and alternative medicine?. 2005 , 13, 258-63	23
1680	Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis. 2005 , 32, 111-6	8
1679	Improved detectability of experimental allergic encephalomyelitis in excised swine spinal cords by high b-value q-space DWI. 2005 , 195, 437-46	38
1678	[Cytoimmunological profile of cerebrospinal fluid in diagnosis of multiple sclerosis]. 2005 , 53, 68-74	7
1677	Cognitive impairment in three subtypes of multiple sclerosis. 2005 , 20, 967-81	104
1676	Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study. 2005 , 2, 13	11
1675	Imaging of multiple sclerosis: role in neurotherapeutics. 2005 , 2, 277-303	83
1674	Issues for clinical drug development in neurodegenerative diseases. 2005 , 65, 2463-79	2
1673	Diagnosis and management of acute myelopathies. 2005 , 11, 2-18	93
1672	Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis. 2005 , 53, 42-4	24
1671	Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management. 2005 , 76, 526-35	8
1670	Genetic variants of Complex I in multiple sclerosis. 2005 , 228, 55-64	28
1669	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. 2005 , 231, 29-34	378
1668	Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies. 2005 , 232, 65-9	24

1667	MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. 2005 , 234, 17-24	92
1666	The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis. 2005 , 235, 11-7	39
1665	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. 2005 , 237, 5-11	13
1664	Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. 2005 , 239, 95-9	42
1663	Multiple Sclerosis. 2005 , 103-131	
1662	Acquired Inflammatory White Matter Diseases. 2005 , 741-761	
1661	B-Cell Immunity in Multiple Sclerosis. 2005 , 113-130	
1660	Signs and Symptoms of Multiple Sclerosis. 2005 , 1-14	
1659	Differential Diagnosis, Clinical Features, and Prognosis of Multiple Sclerosis. 2005 , 15-53	7
1658	Role of Magnetic Resonance Imaging in the Diagnosis and Prognosis of Multiple Sclerosis. 2005 , 55-89	3
1657	Multiple Sclerosis. 2005 , 131-143	
1656	Seeing the Brain So We Can Save It: The Evolution of Magnetic Resonance Imaging as a Clinical Tool. 2005 , 3-19	
1655	MRI in multiple sclerosis. 2005 , 16, 383-409, viii	7
1654	Diagnosis and disease modifying treatments in multiple sclerosis. 2005 , 81, 556-61	6
1653	MR Imaging in White Matter Diseases of the Brain and Spinal Cord. 2005 ,	7
1652	Demyelinating Diseases of the Spinal Cord. 2005 , 269-277	
1651	Exercise therapy for multiple sclerosis. 2005 , CD003980	154
1650	Emerging therapies in multiple sclerosis. 2005 , 10, 797-816	10

1649	Transverse Myelitis. 2005 , 217-236	1
1648	Inflammatory Disorders of the Nervous System. 2005 ,	1
1647	Oral fingolimod (FTY720) for relapsing multiple sclerosis. 2006 , 355, 1124-40	877
1646	Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. 2006 , 12, 47-57	86
1645	Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. 2006 , 12, 294-301	102
1644	[Idiopathic acute transverse myelitis: application of new diagnosis criteria to 17 patients]. 2006 , 162, 980-9	1
1643	Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. 2006 , 12, 143-8	85
1642	Interferon Beta in Acute Optic Neuritis. 2006 , 30, 41-51	1
1641	Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. 2006 , 26, 150-5	10
1640	A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. 2006 , 22, 1671-8	36
1639	APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. 2006 , 66, 1373-83	72
1638	fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume. 2006 , 67, 1640-5	55
1637	Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. 2006 , 67, 1062-4	82
1636	Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. 2006 , 12, 2-12	47
1635	A case of multiple sclerosis masked by depression and diabetic neuropathy. 2006 , 47, 361-3	2
1634	A couvade syndrome variant?. 2006 , 47, 363-4	7
1633	[Strength, postural and gait changes following rehabilitation in multiple sclerosis: a preliminary study]. 2006 , 49, 143-9	16
1632	What went wrong in the natalizumab trials?. 2006 , 367, 708-10	13

1631	Is late-onset multiple sclerosis associated with a worse outcome?. 2006 , 67, 954-9	74
1630	Diagnosis and treatment of multiple sclerosis. 2006 , 332, 525-7	124
1629	Prevalence of multiple sclerosis in Isfahan, Iran. 2006 , 27, 39-44	107
1628	Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. 2006 , 29, 505-14	62
1627	Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. 2006 , 30, 891-8	188
1626	Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. 2006 , 33, 1029-35	120
1625	Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease. 2006 , 2, 143-6	1
1624	Update on multiple sclerosis. 2006 , 14, 203-24, vi	1
1623	3.0 T neuroimaging: technical considerations and clinical applications. 2006 , 16, 217-28, ix	28
1622	Diagnosis and management of multiple sclerosis: case studies. 2006 , 24, 199-214	4
1621	Interferon treatment may trigger primary headaches in multiple sclerosis patients. 2006 , 12, 476-80	34
1620	[Early detection of cognitive impairment in relapsing-remitting multiple sclerosis: functional-anatomical correlations and longitudinal follow-up]. 2006 , 162, 1221-31	8
1619	[Recent advances in the immunology of multiple sclerosis]. 2006 , 162, 162-73	2
1618	Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. 2006 , 4, 96	42
1617	Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. 2006 , 6, 1657-70	39
1616	Disease-modifying drugs for multiple sclerosis: current and future aspects. 2006 , 7 Suppl 1, S1-9	25
1615	A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. 2006 , 354, 899-910	2432
1614	Cognitive changes in early MS: a call for a common framework. 2006 , 245, 47-51	47

1613	Predicting neuropsychological abnormalities in multiple sclerosis. 2006 , 245, 67-72	49
1612	Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. 2006 , 245, 103-9	44
1611	Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. 2006 , 245, 161-7	38
1610	IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. 2006 , 241, 25-9	49
1609	Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. 2006 , 243, 21-30	85
1608	Unusual ocular motor findings in multiple sclerosis. 2006 , 243, 91-5	35
1607	Differences in cerebral activation patterns in idiopathic inflammatory demyelination using the paced visual serial addition task: an fMRI study. 2006 , 244, 11-6	22
1606	Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. 2006 , 244, 59-68	52
1605	Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis. 2006 , 246, 71-7	15
1604	Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients. 2006 , 246, 117-22	120
1603	Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. 2006 , 247, 202-7	50
1602	Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. 2006 , 249, 19-24	81
1601	Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis. 2006 , 249, 145-52	23
1600	Single nucleotide polymorphisms and functional analysis of MxA promoter region in multiple sclerosis. 2006 , 249, 153-7	11
1599	Ipsilateral silent period: a marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis?. 2006 , 250, 133-9	31
1598	Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. 2006 , 251, 91-7	21
1597	Revised diagnostic criteria for neuromyelitis optica. 2006 , 66, 1485-9	2125
1596	Update on multiple sclerosis. 2006 , 44, 79-100, viii	9

1595	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. 2006 , 67, 1242-9	601
1594	Association of pelvic endometriosis with alopecia universalis, autoimmune thyroiditis and multiple sclerosis. 2006 , 29, 182-9	24
1593	The development and validation of the impact of multiple sclerosis scale and the symptoms of multiple sclerosis scale. 2006 , 87, 832-41	10
1592	Suicidal ideation in multiple sclerosis. 2006 , 87, 1073-8	71
1591	Quality of life in multiple sclerosis: does information-processing speed have an independent effect?. 2006 , 21, 167-74	47
1590	The relationship between perceived and objective cognitive functioning in multiple sclerosis. 2006 , 21, 487-94	98
1589	Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. 2006 , 118, 77-82	48
1588	Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. 2006 , 108, 456-60	30
1587	Serum uric acid and multiple sclerosis. 2006 , 108, 527-31	76
1586	The spectrum of multiple sclerosis and treatment decisions. 2006 , 108, 333-8	25
1585	Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. 2006 , 108, 327-32	83
1584	Clinical, MRI, CSF and electrophysiological findings in different stages of multiple sclerosis. 2006 , 108, 271-4	23
1583	Enlargement of the spinal cord: inflammation or neoplasm?. 2006 , 108, 284-9	24
1582	CNS demyelination in autoimmune diseases. 2006 , 108, 318-26	10
1581	Prolonged intracortical delay of long-latency reflexes: electrophysiological evidence for a cortical dysfunction in multiple sclerosis. 2006 , 69, 606-13	8
1580	Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection. 2006 , 36, 69-74	16
1579	Gadolinium dose optimisation in patients with multiple sclerosis: intra- and inter-individual comparisons. 2006 , 57, 37-42	9
1578	Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. 2006 , 26, 208-14	76

1577	SELPLG and SELP single-nucleotide polymorphisms in multiple sclerosis. 2006 , 394, 92-6	13
1576	Bandes oligoclonales et index IgG interpr��t�� selon Reiber dans les maladies inflammatoires du syst��me nerveux central. 2006 , 21, 348-356	3
1575	Acute myelopathy of unknown aetiology: a follow-up investigation. 2006 , 13, 339-42	2
1574	Pediatric multiple sclerosis: detection of clinically silent lesions by multimodal evoked potentials. 2006 , 149, 125-7	42
1573	Multiple sclerosis in children. 2006 , 149, 8	
1572	Multiple sclerosis with childhood onset: report of 21 cases in Taiwan. 2006 , 35, 327-34	18
1571	Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. 2006 , 27, 1-9	63
1570	Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. 2006 , 113, 323.e1-323.e2	44
1569	Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. 2006 , 113, 324-32	497
1568	Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. 2006 , 22, 213-25	18
1567	Multiple sclerosis cerebrospinal fluid biomarkers. 2006 , 22, 187-96	47
1566	Multiple Sclerosis. 2006 , 615-632	2
1565	Influence of the cerebrospinal fluid laboratory parameters in the ELISA test for neurocysticercosis using a total cysticerci antigen. 2006 , 64, 55-9	3
1564	Learning of a novel visuo-postural co-ordination task in adults with multiple sclerosis. 2006 , 38, 295-301	17
1563	Preliminary studies on the clinical features of multiple sclerosis in Korea. 2006 , 2, 231-7	10
1562	Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. 2006 , 6, 460-5	10
1561	The diagnosis of multiple sclerosis. 2006 , 8, 93-6	
1560	Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. 2006 ,	

1559 Lumbar puncture by nurses extends competencies and improves patient access. **2006**, 2, 133-140

1558 Multiple sclerosis. 616-635

1557 Multiple Sclerosis. **2006**,

1556 Acute Relapses of Multiple Sclerosis. 433-442

1555 . **2006**,

3

1554 Interferon inhibitory activity in patients with multiple sclerosis. **2006**, 63, 1579-84

15

1553 Routine Cerebrospinal Fluid (CSF) Analysis. 14-27

1

1552 Correlates of pain interference in multiple sclerosis.. **2006**, 51, 166-174

15

1551 Corticosteroids for the long-term treatment in multiple sclerosis. **2006**,

3

1550 Use of Imaging in Multiple Sclerosis. 45-62

1549 Multidisciplinary rehabilitation for adults with multiple sclerosis. **2006**,

7

1548 Role of clinical neurophysiology in the diagnosis and management of visual disorders. **2006**, 59, 311-6

1

1547 Epidemiology and natural history of multiple sclerosis: new insights. **2006**, 19, 248-54

101

1546 Magnetic resonance imaging at 3.0 tesla detects more lesions in acute optic neuritis than at 1.5 tesla. **2006**, 41, 76-82

29

1545 Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). **2006**, 12, 549-58

494

1544 Magnetic resonance imaging of Asians with multiple sclerosis was similar to that of the West. **2006**, 33, 95-100

11

1543 Pediatric multiple sclerosis. **2006**, 12, 299-310

16

1542 Magnetic resonance spectroscopy and metabolic imaging in white matter diseases and pediatric disorders. **2006**, 17, 275-93

26

1541	Motion-onset and pattern-reversal visual evoked potentials in diagnostics of neuroborreliosis. 2006 , 23, 416-20	14
1540	Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. 2006 , 63, 847-50	50
1539	Three allele combinations associated with multiple sclerosis. 2006 , 7, 63	18
1538	A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. 2006 , 13, 61-71	41
1537	The epidemiology of multiple sclerosis in Europe. 2006 , 13, 700-22	424
1536	Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. 2006 , 13, 862-8	23
1535	Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. 2006 , 13, 913-22	209
1534	EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. 2006 , 13, 313-25	53
1533	Relevance of callosal and periventricular MRI lesions to oligoclonal bands in multiple sclerosis. 2006 , 113, 125-31	21
1532	Benign multiple sclerosis. 2006 , 183, 55-7	37
1531	Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease. 2006 , 113, 433-6	6
1530	A magnetization transfer MRI study of deep gray matter involvement in multiple sclerosis. 2006 , 16, 302-10	22
1529	Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. 2006 , 143, 305-13	38
1528	Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. 2006 , 64, 155-63	25
1527	Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. 2006 , 64, 609-22	33
1526	Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. 2006 , 14, 317-21	30
1525	Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. 2006 , 7, 310-5	44
1524	The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus. 2006 , 7, 327-34	23

1523	Mapping candidate non-MHC susceptibility regions to multiple sclerosis. 2006 , 7, 494-502	11
1522	A subtype of multiple sclerosis defined by an activated immune defense program. 2006 , 7, 522-31	75
1521	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. 2006 , 66, 1178-86	31
1520	The role of interferon beta in multiple sclerosis management. 2006 , 7, 15-19	1
1519	Relationships between brain water content and diffusion tensor imaging parameters (apparent diffusion coefficient and fractional anisotropy) in multiple sclerosis. 2006 , 16, 898-904	12
1518	Imaging of inflammatory lesions at 3.0 Tesla in patients with clinically isolated syndromes suggestive of multiple sclerosis: a comparison of fluid-attenuated inversion recovery with T2 turbo spin-echo. 2006 , 16, 1494-500	26
1517	Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results. 2006 , 16, 1104-10	70
1516	(1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. 2006 , 16, 489-95	47
1515	Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. 2006 , 16, 2067-73	74
1514	Multifocal visual evoked responses to dichoptic stimulation using virtual reality goggles: Multifocal VER to dichoptic stimulation. 2006 , 112, 189-99	6
1513	Frequency doubling illusion VEPs and automated perimetry in multiple sclerosis. 2006 , 113, 29-41	10
1512	Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis. 2006 , 21, 121-37	30
1511	The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. 2006 , 113, 339-45	29
1510	Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica. 2006 , 253, 111-3	8
1509	The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. 2006 , 253, 98-108	401
1508	Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. 2006 , 253, 208-13	11
1507	Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients. 2006 , 253, 231-6	14
1506	Deep gray matter and fatigue in MS: a T1 relaxation time study. 2006 , 253, 896-902	67

1505	Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association?. 2006 , 253, 928-34	46
1504	Cognition in the early stage of multiple sclerosis. 2006 , 253, 1002-10	138
1503	Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. 2006 , 253, 1034-40	19
1502	Multiple sclerosis in Jordan: A clinical and epidemiological study. 2006 , 253, 1210-6	77
1501	Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. 2006 , 253, 1331-6	49
1500	Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach. 2006 , 253 Suppl 1, I32-6	9
1499	Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. 2006 , 27, 58-62	23
1498	[Multiple sclerosis. An update with practical guidelines for ophthalmologists]. 2006 , 103, 621-41; quiz 642-3	3
1497	[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications]. 2006 , 77, 158, 160-2, 164	0
1496	[Revision of McDonald's new diagnostic criteria for multiple sclerosis]. 2006 , 77, 1235, 1237-45	6
1495	[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)]. 2006 , 77, 1506-18	42
1494	Pediatric multiple sclerosis. 2006 , 3, 264-75	27
1493	Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. 2006 , 6, 253-8	16
1492	A 32-year-old man with relapsing-progressive brainstem symptoms. 2006 , 5, 97-102	6
1491	OSMS is NMO, but not MS: proven clinically and pathologically. 2006 , 5, 110-1	63
1490	The measurement and clinical relevance of brain atrophy in multiple sclerosis. 2006 , 5, 158-70	341
1489	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. 2006 , 5, 221-7	94
1488	Secondary progressive multiple sclerosis: current knowledge and future challenges. 2006 , 5, 343-54	206

1487	Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. 2006 , 5, 565-71	34
1486	Case-control studies in the genomic era: a clinician's guide. 2006 , 5, 701-7	41
1485	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". 2006 , 5, 841-52	194
1484	In vitro Th2 deviation of myelin-specific peripheral blood lymphocytes from patients with multiple sclerosis. 2006 , 171, 156-62	3
1483	No association of leukemia inhibitory factor (LIF) DNA polymorphisms with multiple sclerosis. 2006 , 171, 189-92	5
1482	Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. 2006 , 171, 163-70	33
1481	An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. 2006 , 173, 196-9	32
1480	T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. 2006 , 174, 108-18	49
1479	IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. 2006 , 175, 176-82	47
1478	Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. 2006 , 176, 106-14	9
1477	Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. 2006 , 176, 153-61	52
1476	High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. 2006 , 176, 134-40	15
1475	Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. 2006 , 177, 146-50	29
1474	Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. 2006 , 177, 132-5	32
1473	Upregulation of myeloperoxidase in patients with optico-spinal multiple sclerosis: positive correlation with disease severity. 2006 , 178, 156-60	50
1472	Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. 2006 , 178, 130-9	37
1471	CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment. 2006 , 179, 163-72	15
1470	Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients. 2006 , 180, 40-9	19

1469	Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. 2006 , 180, 17-28		244
1468	CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. 2006 , 180, 178-84		109
1467	Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations. 2006 , 180, 193-8		11
1466	Increased serum levels of soluble CD14 indicate stable multiple sclerosis. 2006 , 181, 145-9		18
1465	Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy. 2006 , 7, 14		28
1464	Differential cognitive impairment for diverse forms of multiple sclerosis. 2006 , 7, 39		27
1463	Childhood multiple sclerosis: a review. 2006 , 12, 147-56		7
1462	pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. 2006 , 84, 1027-36		111
1461	Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2006 , 59, 237-47	9.4	84
1460	Overdiagnosis of multiple sclerosis by magnetic resonance imaging. <i>Annals of Neurology</i> , 2006 , 59, 575-6; author reply 576	9.4	5
1459	Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. <i>Annals of Neurology</i> , 2006 , 59, 780-7	9.4	160
1458	Exercise and myotonic dystrophy: a 31P magnetic resonance spectroscopy and magnetic resonance imaging case study. <i>Annals of Neurology</i> , 2006 , 59, 871-2	9.4	6
1457	Reply: To PMID 11456302. <i>Annals of Neurology</i> , 2006 , 59, 871	9.4	11
1456	Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. <i>Annals of Neurology</i> , 2006 , 60, 45-55	9.4	127
1455	Methylthioadenosine reverses brain autoimmune disease. <i>Annals of Neurology</i> , 2006 , 60, 323-34	9.4	52
1454	High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. 2006 , 63, 1388-93		48
1453	Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. 2006 , 12, 437-44		131
1452	Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. 2006 , 129, 1993-2007		34

1451	Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis. 2006 , 27, 28-32	17
1450	Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. 2006 , 129, 1031-9	83
1449	The role of spinal cord imaging in the diagnosis of multiple sclerosis. 2006 , 2, 283-6; quiz 287	2
1448	Brain acetylcholinesterase activity in FTDP-17 studied by PET. 2006 , 66, 1276-7	15
1447	Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. 2006 , 67, 511-3	84
1446	Complementary and alternative medicine use in veterans with multiple sclerosis: Prevalence and demographic associations. 2006 , 43, 99-110	23
1445	Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological tests. 2006 , 43, 73-82	48
1444	Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. 2006 , 354, 911-23	1048
1443	Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. 2006 , 77, 1030-5	114
1442	Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment. 2006 , 6, 843-55	11
1441	Neuro-ophthalmology and multiple sclerosis. 2006 , 56, 72-85	3
1440	Memory performance in multiple sclerosis patients correlates with central brain atrophy. 2006 , 12, 428-36	42
1439	Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. 2006 , 77, 1073-5	173
1438	Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. 2006 , 66, 576-8	94
1437	Increase in multiple sclerosis relapse rate following in vitro fertilization. 2006 , 66, 1280-1	43
1436	Increasing benefit of magnetic resonance imaging in multiple sclerosis. 2006 , 47, 960-71	2
1435	Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. 2006 , 39, 513-7	21
1434	Multiple sclerosis therapy monitoring based on gene expression. 2006 , 12, 3761-79	5

1433	The clinical features, MRI findings, and outcome of optic neuritis in children. 2006 , 67, 258-62	151
1432	Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. 2006 , 43, 83-90	29
1431	Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. 2006 , 66, 572-5	46
1430	Trichotillomania: an NREM sleep parasomnia?. 2006 , 66, 1276	23
1429	Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine. 2006 , 12, 652-8	5
1428	The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. 2006 , 12, 24-38	198
1427	The relation between menarche and the age of first symptoms in a multiple sclerosis cohort. 2006 , 12, 333-9	43
1426	Immunogenetics of Autoimmune Disease. 2006 ,	
1425	Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. 2006 , 12, 58-65	88
1424	CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population. 2006 , 12, 511-4	37
1423	Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. 2006 , 77, 185-8	36
1422	Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. 2006 , 77, 830-3	136
1421	Ventricular enlargement in MS: one-year change at various stages of disease. 2006 , 66, 693-8	35
1420	Neuromyelitis optica (Devic's syndrome) as first manifestation of systemic lupus erythematosus. 2006 , 15, 107-9	45
1419	Trigeminal somatosensory evoked potentials in multiple sclerosis: a case report. 2006 , 37, 243-6	2
1418	Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. 2006 , 63, 614-9	73
1417	Prognostic factors for early severity in a childhood multiple sclerosis cohort. 2006 , 118, 1133-9	89
1416	Handbook of Multiple Sclerosis. 2006 ,	6

1415	Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. 2006 , 63, 1301-6	253
1414	REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. 2006 , 66, 1277-9	86
1413	Balance performance in three forms of multiple sclerosis. 2006 , 28, 555-62	81
1412	Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. 2006 , 12, 302-8	20
1411	Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. 2006 , 12, 253-64	26
1410	Differential effects of left and right hemispheric seizure onset on heart rate. 2006 , 66, 1279-80	8
1409	Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. 2006 , 332, 875-84	43
1408	Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. 2006 , 77, 739-42	40
1407	Antibiotic use and risk of multiple sclerosis. 2006 , 163, 997-1002	39
1406	Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. 2006 , 66, 472-6	128
1405	Men transmit MS more often to their children vs women: the Carter effect. 2006 , 67, 305-10	66
1404	Demyelinating diseases. 2006 , 59, 1151-9	187
1403	Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. 2006 , 176, 3293-8	91
1402	Brain atrophy in multiple sclerosis: what we know and would like to know. 2006 , 12, 679-87	62
1401	De-stabilizing and training effects of foot orthoses in multiple sclerosis. 2006 , 12, 219-26	31
1400	Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. 2006 , 12, 354-6	38
1399	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. 2006 , 67, 968-72	209
1398	Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. 2006 , 6, 333-46	15

1397	Evaluation of the Optic Nerve Head Using Confocal Scanning Laser Ophthalmoscopy in Patients with Multiple Sclerosis. 2006 , 30, 23-28	1
1396	Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. 2006 , 129, 1493-506	172
1395	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. 2006 , 67, 881-3	35
1394	Activities of daily living and social activities in people with multiple sclerosis in Stockholm County. 2006 , 20, 543-51	75
1393	The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. 2006 , 22, 223-39	21
1392	Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis. 2006 , 6, 323-31	7
1391	Working memory deficits in multiple sclerosis: comparison between the n-back task and the Paced Auditory Serial Addition Test. 2006 , 12, 677-87	51
1390	Differential expression of CD11c by peripheral blood NK cells reflects temporal activity of multiple sclerosis. 2006 , 177, 5659-67	34
1389	Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis. 2006 , 66, 1568-70	18
1388	Optic neuritis and the neuro-ophthalmology of multiple sclerosis. 2007 , 79, 633-63	20
1387	Diagnostic biomarkers in multiple sclerosis. 2007 , 1, 225-33	2
1386	Prognostic factors in multiple sclerosis. 2007 , 79, 423-47	76
1385	Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. 2007 , 7, 271-9	17
1384	Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. 2007 , 68, 283-7	42
1383	MRI features of pediatric multiple sclerosis. 2007 , 68, S46-53	57
1382	Interlaboratory reproducibility of isoelectric focusing in oligoclonal band detection. 2007 , 53, 1557-8	24
1381	Neck pain and calcium deposition. 2007 , 68, 383	
1380	Clinically isolated syndromes: predicting and delaying multiple sclerosis. 2007 , 68, S12-5	45

1379	The paradox in translational medicine. 2007 , 53, 1553	23
1378	Serum and plasma cardiac troponin I 99th percentile reference values for 3 2nd-generation assays. 2007 , 53, 1558-60	42
1377	Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. 2007 , 13, 269-71	61
1376	Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. 2007 , 13, 376-85	74
1375	Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. 2007 , 13, 25-32	32
1374	Recognition by French courts of compensation for post-vaccination multiple sclerosis: the consequences with regard to expert practice. 2007 , 47, 185-90	3
1373	A dinucleotide deletion in CD24 confers protection against autoimmune diseases. 2007 , 3, e49	61
1372	Validation of the NARCOMS registry: diagnosis. 2007 , 13, 770-5	92
1371	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. 2007 , 13, 412-9	68
1370	Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). 2007 , 13, 645-51	41
1369	Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. 2007 , 13, 336-42	31
1368	Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. 2007 , 69, 1224-9	46
1367	Detection of autoantibodies against NMDA-type glutamate receptor in a patient with recurrent optic neuritis and transient cerebral lesions. 2007 , 38, 257-60	24
1366	UCP2 and mitochondrial haplogroups as a multiple sclerosis risk factor. 2007 , 13, 454-8	16
1365	Intracranial venous haemodynamics in multiple sclerosis. 2007 , 4, 252-8	88
1364	Vestibular click-evoked myogenic potentials: sensitivity and factors determining abnormality in patients with multiple sclerosis. 2007 , 13, 193-8	40
1363	Clinical evaluation of a speed optimized T2 weighted fast spin echo sequence at 3.0 T using variable flip angle refocusing, half-Fourier acquisition and parallel imaging. 2007 , 80, 668-73	5
1362	The accuracy of prevalence rates of multiple sclerosis: a critical review. 2007 , 29, 150-5	38

1361	Chapter 13 Differential Diagnosis of Acquired Causes of Spastic Paraplegia. 2007 , 31, 286-295	
1360	Acute fulminant demyelinating disease: a descriptive study of 60 patients. 2007 , 64, 1426-32	117
1359	Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. 2007 , 130, 2220-31	139
1358	Sexual dysfunction and sympathetic skin response recorded from the genital region in women with multiple sclerosis. 2007 , 13, 742-8	25
1357	Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. 2007 , 64, 1292-8	41
1356	[Diagnosis and pharmacological treatment of multiple sclerosis]. 2007 , 75, 363-71; quiz 372-4	
1355	Relapsing neuromyelitis optica and relapsing-remitting multiple sclerosis: differentiation at diffusion-tensor MR imaging of corpus callosum. 2007 , 244, 249-56	32
1354	Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. 2007 , 7, 35-63	31
1353	T-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies. 2007 , 3, 57-72	6
1352	Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. 2007 , 188, 697-702	47
1351	Relation of vision to global and regional brain MRI in multiple sclerosis. 2007 , 69, 2128-35	56
1350	Optic neuritis. 2007 , 27, 211-20	12
1349	The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. 2007 , 130, 2543-53	151
1348	Conjugal multiple sclerosis in Isfahan, Iran: a population-based study. 2007 , 13, 673-5	6
1347	Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis. 2007 , 67, 696-706	13
1346	A population-based survey of multiple sclerosis in Shanghai, China. 2007 , 68, 1495-500	48
1345	MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. 2008 , 79, 646-51	46
1344	Consensus definitions proposed for pediatric multiple sclerosis and related disorders. 2007 , 68, S7-12	594

1343	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. 2007 , 13, 975-80	21
1342	Clinical features of children and adolescents with multiple sclerosis. 2007 , 68, S37-45	91
1341	Neurodegeneration in Multiple Sclerosis. 2007 ,	
1340	Predictors of well-being among significant others of persons with multiple sclerosis. 2007 , 13, 238-49	37
1339	Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. 2007 , 64, 1416-22	249
1338	Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. 2007 , 13, 7-16	38
1337	Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. 2007 , 179, 1322-30	190
1336	The differential diagnosis of Axis I psychopathology presenting to a university-based multiple sclerosis clinic. 2007 , 13, 749-53	8
1335	An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis. 2007 , 13, 697-700	7
1334	Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria. 2007 , 13, 622-5	11
1333	Optical coherence tomography and disease subtype in multiple sclerosis. 2007 , 69, 2085-92	235
1332	Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. 2007 , 13, 701-7	20
1331	More severe disability of North Africans vs Europeans with multiple sclerosis in France. 2007 , 68, 29-32	50
1330	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. 2007 , 13, 722-30	81
1329	Low choline concentrations in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. 2007 , 28, 1306-12	23
1328	Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. 2007 , 13, 717-21	5
1327	The relationship between subjective fatigue and cognitive fatigue in advanced multiple sclerosis. 2007 , 13, 73-80	89
1326	Increased transcriptional activity of milk-related genes following the active phase of experimental autoimmune encephalomyelitis and multiple sclerosis. 2007 , 179, 4074-82	16

1325	Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. 2007 , 69, 1603-9	317
1324	The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study. 2007 , 13, 402-11	25
1323	Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. 2007 , 13, 95-105	58
1322	Subtle upper limb impairment in asymptomatic multiple sclerosis subjects. 2007 , 13, 428-32	27
1321	Multiple sclerosis in children: clinical, diagnostic, and therapeutic aspects. 2007 , 79, 269-79	5
1320	The relationship between HLA-DRB1 alleles and optic neuritis in Irish patients and the risk of developing multiple sclerosis. 2007 , 91, 1288-92	3
1319	Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. 2007 , 13, 124-7	190
1318	Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. 2007 , 13, 313-31	52
1317	Validity of performance scales for disability assessment in multiple sclerosis. 2007 , 13, 1176-82	200
1316	Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. 2007 , 68, 1045-50	122
1315	Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. 2007 , 64, 196-202	121
1314	Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-I. 2007 , 68, 206-13	40
1313	A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. 2007 , 13, 265-8	19
1312	Migraine in multiple sclerosis. 2007 , 79, 281-302	10
1311	Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. 2007 , 161, 1176-82	50
1310	Walking capacities in multiple sclerosis measured by global positioning system odometer. 2007 , 13, 220-3	31
1309	Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. 2007 , 28, 1645-9	157
1308	Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. 2007 , 16, 2659-68	79

1307	Truth-telling, autonomy and paternalism in healthcare: a commentary on the case of Gary Dimmock v East Sussex NHS Trust. 2007 , 13, 226-228	1
1306	Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis--a two-year longitudinal MRI/MRSI study of corpus callosum. 2007 , 13, 41-51	46
1305	An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis. 2007 , 13, 895-9	11
1304	Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors. 2007 , 13, 985-95	92
1303	Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients. 2007 , 13, 1138-45	13
1302	One question as a screening instrument for depression in people with multiple sclerosis. 2007 , 21, 460-4	22
1301	Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. 2007 , 13, 52-7	238
1300	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. 2007 , 13, 731-6	4
1299	Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. 2007 , 13, 1086-94	41
1298	Challenges in the classification of pediatric multiple sclerosis and future directions. 2007 , 68, S70-4	22
1297	[Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg)]. 2007 , 129, 209-17	
1296	Multiple sclerosis: diagnosis and definitions. 1-27	
1295	NeuroBj^¶lgren's Syndrome. 179-184	
1294	Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. 2007 , 64, 190-4	23
1293	Multiple Sclerosis. 2007 ,	
1292	HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. 2007 , 110, 568-77	149
1291	Multiple Sclerosis. 27-82	
1290	Improved CSF classification and lesion detection in MR brain images with multiple sclerosis. 2007 ,	4

1289	Diagnosis and treatment of neuromyelitis optica. 2007 , 13, 2-11	82
1288	Amantadine for fatigue in multiple sclerosis. 2007 , CD002818	72
1287	A retrospective study of multiple sclerosis in Siriraj Hospital, Bangkok, Thailand. 2007 , 34, 99-104	14
1286	Reliability of visual temporal thresholds. 2007 , 34, 433-7	
1285	Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis. 2007 , 20, 531-40	3
1284	Natural history of the visual impairment of relapsing neuromyelitis optica. 2007 , 114, 810-5	116
1283	Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients. 2007 , 204, 759-66	6
1282	Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis. 2007 , 109, 23-6	9
1281	Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population. 2007 , 109, 32-7	10
1280	Epidemiology of multiple sclerosis in western Herzegovina. 2007 , 109, 779-83	12
1279	Re: Inamasu J, Nakatsukasa M, Blood patch for spontaneous intracranial hypotension caused by cerebrospinal fluid leak at C1-2, Clin Neurol Neurosurg (2007), doi:10.1016/j.clineuro.2007.05.006. 2007 , 109, 933-4	
1278	Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. 2007 , 29, 1128-45	34
1277	Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. 2007 , 17, 472-9	38
1276	[Increased risk of relapse in multiple sclerosis patients after ovarian stimulation for in vitro fertilization]. 2007 , 35, 1047-50	10
1275	Interferons in multiple sclerosis: ten years' experience. 2007 , 89, 899-902	17
1274	The cost of multiple sclerosis in Australia. 2007 , 14, 532-9	28
1273	Clinical characteristics of multiple sclerosis and associated optic neuritis in Korean children. 2007 , 11, 559-63	7
1272	APOE genotypes in African American female multiple sclerosis patients. 2007 , 414, 51-6	11

1271	Aberrant transcriptional regulatory network in T cells of multiple sclerosis. 2007 , 422, 30-3	22
1270	Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. 2007 , 425, 173-6	5
1269	The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis. 2007 , 68, 934-7	29
1268	Importance of axial postcontrast images in the differential diagnosis between inflammatory and neoplastic spinal cord enlargement. 2007 , 109, 931-3	3
1267	Diffusion tensor imaging of post mortem multiple sclerosis brain. 2007 , 35, 467-77	306
1266	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. 2007 , 36, 746-54	42
1265	Fractal dimension and white matter changes in multiple sclerosis. 2007 , 36, 543-9	73
1264	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. 2007 , 36, 1294-300	100
1263	Structure of WM bundles constituting the working memory system in early multiple sclerosis: a quantitative DTI tractography study. 2007 , 36, 1324-30	83
1262	Distinct mechanisms of altered brain activation in patients with multiple sclerosis. 2007 , 37, 937-46	57
1261	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. 2007 , 370, 389-97	417
1260	Esclerosis múltiple. Concepto. Etiopatogenia. Fisiopatología. Manifestaciones clínicas. Investigaciones paraclínicas. Diagnóstico. Historia natural. 2007 , 9, 4867-4877	
1259	Protocolo diagnóstico del paciente con sospecha de enfermedad desmielinizante. 2007 , 9, 4901-4904	
1258	Protocolo terapéutico de la esclerosis múltiple. 2007 , 9, 4913-4916	
1257	Familial effects on the clinical course of multiple sclerosis. 2007 , 68, 376-83	65
1256	Interferon-beta1b in multiple sclerosis. 2007 , 7, 227-39	34
1255	Multiple sclerosis in Isfahan, Iran. 2007 , 79, 357-75	84
1254	Prevalence of multiple sclerosis in Bogotá, Colombia. 2007 , 28, 33-8	35

1253	Risk alleles for multiple sclerosis identified by a genomewide study. 2007 , 357, 851-62	1327
1252	[Contribution of cognitive evoked potentials for detecting early cognitive disorders in multiple sclerosis]. 2007 , 163, 1065-74	7
1251	[Mills' syndrome: a rare clinical entity]. 2007 , 163, 335-40	5
1250	An Ontology Approach for Classification of Abnormal White Matter in Patients with Multiple Sclerosis. 2007 , 389-402	
1249	Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. 2007 , 13, 224-31	84
1248	Cerebrospinal fluid analysis in multiple sclerosis. 2007 , 79, 341-56	22
1247	Immune Regulation and Immunotherapy in Autoimmune Disease. 2007 ,	
1246	Identification of molecular biomarkers for multiple sclerosis. 2007 , 9, 197-204	22
1245	Treatment for ataxia in multiple sclerosis. 2007 , CD005029	56
1244	Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control. 2007 , 13, 1161-7	69
1243	A follow-up study of Nordic multiple sclerosis candidate gene regions. 2007 , 13, 584-9	
1242	Immunopathogenesis of Multiple Sclerosis: Overview. 2007 , 171-187	
1241	Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. 2007 , 21, 331-7	79
1240	Clinical Features of Optic Neuritis in China. 2007 , 31, 133-136	15
1239	Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. 2007 , 130, 2589-95	139
1238	The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. 2007 , 23, 2667-76	63
1237	Longitudinal neuropsychological assessment in pediatric multiple sclerosis. 2007 , 32, 625-44	74
1236	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. 2007 , 68, 1390-401	260

1235	Differential diagnosis of multiple sclerosis. 2007 , 79, 393-422	21
1234	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. 2007 , 23, 2823-32	7
1233	Cerebrospinal fluid proteome profile in multiple sclerosis. 2007 , 13, 840-9	62
1232	Predictors of subjective well-being among individuals with multiple sclerosis. 2007 , 21, 239-62	34
1231	Lack of association between antimyelin antibodies and progression to multiple sclerosis. 2007 , 356, 371-8	197
1230	Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. 2007 , 29, 215-23	66
1229	Thalamic atrophy and cognition in multiple sclerosis. 2007 , 69, 1213-23	363
1228	[Phenotypical aspects and clinical course of multiple sclerosis in 76 patients with a North African ethnic background followed at the Nice University Hospital]. 2007 , 163, 440-7	12
1227	Les formes aiguës de maladies inflammatoires démyélinisantes du système nerveux central. 2007 , 16, 329-333	1
1226	Clinical and immunologic evaluation of women with multiple sclerosis during and after pregnancy. 2007 , 4, 45-55	37
1225	[Pseudotumoral presentation of multiple sclerosis]. 2007 , 53, 379-82	1
1224	Multidisciplinary rehabilitation for adults with multiple sclerosis. 2007 , CD006036	128
1223	Inflammatory demyelination and neurodegeneration in early multiple sclerosis. 2007 , 259, 7-15	60
1222	Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. 2007 , 252, 57-61	135
1221	Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study. 2007 , 252, 121-9	35
1220	MRI relapses have significant pathologic and clinical implications in multiple sclerosis. 2007 , 256 Suppl 1, S19-22	14
1219	The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. 2007 , 258, 69-74	33
1218	Multiple Sclerosis in Keralite siblings after migration to the Middle East: a report of familial Multiple Sclerosis from India. 2007 , 260, 244-8	2

1217	Migration and multiple sclerosis: the French West Indies experience. 2007 , 262, 117-21	20
1216	Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. 2007 , 263, 15-9	104
1215	[Multiple sclerosis presenting as acute psychosis]. 2007 , 129, 718-9	1
1214	Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study. 2007 , 4, 16	14
1213	Demyelinating and infectious diseases of the spinal cord. 2007 , 17, 37-55	17
1212	Esclerosis múltiple. Una visión general. 2007 , 6, 147-150	
1211	Dietary interventions for multiple sclerosis. 2007 , CD004192	27
1210	HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. 2007 , 79, 521-35	47
1209	[Relation between fatigue and autonomic disturbances in multiple sclerosis]. 2007 , 65, 663-8	14
1208	Demyelinating Disorders of the Central Nervous System. 2007 , 1103-1133	6
1207	Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. 2007 , 2, e595	68
1206	HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. 2007 , 2, e664	125
1205	Safety of vitamin D3 in adults with multiple sclerosis. 2007 , 86, 645-51	175
1204	Perceived behavioral changes in early multiple sclerosis. 2007 , 18, 81-90	25
1203	Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. 2007 , 65, 15-9	8
1202	Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis. 2007 , 2, 117727190700200	5
1201	[Health-related quality of life in multiple sclerosis]. 2007 , 65, 454-60	7
1200	Electrophysiological evidence for heterogeneity of lesions in optic neuritis. 2007 , 48, 4549-56	46

1199	Corpus callosum index: a practical method for long-term follow-up in multiple sclerosis. 2007 , 65, 931-5		41
1198	Prevalence of multiple sclerosis in the city of Santos, SP. 2007 , 10, 479-482		19
1197	W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th century. 2007 , 64, 452-4		2
1196	. 2007 ,		
1195	Neuroimaging correlates of cognitive dysfunction. 178-213		
1194	Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. 2007 , 56, 2774-83		43
1193	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. 2007 , 56, 3420-32		44
1192	Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 62, 197-200; discussion 205	9.4	15
1191	Cleavage of cystatin C is not associated with multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 62, 201-4; discussion 205	9.4	33
1190	A second major histocompatibility complex susceptibility locus for multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 61, 228-36	9.4	140
1189	Promises, promises. <i>Annals of Neurology</i> , 2007 , 61, 1-2	9.4	1
1188	New natural history of interferon-beta-treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 61, 300-6	9.4	208
1187	Imaging correlates of axonal swelling in chronic multiple sclerosis brains. <i>Annals of Neurology</i> , 2007 , 62, 219-28	9.4	97
1186	Compensatory activations in patients with multiple sclerosis during preserved performance on the auditory N-back task. 2007 , 28, 424-30		48
1185	Effect of corpus callosum damage on ipsilateral motor activation in patients with multiple sclerosis: a functional and anatomical study. 2007 , 28, 636-44		97
1184	Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. 2007 , 26, 41-51		196
1183	Application of voxelwise analysis in the detection of regions of reduced fractional anisotropy in multiple sclerosis patients. 2007 , 26, 552-6		11
1182	A cytokine immunosensor for multiple sclerosis detection based upon label-free electrochemical impedance spectroscopy. 2007 , 23, 428-31		32

1181	Interferon-beta treatment for multiple sclerosis. 2007 , 4, 633-46	56
1180	MRI in multiple sclerosis: what's inside the toolbox?. 2007 , 4, 602-17	70
1179	Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. 2007 , 1, 963-71	15
1178	Candidate antigens specifically detected by cerebrospinal fluid-IgG in oligoclonal IgG bands-positive multiple sclerosis patients. 2007 , 1, 681-7	2
1177	In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. 2007 , 13, 1253-8	243
1176	SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. 2008 , 71, 42-50	38
1175	Neuromyelitis optica following CMV primo-infection. 2007 , 261, 500-3	24
1174	Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. 2007 , 147, 412-8	145
1173	Fibronectin is elevated in the cerebrospinal fluid of patients suffering from bacterial meningitis and enhances inflammation caused by bacterial products in primary mouse microglial cell cultures. 2007 , 102, 2049-2060	18
1172	Unilateral progressive brain lesions confirmed as multiple sclerosis. 2007 , 14, e34-5	2
1171	CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. 2007 , 14, 162-7	19
1170	False perception of visual verticality in multiple sclerosis. 2007 , 14, 228-32	15
1169	Modafinil improves primary nocturnal enuresis in multiple sclerosis. 2007 , 14, e1	1
1168	Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran. 2007 , 14, 403-7	19
1167	High prevalence of restless legs syndrome in multiple sclerosis. 2007 , 14, 534-9	108
1166	The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. 2007 , 14, 835-40	60
1165	Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. 2007 , 14, 907-11	33
1164	Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort. 2007 , 14, 1048-52	25

1163	Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. 2007 , 14, 1216-21	45
1162	The role of MRI of the brain and spinal cord, and CSF examination for the diagnosis of primary progressive multiple sclerosis. 2007 , 14, 1292-5	7
1161	Early relapse risk after a first CNS inflammatory demyelination episode: examining international consensus definitions. 2007 , 49, 887-93	53
1160	Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. 2007 , 17, 61-8	44
1159	Conventional MRI in multiple sclerosis. 2007 , 17 Suppl 1, 35-9S	46
1158	Detection of anti-Nogo receptor autoantibody in the serum of multiple sclerosis and controls. 2007 , 115, 153-60	11
1157	Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients. 2007 , 115, 67-72	49
1156	Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. 2007 , 115, 137-46	159
1155	Cerebrospinal fluid IgG profiles and oligoclonal bands in Chinese patients with multiple sclerosis. 2007 , 115, 319-24	8
1154	Isoelectric focusing is superior to immunofixation electrophoresis in diagnosing CNS inflammation. 2007 , 115, 122-5	11
1153	Antibodies against light neurofilaments in multiple sclerosis patients. 2007 , 116, 100-7	38
1152	Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. 2007 , 115, 325-30	38
1151	Chemokine receptor CCR5 in interferon-treated multiple sclerosis. 2007 , 115, 413-8	13
1150	Nosology of idiopathic transverse myelitis syndromes. 2007 , 115, 371-6	51
1149	Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. 2007 , 116, 207-10	16
1148	The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis. 2007 , 116, 231-4	4
1147	Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review. 2007 , 116, 201-6	31
1146	CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. 2007 , 123, 105-13	50

1145	Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. 2007 , 124, 284-93	24
1144	Intrathecal synthesis of anti-viral antibodies in pediatric patients. 2007 , 11, 29-34	16
1143	Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. 2007 , 11, 90-5	128
1142	Progressive impairment of autonomic control of heart rate in patients with multiple sclerosis. 2007 , 38, 322-5	31
1141	COX-2 promoter region polymorphisms in multiple sclerosis: lack of association of -765G>C with disease risk. 2007 , 34, 71-4	3
1140	Detection of anti-heat shock protein 90 beta (Hsp90beta) antibodies in cerebrospinal fluid. 2007 , 318, 153-7	7
1139	Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. 2007 , 183, 168-74	33
1138	Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. 2007 , 184, 227-31	72
1137	ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. 2007 , 186, 193-8	20
1136	Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. 2007 , 187, 139-46	57
1135	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. 2007 , 187, 159-65	40
1134	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. 2007 , 188, 146-58	39
1133	Detection of apoptotic cells in cerebrospinal fluid of patients suffering from neurological disease. 2007 , 188, 175-80	1
1132	IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. 2007 , 189, 102-10	27
1131	Matrix metalloproteinase-9 -1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. 2007 , 189, 147-50	21
1130	ITGA4 polymorphisms and susceptibility to multiple sclerosis. 2007 , 189, 151-7	11
1129	TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. 2007 , 190, 170-6	33
1128	Genetic association analysis of the interleukin 7 gene (IL7) in multiple sclerosis. 2007 , 192, 171-3	17

1127	Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis. 2007 , 192, 219-25	33
1126	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. 2007 , 6, 677-86	246
1125	New MRI criteria in the diagnosis of multiple sclerosis. 2007 , 6, 664-5	5
1124	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. 2007 , 6, 773-81	249
1123	The spectrum of neuromyelitis optica. 2007 , 6, 805-15	1584
1122	Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. 2007 , 6, 887-902	294
1121	Primary-progressive multiple sclerosis. 2007 , 6, 903-12	325
1120	Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. 2007 , 17, 67-71	10
1119	Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications. 2007 , 13, 347-52	41
1118	Current treatment options in multiple sclerosis. 2007 , 9, 176-86	9
1117	Idiopathic inflammatory-demyelinating diseases of the central nervous system. 2007 , 49, 393-409	91
1116	Neurological manifestations of connective tissue diseases mimicking multiple sclerosis. 2007 , 28, 15-20	7
1115	[Steroids for optic nerve diseases?]. 2007 , 104, 517-20	0
1114	[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]. 2007 , 78, 883-911	2
1113	[Simultaneous presentation of amyotrophic lateral sclerosis and multiple sclerosis]. 2007 , 78, 1440-3	5
1112	Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage. 2007 , 37, 221-8	2
1111	Validation and cross-cultural adaptation of the disease-specific questionnaire MSQOL-54 in Serbian multiple sclerosis patients sample. 2007 , 16, 1383-7	30
1110	Pattern visual evoked potentials in Japanese patients with multiple sclerosis without history of visual pathway involvement. 2007 , 115, 105-9	7

1109	Erfolgreiche Behandlung einer Multiplen Sklerose vom Typ Marburg mit Mitoxantron. 2007 , 44, 515-519	
1108	The "enhanced N35" somatosensory evoked potential: its associations and potential utility in the clinical evaluation of dystonia and myoclonus. 2007 , 254, 46-52	17
1107	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. 2007 , 254, 78-83	15
1106	X-linked Charcot-Marie-Tooth disease and multiple sclerosis. 2007 , 254, 953-5	13
1105	Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities. 2007 , 254, 220-7	24
1104	A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. 2007 , 254, 306-14	24
1103	Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. 2007 , 254, 471-7	191
1102	Treatment of active secondary progressive multiple sclerosis with treosulfan. 2007 , 254, 884-9	20
1101	Cortical atrophy is relevant in multiple sclerosis at clinical onset. 2007 , 254, 1212-20	182
1100	Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. 2007 , 254, 1370-5	17
1099	Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort. 2007 , 254, 1736-41	70
1098	Spectral filters can improve reading and visual search in patients with multiple sclerosis. 2007 , 254, 1729-35	21
1097	Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. 2007 , 254 Suppl 2, II53-7	29
1096	Complex gene-gene interactions in multiple sclerosis: a multifactorial approach reveals associations with inflammatory genes. 2007 , 8, 11-20	31
1095	Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis. 2007 , 8, 201-5	16
1094	The role of the clinician in interpreting conventional neuroimaging findings in migraine patients. 2007 , 28 Suppl 2, S114-7	9
1093	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. 2007 , 28, 127-32	49
1092	Multiple sclerosis and headache co-morbidity. A case-control study. 2007 , 28, 133-5	43

1091	New directions in optic neuritis and multiple sclerosis. 2007 , 7, 259-64	5
1090	A cytoskeleton motor protein genetic variant may exert a protective effect on the occurrence of multiple sclerosis: the janus face of the kinesin light-chain 1 56836CC genetic variant. 2007 , 9, 335-9	8
1089	Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b. 2007 , 32, 169-78	28
1088	The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis. 2007 , 112, 1244-51	4
1087	Omega-3 fatty acids and multiple sclerosis: relationship to depression. 2008 , 31, 127-35	17
1086	Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. 2008 , 28, 122-30	14
1085	[Choice of early and escalation treatment options for multiple sclerosis]. 2008 , 79, 1123-4,1126-8,1130-2 passim	0
1084	[Acute disseminated encephalomyelitis]. 2008 , 48, 553-9	3
1083	[Magnetic resonance spectroscopy for inflammatory brain diseases]. 2008 , 48, 582-7	4
1082	Late-onset tumefactive multiple sclerosis. 2008 , 26, 549-52	7
1081	Pediatric multiple sclerosis. 2008 , 8, 434-41	24
1080	A case of longitudinally extensive transverse myelitis (LETM): neuromyelitis optica. 2008 , 27 Suppl 2, S67-9	40
1079	Primary headache and multiple sclerosis: preliminary results of a prospective study. 2008 , 29 Suppl 1, S146-8	36
1078	Clustering of organ-specific autoimmunity: a case presentation of multiple sclerosis and connective tissue disorders. 2008 , 29, 471-5	6
1077	Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome. 2008 , 29, 435-44	14
1076	Typical trigeminal neuralgia associated with brainstem white matter lesions on MRI in patients without criteria of multiple sclerosis. 2008 , 150, 1157-61	14
1075	[Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis]. 2008 , 158, 98-109	1
1074	Head and Neck Imaging. 2008 , 18, 35-45	

1073	Acute transverse myelitis with normal brain MRI : long-term risk of MS. 2008 , 255, 89-93	28
1072	Preserved decision making ability in early multiple sclerosis. 2008 , 255, 1762-9	17
1071	Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. 2008 , 255, 1449-63	173
1070	Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?. 2008 , 255, 183-91	59
1069	Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. 2008 , 255, 231-8	73
1068	Contribution of relapses to disability in multiple sclerosis. 2008 , 255, 280-7	105
1067	Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. 2008 , 255, 581-6	102
1066	Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. 2008 , 255, 623-7	58
1065	Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. 2008 , 255, 848-52	39
1064	A three-year, multi-parametric MRI study in patients at presentation with CIS. 2008 , 255, 683-91	65
1063	Clinical characteristics of patients with late-onset multiple sclerosis. 2008 , 255, 697-702	74
1062	Bal ⁺ β concentric sclerosislike lesion in the brainstem of a multiple sclerosis patient. 2008 , 255, 760-1	14
1061	Identification of internuclear ophthalmoplegia signs in multiple sclerosis patients. Saccade test analysis. 2008 , 255, 1006-11	15
1060	Does high field MRI allow an earlier diagnosis of multiple sclerosis?. 2008 , 255, 1159-63	50
1059	A clinically isolated syndrome: a challenging entity: multiple sclerosis or collagen tissue disorders: clues for differentiation. 2008 , 255, 1625-35	11
1058	Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. 2008 , 255, 1473-8	25
1057	Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. 2008 , 255, 1508-14	96
1056	Rationale for early intervention with immunomodulatory treatments. 2008 , 255 Suppl 1, 37-43	71

1055	The search for a balance between short and long-term treatment outcomes in multiple sclerosis. 2008 , 255 Suppl 1, 75-83		7
1054	Immunomodulatory treatment strategies in multiple sclerosis. 2008 , 255 Suppl 6, 15-21		23
1053	Isolated, relapsing and progressive demyelinating diseases of the central nervous system. 2008 , 255 Suppl 6, 69-76		10
1052	Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. 2008 , 255 Suppl 6, 109-14		26
1051	Diagnostic algorithm for the differentiation of leukodystrophies in early MS. 2008 , 255 Suppl 6, 123-6		19
1050	Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. 2008 , 8, 1576-85		57
1049	Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. 2008 , 17, 565-76		65
1048	Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. 2008 , 21, 589-97		152
1047	IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. 2008 , 38, 576-86		104
1046	Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. 2008 , 38, 1297-309		18
1045	Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals. 2008 , 38, 1889-99		45
1044	Functional cortical changes of the sensorimotor network are associated with clinical recovery in multiple sclerosis. 2008 , 29, 562-73		69
1043	Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. <i>Annals of Neurology</i> , 2008 , 63, 98-111	9.4	65
1042	Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. <i>Annals of Neurology</i> , 2008 , 63, 395-400	9.4	386
1041	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 63, 611-20	9.4	143
1040	Impact of exposure to war stress on exacerbations of multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 64, 143-8	9.4	47
1039	Will Rogers phenomenon in multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 64, 428-33	9.4	66
1038	Axonal loss and myelin in early ON loss in postacute optic neuritis. <i>Annals of Neurology</i> , 2008 , 64, 325-31	9.4	120

1037	Texture analysis of multiple sclerosis: a comparative study. 2008 , 26, 1160-6	72
1036	Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. 2008 , 14, 577-94	31
1035	Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. 2008 , 14, 73-7	51
1034	Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. 2008 , 14, 130-5	22
1033	Accumulation of human T-lymphotropic virus type I (HTLV-I)-infected cells in the cerebrospinal fluid during the exacerbation of HTLV-I-associated myelopathy. 2008 , 14, 459-63	17
1032	Multiple sclerosis: an immune or neurodegenerative disorder?. 2008 , 31, 247-69	1201
1031	Neuropathic pain: redefinition and a grading system for clinical and research purposes. 2008 , 70, 1630-5	1958
1030	IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. 2008 , 28, 317-31	39
1029	Analysis of the association of allelic variants of apolipoprotein E and interleukin 1 beta genes with multiple sclerosis in ethnic Tatars. 2008 , 44, 350-356	2
1028	Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients. 2008 , 18, 1736-40	8
1027	Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. 2008 , 18, 2311-20	77
1026	Alexithymia in multiple sclerosis: relationship with fatigue and depression. 2008 , 118, 18-23	39
1025	The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis. 2008 , 118, 120-5	17
1024	Diagnosis and treatment of multiple sclerosis. 2008 , 188, 12-21	28
1023	Regional specificity of magnetization transfer imaging in multiple sclerosis. 2008 , 18, 130-6	11
1022	Magnetic resonance imaging findings in acute canine distemper virus infection. 2008 , 49, 460-7	19
1021	IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. 2008 , 9, 259-63	97
1020	Variations of the perforin gene in patients with multiple sclerosis. 2008 , 9, 438-44	35

1019	HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. 2008 , 9, 570-4	21
1018	Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. 2008 , 9, 624-30	104
1017	SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. 2008 , 88, 243-55	56
1016	Polymorphism of the apolipoprotein E gene and risk of multiple sclerosis in ethnic Russians. 2008 , 42, 852-858	1
1015	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. 2008 , 9, 7-15	19
1014	Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. 2008 , 28, 164-71	85
1013	Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale. 2008 , 15, 284-8	8
1012	Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-relapsing multiple sclerosis in Argentina. 2008 , 15, 386-93	55
1011	Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. 2008 , 15, 1173-9	17
1010	CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. 2008 , 15, 998-1001	31
1009	Natural history of multiple sclerosis in a population-based cohort. 2008 , 15, 916-21	118
1008	Prospective combined brain and spinal cord MRI in clinically isolated syndromes and possible early multiple sclerosis: impact on dissemination in space and time. 2008 , 15, 1359-64	15
1007	A systematic review of the epidemiology of multiple sclerosis in South America. 2008 , 15, 1273-8	58
1006	Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility. 2008 , 72, 54-9	19
1005	Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-relapsing multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. 2008 , 123, 79-89	251
1004	Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease. 2008 , 67, 626-31	28
1003	Quantitative electroencephalography reveals different physiological profiles between benign and relapsing-relapsing multiple sclerosis patients. 2008 , 8, 44	13
1002	The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. 2008 , 7, 621-5	80

1001	Callosal function in MS patients with mild and severe callosal damage as reflected by diffusion tensor imaging. 2008 , 1226, 218-25	11
1000	Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. 2008 , 129, 31-5	56
999	Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. 2008 , 12, 205-9	53
998	MRI in multiple sclerosis: current status and future prospects. 2008 , 7, 615-25	262
997	Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. 2008 , 7, 796-804	382
996	Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. 2008 , 7, 903-14	386
995	BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the Polish population. Gender differences. 2008 , 193, 170-2	32
994	Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. 2008 , 194, 153-64	93
993	IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. 2008 , 195, 116-20	39
992	Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. 2008 , 196, 159-65	49
991	Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. 2008 , 196, 181-7	96
990	Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. 2008 , 197, 54-62	13
989	CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. 2008 , 199, 126-32	29
988	Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. 2008 , 197, 140-6	23
987	The SH2D2A gene and susceptibility to multiple sclerosis. 2008 , 197, 152-8	13
986	CCL genes in multiple sclerosis and systemic lupus erythematosus. 2008 , 200, 145-52	15
985	Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. 2008 , 200, 125-8	57
984	Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. 2008 , 205, 105-9	32

983	Apoptosis-related molecules in blood in multiple sclerosis. 2008 , 205, 135-41	26
982	The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. 2008 , 205, 126-34	18
981	Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. 2008 , 205, 142-7	76
980	Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. 2008 , 164, 274-82	38
979	Taking a neurological history. 2008 , 36, 509-514	
978	Multiple sclerosis. 2008 , 36, 625-629	4
977	Diffusion weighted callosal integrity reflects interhemispheric communication efficiency in multiple sclerosis. 2008 , 46, 2258-64	21
976	Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. 2008 , 84, 1248-55	151
975	Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. 2008 , CD005278	36
974	Multiple Sclerosis and Other Demyelinating Diseases. 2008 , 239-255	1
973	Multiple Sclerosis. 2008 , 589-603	
972	Demyelinating Diseases - I. 2008 , 38-44	
971	Demyelinating Diseases - II. 2008 , 45-48	
970	Sleep and Quality of Life in Multiple Sclerosis. 2008 , 199-207	2
969	Preliminary evidences of a NOS2A protective effect from relapsing-remitting multiple sclerosis. 2008 , 264, 112-7	7
968	Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. 2008 , 266, 25-30	22
967	Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. 2008 , 266, 34-7	22
966	Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. 2008 , 266, 115-25	29

965	Association of the MMP-3 5A/6A gene polymorphism with multiple sclerosis in patients from Serbia. 2008 , 267, 62-5	4
964	Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. 2008 , 267, 86-90	26
963	Cognitive impairment in different MS subtypes and clinically isolated syndromes. 2008 , 267, 100-6	184
962	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. 2008 , 268, 12-7	129
961	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. 2008 , 269, 49-53	63
960	Clinical characteristics of multiple sclerosis in Lebanon. 2008 , 270, 88-93	34
959	The reliability of specific primary progressive MS criteria in an ethnically diverse population. 2008 , 270, 159-64	4
958	Somatosensory evoked potentials reflect the upper limb motor performance in multiple sclerosis. 2008 , 273, 99-102	8
957	T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired. 2008 , 275, 22-8	35
956	New treatment measurements for treatment effects on relapses and progression. 2008 , 274, 80-3	5
955	Pharmacological treatment of early multiple sclerosis. 2008 , 68, 73-83	36
954	Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. 2008 , 14, 59-66	53
953	Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. 2008 , 6, 67	53
952	B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. 2008 , 98, 121-49	66
951	Molecular probes for imaging myelinated white matter in CNS. 2008 , 51, 6682-8	60
950	Pilot study exploring quality of life and barriers to leisure-time physical activity in persons with moderate to severe multiple sclerosis. 2008 , 1, 58-65	60
949	Advances in multiple Sclerosis and Experimental Demyelinating Diseases. 2008 ,	3
948	Regional hippocampal atrophy in multiple sclerosis. 2008 , 131, 1134-41	289

947	Sleep and Quality of Life in Clinical Medicine. 2008 ,	22
946	Spine and Spinal Canal. 2008 , 535-662	
945	NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity. 2008 , 7, 251	13
944	Differential diagnosis of suspected multiple sclerosis: a consensus approach. 2008 , 14, 1157-74	450
943	Conventional MR imaging. 2008 , 18, 651-73, x	19
942	Lifetime and actual prevalence of pain and headache in multiple sclerosis. 2008 , 14, 514-21	73
941	Soluble MHC class I chain-related protein B serum levels correlate with disease activity in relapsing-remitting multiple sclerosis. 2008 , 69, 235-40	23
940	[New frontiers in multiple sclerosis]. 2008 , 37, 77-9	1
939	Coagulation status and biochemical and inflammatory markers in multiple sclerosis. 2008 , 15, 393-7	42
938	3'UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. 2008 , 431, 36-8	33
937	Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. 2008 , 436, 72-6	48
936	Study of Cbl-b dynamics in peripheral blood lymphocytes isolated from patients with multiple sclerosis. 2008 , 440, 336-9	11
935	Chlamydomphila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis. 2008 , 62, 58-61	21
934	Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. 2008 , 8, 881-6	10
933	Acute disseminated encephalomyelitis in children: focus on relapsing patients. 2008 , 39, 12-7	32
932	Acute combined central and peripheral nervous system demyelination in children. 2008 , 39, 307-16	22
931	NMO-IgG and Devic's neuromyelitis optica: a French experience. 2008 , 14, 440-5	95
930	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. 2008 , 14, 399-405	80

929	A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. 2008 , 14, 1076-83	61
928	Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. 2008 , 214, 315-21	36
927	MR in the diagnosis and monitoring of multiple sclerosis: an overview. 2008 , 67, 409-14	75
926	Glutamyl cyclase activity is a characteristic feature of human cerebrospinal fluid. 2008 , 389, 152-9	4
925	MRI of the cranium: Normal anatomy and common pathologies. 2008 , 11, 90-102	
924	Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis. 2008 , 110, 233-8	16
923	Disseminated encephalomyelitis in children. 2008 , 110, 928-38	37
922	Isolated cranial nerve palsies in multiple sclerosis. 2008 , 110, 886-8	54
921	The natural history of multiple sclerosis with childhood onset. 2008 , 110, 897-904	43
920	Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. 2008 , 110, 992-6	18
919	Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. 2008 , 30, 1102-12	13
918	La sclérose en plaques, première cause non traumatique de handicap sexuel acquis. 2008 , 4, 14-16	1
917	Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. 2008 , 42, 1324-8	51
916	The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. 2008 , 119, 504-532	438
915	The impact of stressful life events on risk of relapse in women with multiple sclerosis: a prospective study. 2008 , 23, 497-504	39
914	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. 2008 , 69, 837-9	16
913	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. 2008 , 372, 1463-72	398
912	Multiple sclerosis. 2008 , 372, 1502-17	3360

911	Multiple sclerosis and cannabis: a cognitive and psychiatric study. 2008 , 71, 164-9	29
910	Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study. 2008 , 14, 1262-8	46
909	Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. 2008 , 14, 919-26	36
908	Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. 2008 , 264, 145-50	26
907	Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis. 2008 , 269, 85-91	99
906	The clinical course of multiple sclerosis patients in Hong Kong. 2008 , 268, 78-82	22
905	B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. 2008 , 358, 676-88	1723
904	[Multiple sclerosis and familial Mediterranean fever: a case report]. 2008 , 164, 943-7	7
903	[Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study]. 2008 , 164, 47-52	9
902	Relapses in multiple sclerosis are age- and time-dependent. 2008 , 79, 1368-74	138
901	Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. 2008 , 79, 1230-5	70
900	[Retinal atrophy using optical coherence tomography (OCT) in 15 patients with multiple sclerosis and comparison with healthy subjects]. 2008 , 164, 927-34	21
899	[Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]. 2008 , 164, 1028-34	4
898	Immunologic mechanisms of multiple sclerosis. 2008 , 18, 577-88, ix	20
897	The clinical epidemiology of multiple sclerosis. 2008 , 18, 589-622, ix-x	47
896	Diagnostic value of contrast-enhanced fluid-attenuated inversion-recovery and delayed contrast-enhanced brain MRI in multiple sclerosis. 2008 , 15, 15-23	11
895	Interferon-beta-1b: in newly emerging multiple sclerosis. 2008 , 22, 787-92	5
894	CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis. 2008 , 14, 446-54	36

893	Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. 2008 , 180, 8434-43	136
892	Linkage disequilibrium analyses within chromosome 19p in multiple sclerosis. 2008 , 14, 433-9	0
891	DNA-based vaccines: the future of multiple sclerosis therapy?. 2008 , 8, 351-60	10
890	Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. 2008 , 14, 557-60	19
889	Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. 2008 , 14, 694-7	34
888	Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. 2008 , 14, 663-70	76
887	Multiple sclerosis following etanercept treatment for ankylosing spondylitis. 2008 , 37, 397-9	29
886	The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results. 2008 , 118, 1645-58	5
885	Ocular Manifestations in Korean Patients with Multiple Sclerosis. 2008 , 32, 55-61	1
884	Encyclopedia of Neuroscience. 2008 , 2197-2526	1
883	Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. 2008 , 14, 759-63	38
882	Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. 2008 , 30, 1-9	16
881	Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. 2008 , 14, 1220-4	257
880	Seasonal pattern of births in patients with multiple sclerosis. 2008 , 39, 413-416	2
879	Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis. 2008 , 14, 564-6	11
878	Optical coherence tomography: a window into the mechanisms of multiple sclerosis. 2008 , 4, 664-75	239
877	Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. 2008 , 31, 271-9	121
876	Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. 2008 , 22, 661-71	108

875	Dose comparison trial of sustained-release fampridine in multiple sclerosis. 2008 , 71, 1134-41	144
874	Diseases of the Brain, Head & Neck, Spine. 2008 ,	2
873	Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. 2008 , 131, 1759-75	318
872	Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. 2008 , 65, 1434-9	75
871	Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. 2008 , 105, 11839-44	83
870	Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. 2008 , 14, 278-83	36
869	Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment. 2008 , 14, 995-8	48
868	Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. 2008 , 79, 1027-31	66
867	Perivascular spaces--MRI marker of inflammatory activity in the brain?. 2008 , 131, 2332-40	156
866	MRI Atlas of MS Lesions. 2008 ,	3
865	Influence of oligoclonal IgM specificity in multiple sclerosis disease course. 2008 , 14, 183-7	54
864	Chapter 6 Optic Neuritis. 2008 , 32, 134-152	3
863	Multiple sclerosis: relapses and timing of remissions. 2008 , 59, 44-8	13
862	Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. 2008 , 65, 727-32	308
861	Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis. 2008 , 67, 1193-4	10
860	Characterisation of the spectrum of demyelinating disease in Western Australia. 2008 , 79, 1022-6	39
859	Long-term follow-up of suspected though unconfirmed MS. 2008 , 14, 985-7	3
858	Multiple sclerosis onset during etanercept treatment. 2008 , 59, 91-3	37

857	Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. 2008 , 60, 1-11	41
856	Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. 2008 , 14, 880-6	37
855	Predictive role of evoked potential examinations in patients with clinically isolated optic neuritis in light of the revised McDonald criteria. 2008 , 14, 472-8	15
854	MDC/CCL22 intrathecal levels in patients with multiple sclerosis. 2008 , 14, 547-9	21
853	At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. 2008 , 14, 428-30	4
852	Clinical features of optico-spinal multiple sclerosis with anti-aquaporin 4 antibody. 2008 , 60, 37-42	12
851	Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach. 2008 , 131, 1783-92	36
850	Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. 2008 , 131, 3081-91	180
849	Cerebrospinal fluid: the role of biochemical analysis. 2008 , 69, 218-21	4
848	Persistence of immunopathological and radiological traits in multiple sclerosis. 2008 , 65, 1527-32	36
847	Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. 2008 , 65, 913-9	212
846	The prevalence of multiple sclerosis in the Middle East. 2008 , 31, 129-37	36
845	The treatment of multiple sclerosis with beta-interferon. 2008 , 31, 157-8	
844	Awareness of deficit in multiple sclerosis. 2008 , 30, 301-11	21
843	Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8 ^{low} cells. 2008 , 131, 1701-11	61
842	Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. 2008 , 71, 1390-5	108
841	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. 2008 , 70, 1079-83	265
840	Evidence of thalamic gray matter loss in pediatric multiple sclerosis. 2008 , 70, 1107-12	118

839	Optic neuritis and the risk of multiple sclerosis--what can we learn from a brain MRI scan?. 2008 , 4, 532-3	2
838	Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. 2008 , 79, 1224-9	52
837	NMO-IgG predicts the outcome of recurrent optic neuritis. 2008 , 70, 2197-200	299
836	Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. 2008 , 14, 1026-30	98
835	Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. 2008 , 180, 6988-96	148
834	Demyelination in rheumatic diseases. 2006 , 77, 290-5	48
833	Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. 2008 , 181, 5473-80	83
832	Neuroimaging Modalities in Neuroimmunology. 2021 , 29-42	
831	References. 2021 , 1000-1023	
830	The Effect of Different Administration Time and Dosage of Vitamin D Supplementation in Patients with Multiple Sclerosis: A Meta-Analysis of Randomized Controlled Trials. 2021 , 28, 118-128	4
829	Multiple sclerosis, emotion perception and social functioning. 2021 , 15, 500-515	1
828	Transcriptomic analysis of Multiple Sclerosis patient-derived monocytes by RNA-Sequencing for candidate gene discovery. 2021 , 23, 100563	0
827	Effects of Eight Weeks of Core Stability Training on Serum level of Progranulin and Tumor Necrosis Factor Alpha in Women with Multiple Sclerosis. 2021 , 15, 8-12	1
826	A Computer-Aided Diagnosis System in the Diagnosis of Multiple Sclerosis. 2021 , 277-284	
825	Negative prognostic factors in multiple sclerosis. 2021 , 21, 448-452	
824	The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis. 2021 , 13, 11795735211028769	
823	Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches. 2021 , 16, 11772719211013352	
822	Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis. 2021 , 31, 493-500	1

821	A model for interrogating the clinico-radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia. 2021 , 28, 1617-1626	0
820	Ozanimod for relapsing-remitting multiple sclerosis.	
819	Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance. 2021 , 42, 2399-2415	3
818	Clinical Features of Multiple Sclerosis. 2021 , 21-36	
817	Comorbidity in multiple sclerosis patients from Nordland County, Norway - validated data from the Norwegian Patient Registry. 2021 , 48, 102691	4
816	Effects of diminished positive mood and depressed mood upon verbal learning and memory among people with multiple sclerosis. 2021 , 43, 117-128	2
815	Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes. 2021 , 58, 2886-2896	5
814	Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. 2021 , 17, 587-604	3
813	Rituximab for people with multiple sclerosis.	78
812	Advances for the Development of In Vitro Immunosensors for Multiple Sclerosis Diagnosis. 2021 , 15, 205-215	2
811	Clinical and radiological features of MS, NMOSD, and MOGAD, and evolution of the diagnostic processes in Thailand. 2021 , 9, 282-291	0
810	[MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis]. 2021 , 89, 374-381	1
809	Early-Onset Multiple Sclerosis With Frequent Relapses: A Challenging Diagnosis With a Less Favorable Prognosis. 2021 , 13, e13963	
808	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial. 2021 , 8,	7
807	Familial coexistence of demyelinating diseases and familial Mediterranean fever. 2021 , 1	1
806	Clinically isolated syndrome: diagnosis and risk of developing clinically definite multiple sclerosis. 2021 ,	
805	Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses. 2021 , 27, 2232-2239	2
804	German translation, cultural adaptation and validation of the unidimensional self-efficacy scale for multiple sclerosis. 2021 , 21, 163	1

803	Prevalence of comorbidities in multiple sclerosis patients with neurogenic bladder. 2021 , 31, 732-738	1
802	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. 2021 , 8,	2
801	Impact of adherence to disease-modifying therapies on employment among veterans with multiple sclerosis. 2021 , 1-6	
800	Esophageal Disease in Older Patients. 2021 , 804-853	
799	Neuropsychiatric involvement in systemic lupus erythematosus: A review. 2021 , 20, 102780	10
798	Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage. 2021 , 42, 2615-2618	3
797	Artificial Intelligence in Diagnosis and Prediction of the Multiple Sclerosis Progression: A Scoping Review (Preprint).	
796	Effect of dual-task training on balance in patients with multiple sclerosis: A systematic review and meta-analysis. 2021 , 35, 1399-1412	5
795	Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis. 2021 , 49, 102769	3
794	Deciphering Multiple Sclerosis Progression. 2021 , 12, 608491	7
793	An Overview of Venous Abnormalities Related to the Development of Lesions in Multiple Sclerosis. 2021 , 12, 561458	2
792	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. 2021 , 50, 102840	1
791	Un caso di vertigine a esordio acuto/subacuto in un adolescente. 2021 , 24, 130-137	
790	Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: A clinical trial study. 2021 , 35, e22800	2
789	Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression. 2021 , 50, 102814	
788	Accuracy of the Brazilian version of the DYMUS questionnaire for the screening of oropharyngeal dysphagia in multiple sclerosis. 2021 , 50, 102772	0
787	Does multiple sclerosis increase the risk of preeclampsia? A systematic review and meta-analysis. 2021 , 40, 180-185	0
786	Endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis. 2021 , 50, 102868	1

785	Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort. 2021 , 28, 2238-2248	2
784	Serum Homocysteine Level Is a Predictor of Relapse and Prognosis in Patients With First-Attack Neuromyelitis Optica Spectrum Disorders. 2021 , 12, 667651	2
783	Vitamin D changes expression of DNA repair genes in the patients with multiple sclerosis. 2021 , 781, 145488	3
782	Comparison of efficacy of vestibular rehabilitation and noisy galvanic vestibular stimulation to improve dizziness and balance in patients with multiple sclerosis. 2021 , 31, 541-551	1
781	Physical activity may contribute to brain health in multiple sclerosis: An MR volumetric and spectroscopy study. 2021 , 31, 714-723	0
780	Cognitive trajectories in multiple sclerosis: a long-term follow-up study. 2021 , 1	1
779	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. 2021 , 13524585211023365	2
778	Disease-modifying therapies for T1 hypointense lesions (Black Holes) volume in patients with multiple sclerosis: Protocol for a systematic review and meta-analysis.	
777	Measuring Gait Stability in People with Multiple Sclerosis Using Different Sensor Locations and Time Scales. 2021 , 21,	4
776	New Prospects for Ultra-High-Field Magnetic Resonance Imaging in Multiple Sclerosis. 2021 , 56, 773-784	5
775	Machine learning in diagnosis and disability prediction of multiple sclerosis using optical coherence tomography. 2021 , 133, 104416	9
774	Marqueurs biologiques utilis�s dans le diagnostic de la scl�rose en plaques. 2021 , 2021, 66-73	
773	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. 2021 , 7, 20552173211024298	2
772	Ensemble Learning for Multiple Sclerosis Disability Estimation Using Brain Structural Connectivity. 2021 ,	1
771	Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial. 2021 , 57,	6
770	Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. 2021 , 97, e890-e901	4
769	Azathioprine for people with multiple sclerosis. 2021 , 2021,	1
768	Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. 2021 , 21, 895-911	0

767	Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis. 2021 , 52, 102972		0
766	Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study. 2021 , 11, 14987		1
765	Review of neurological rehabilitation for Multiple Sclerosis in the British Military. 2021 ,		0
764	Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions. 2021 , 14, 183		2
763	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. 2021 , 52, 102977		
762	Magnetic Resonance Imaging Correlates of Multiple Sclerosis Immunopathological Patterns. <i>Annals of Neurology</i> , 2021 , 90, 440-454	9-4	3
761	Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder. 2021 , 1		0
760	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. 2021 , 144, 680-686		1
759	Clinical Presentation and Causes of Non-traumatic Spinal Cord Injury: An Observational Study in Emergency Patients. 2021 , 12, 701927		0
758	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. 2021 , 97, e1560-e1570		4
757	Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. 2021 , 8,		3
756	Multiple Sclerosis: Enzymatic Cross Site-Specific Hydrolysis of H1 Histone by IgGs against H1, H2A, H2B, H3, H4 Histones, and Myelin Basic Protein. 2021 , 11,		1
755	Coping with stress during the first wave of the COVID-19 pandemic by Turkish people with Multiple Sclerosis: The relationship between perceived stress and quality of life. 2021 , 53, 103039		3
754	A Non-invasive Method of Cerebrospinal fluid collection from rats for assessing the Cerebrospinal fluid drug content. 2021 , 4085-4086		1
753	Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases. 2021 , 108-111		
752	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. 2021 , 97, e1334-e1342		2
751	Biopsychosocial implications of living with multiple sclerosis: a qualitative study using interpretative phenomenological analysis. 2021 , 11, e049041		2
750	Childhood pet ownership and multiple sclerosis: A systematic review and meta-analysis. 2021 , 53, 103046		

- 749 Longitudinal changes of financial hardship in patients with multiple sclerosis. **2021**, 53, 103037 1
- 748 Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. **2021**, 1 1
- 747 MRI of the Entire Spinal Cord-Worth the While or Waste of Time? A Retrospective Study of 74 Patients with Multiple Sclerosis. **2021**, 11, 0
- 746 Genetic susceptibility to multiple sclerosis in African Americans. **2021**, 16, e0254945 0
- 745 Quantitative Assessment of Ataxia in Multiple Sclerosis Patients using Spatiotemporal Parameters: A Relief-Based Machine Learning Analysis. 1
- 744 Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS. 0
- 743 The clinical and paraclinical correlates of employment status in multiple sclerosis. **2021**, 1 1
- 742 Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. **2021**, 96, 1407-1419 0
- 741 Epidemiology of multiple sclerosis in the Sultanate of Oman: A hospital based study. **2021**, 53, 103034 2
- 740 End of life in multiple sclerosis: Disability, causes and place of death among cases diagnosed from 1981 to 2010 in Pirkanmaa hospital district in Western Finland. **2021**, 54, 103139 0
- 739 Interaction of MS prevalence, radon gas concentration, and patient nutrition: a case-control study. **2021**, 11, 17906
- 738 Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort. **2021**, 28, 4153-4166 3
- 737 Potential protective role of a NOD2 polymorphism in the susceptibility to multiple sclerosis is not associated with interferon therapy. **2021**, 15, 100
- 736 Effects of walking exercise training on learning and memory and hippocampal neuroimaging outcomes in MS: A targeted, pilot randomized controlled trial. **2021**, 110, 106563 3
- 735 Possible Role of Butyrylcholinesterase in Fat Loss and Decreases in Inflammatory Levels in Patients with Multiple Sclerosis after Treatment with Epigallocatechin Gallate and Coconut Oil: A Pilot Study. **2021**, 13, 1
- 734 Psychotic symptoms prior or concomitant to diagnosis of multiple sclerosis: a systematic review of case reports and case series. **2021**, 1-7 0
- 733 Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. **2021**, 1 1
- 732 Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. **2021**, 1 0

731	The Effectiveness of Statins as Potential Therapy for Multiple Sclerosis: A Systematic Review of Randomized Controlled trials. 2021 , 13, e18092	0
730	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. 2021 , 97, e1641-e1652	6
729	Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response. 2021 , 11, 19462	
728	Rational laboratory testing in uveitis: A Bayesian analysis. 2021 , 66, 802-825	2
727	Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis. 2021 , 54, 103119	6
726	Apparent changes in the epidemiology and severity of multiple sclerosis. 2021 , 17, 676-688	6
725	Secondary Impacts of COVID-19 Pandemic in Fatigue, Self-Compassion, Physical and Mental Health of People with Multiple Sclerosis and Caregivers: The Teruel Study. 2021 , 11,	1
724	Assessment of commonly used methods to determine myelin-reactivity of T cells in multiple sclerosis. 2021 , 230, 108817	0
723	Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal. 2021 , 54, 103091	0
722	Serum GFAP and NFL levels in benign relapsing-remitting multiple sclerosis. 2021 , 56, 103280	1
721	Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study. 2021 , 11, 18528	0
720	Wearable inertial sensors are highly sensitive in the detection of gait disturbances and fatigue at early stages of multiple sclerosis. 2021 , 21, 337	6
719	Multi-parametric MRI phenotype with trustworthy machine learning for differentiating CNS demyelinating diseases. 2021 , 19, 377	0
718	Upper-lower limb and breathing exercise program for improving sleep quality and psychological status in multiple sclerosis: a pilot randomized controlled trial. 1-17	0
717	[Supporting the adaptation to the announcement of multiple sclerosis]. 2021 , 70, 37-39	0
716	Post-partum relapse in women with multiple sclerosis after neuraxial labour analgesia or neuraxial anaesthesia: A multicentre retrospective cohort study. 2021 , 40, 100834	1
715	Home-based exercise training influences gut bacterial levels in multiple sclerosis. 2021 , 45, 101463	5
714	Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. 2021 , 56, 103249	1

713	Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis. 2021 , 68, 126831	2
712	Diagnosis of multiple sclerosis using multifocal ERG data feature fusion. 2021 , 76, 157-167	0
711	Test-Retest Reliability of the Mini-BESTest in People With Mild to Moderate Multiple Sclerosis. 2021 , 101,	1
710	icobrain ms 5.1: Combining unsupervised and supervised approaches for improving the detection of multiple sclerosis lesions. 2021 , 31, 102707	1
709	Clinical Trial Design in Neuroimmunology. 2021 , 43-57	
708	Study protocol: randomised controlled trial evaluating exercise therapy as a supplemental treatment strategy in early multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES). 2021 , 11, e043699	4
707	Noninvasive Electrophysiology. 2021 , 251-265	
706	Revealing vascular abnormalities and measuring small vessel density in multiple sclerosis lesions using USPIO. 2021 , 29, 102525	4
705	Cannabinoids for multiple sclerosis.	1
704	Interferon beta for primary progressive multiple sclerosis.	3
703	Memory rehabilitation for people with multiple sclerosis. 2021 , 10, CD008754	3
702	Multiple Sclerosis: Critical Review of the Evidence for each Question. 221-233	3
701	Depression and Multiple Sclerosis. 157-176	3
700	Predicting Clinical Course. 163-180	1
699	Assessing environmental epidemiology questions in practice with a causal inference pipeline: An investigation of the air pollution-multiple sclerosis relapses relationship. 2021 , 40, 1321-1335	5
698	Conventional MRI Techniques in Multiple Sclerosis. 2005 , 211-223	3
697	Multiple Sclerosis. 2005 , 566-603	1
696	Liquordiagnostik. 2006 , 136-170	1

695	High-Field Strength MRI (3.0 T or More) in White Matter Diseases. 2006 , 186-193	3
694	Multiple Sclerosis and Autoimmune Encephalomyelitis. 2007 , 373-404	1
693	Children with Multiple Sclerosis. 2012 , 213-230	1
692	Disease Influence on BBB Transport in Neurodegenerative Disorders. 2014 , 591-634	3
691	Magnetic Resonance Elastography of the Brain. 2014 , 89-98	1
690	Cognitive and Affective Neuroscience Theories of Cognition and Depression in Multiple Sclerosis and GuillainBarré Syndrome. 2019 , 443-461	1
689	Systematic Understanding of Bioactive Lipids in Neuro-Immune Interactions: Lessons from an Animal Model of Multiple Sclerosis. 2019 , 1161, 133-148	7
688	Multifractal Analysis with L2 Norm Denoising Technique: Modelling of MS Subgroups Classification. 2019 , 257-269	2
687	Magnetic Resonance Imaging of the Brain. 2010 , 107-195	10
686	Multiple Sclerosis. 2016 , 851-861	1
685	Demyelinating and Degenerative Disease. 2009 , 141-166	1
684	Liquordiagnostik. 2011 , 143-178	2
683	Brain White Matter Lesions Classification in Multiple Sclerosis Subjects for the Prognosis of Future Disability. 2011 , 400-409	3
682	Früherkennung und Diagnostik der Multiplen Sklerose. 2016 , 23-54	1
681	Entzündliche Erkrankungen. 2019 , 51-98	0
680	Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. 2004 , 1, 284	1
679	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. 2020 , 9, 359-374	6
678	Neuroimaging of Multiple Sclerosis: An Update. 2011 , 81-105	1

677	Rationale for Quantitative MRI of the Human Spinal Cord and Clinical Applications. 2014 , 3-21	1
676	Multiple Sclerosis. 2003 , 677-706	1
675	Natural History of Multiple Sclerosis: When Do Axons Degenerate?. 2005 , 185-200	2
674	Optic Neuritis. 2008 , 3871-3885	1
673	Visual loss: optic neuropathies. 2010 , 103-198	3
672	Clinically Isolated Syndromes. 2010 , 206-218	1
671	Historique de la sclérose en plaques. 2019 , 3-30	1
670	Speech discrimination performance in multiple sclerosis dataset. 2020 , 33, 106614	1
669	Heart rate variability analysis in patients with multiple sclerosis. 2018 , 24, 64-68	13
668	Conduction studies in multiple sclerosis. 1-7	1
667	Social support among veterans with multiple sclerosis.. 2004 , 49, 106-113	16
666	Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers. 2005 , 94, 466-468	1
665	Multiple Sclerosis. 2004 , 188-222	1
664	Cardiopulmonary Exercise Testing Using the Modified Balke Protocol in Fully Ambulatory People With Multiple Sclerosis. 2021 , 32, 57-65	1
663	Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis. 2021 , 31, 40-47	3
662	Characterization of multiple sclerosis plaques using susceptibility-weighted imaging at 1.5 T: can perivenular localization improve specificity of imaging criteria?. 2015 , 39, 317-20	15
661	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. 2020 , 33, 294-300	1
660	Systematic Review of Studies on Telomere Lengths in Patients with Multiple Sclerosis.	1

659	Genetic Susceptibility to Multiple Sclerosis: Interactions between Conserved Extended Haplotypes of the MHC and other Susceptibility Regions.	1
658	Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis.	2
657	Adolescent-onset Krabbe disease with an initial diagnosis of multiple sclerosis and a novel mutation. 2015 , 2015,	6
656	Making the diagnosis of multiple sclerosis. 2001 , 71 Suppl 2, ii3-8	8
655	Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis. 2019 , 4,	12
654	Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis. 2020 , 5,	4
653	Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. 2005 , 115, 1352-1360	214
652	Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. 2005 , 115, 1352-60	94
651	Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. 2008 , 118, 3411-9	87
650	The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. 2010 , 16, 139-46	23
649	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. 2021 , 96, e482-e490	6
648	The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee. 2004 , 63, 1140; author reply 1140	3
647	Expression of Th-17 and ROR β mRNA in Beh \acute{c} t's Disease. 2011 , 17, CR227-34	66
646	Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses. 2011 , 17, CR704-10	13
645	Effect of Chronic Medical Conditions in Veterans with Multiple Sclerosis on Long-Term Disability. 2016 , 22, 2768-74	1
644	Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions. 2015 , 3, 525-32	3
643	Interaction of * and in a Population-based Case-control Study of Multiple Sclerosis. 2013 , 1, 10-17	1
642	Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. 2007 , 4, e133	151

641	Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. 2015 , 12, e1001866	252
640	Differential micro RNA expression in PBMC from multiple sclerosis patients. 2009 , 4, e6309	184
639	Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. 2010 , 5, e13058	65
638	Genome-wide analysis of copy number variation in type 1 diabetes. 2010 , 5, e15393	29
637	The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1. 2011 , 6, e16652	57
636	Switching multiple sclerosis patients with breakthrough disease to second-line therapy. 2011 , 6, e16664	44
635	Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. 2011 , 6, e16802	14
634	Automated discrimination of brain pathological state attending to complex structural brain network properties: the shiverer mutant mouse case. 2011 , 6, e19071	17
633	T regulatory cells are markers of disease activity in multiple sclerosis patients. 2011 , 6, e21386	51
632	TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis. 2011 , 6, e21766	14
631	Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. 2011 , 6, e27476	21
630	A functional variant in ERAP1 predisposes to multiple sclerosis. 2012 , 7, e29931	41
629	Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. 2012 , 7, e36140	41
628	Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. 2012 , 7, e44991	100
627	Geographical variations in sex ratio trends over time in multiple sclerosis. 2012 , 7, e48078	139
626	Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. 2012 , 7, e50347	18
625	Multiple sclerosis decreases explicit counterfactual processing and risk taking in decision making. 2012 , 7, e50718	20
624	The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity. 2013 , 8, e53623	51

623	Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis. 2013 , 8, e56375	25
622	Interaction between HLA-DRB1-DQB1 haplotypes in Sardinian multiple sclerosis population. 2013 , 8, e59790	23
621	Fine mapping and functional analysis of the multiple sclerosis risk gene CD6. 2013 , 8, e62376	15
620	Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. 2013 , 8, e64408	22
619	Evidence of impaired brain activity balance after passive sensorimotor stimulation in multiple sclerosis. 2013 , 8, e65315	11
618	Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?. 2013 , 8, e71894	37
617	Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients. 2013 , 8, e81685	25
616	Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. 2013 , 8, e82325	23
615	Kappa free light chains: diagnostic and prognostic relevance in MS and CIS. 2014 , 9, e89945	55
614	Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysis. 2014 , 9, e90182	24
613	Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression. 2014 , 9, e90482	31
612	MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. 2014 , 9, e94794	12
611	Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: a randomized controlled trial. 2014 , 9, e107710	20
610	High nationwide incidence of multiple sclerosis in Sweden. 2014 , 9, e108599	41
609	Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. 2014 , 9, e113371	26
608	Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. 2015 , 10, e0122048	39
607	Combinations of susceptibility genes are associated with higher risk for multiple sclerosis and imply disease course specificity. 2015 , 10, e0127632	3
606	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. 2015 , 10, e0132033	40

605	Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. 2015 , 10, e0134583	32
604	Validation of the Serbian Version of Multiple Sclerosis Spasticity Scale 88 (MSSS-88). 2016 , 11, e0147042	5
603	Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study. 2016 , 11, e0147195	21
602	Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS. 2016 , 11, e0152180	9
601	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. 2016 , 11, e0153466	20
600	Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up. 2016 , 11, e0156122	25
599	Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. 2018 , 13, e0190043	14
598	Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis. 2018 , 13, e0190601	20
597	Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study. 2018 , 13, e0194115	7
596	25-hydroxyvitamin D3 concentration in serum and cerebrospinal fluid of patients with remitting-relapse multiple sclerosis. 2013 , 114, 162-71	8
595	The effect of high-dose steroid treatment used for the treatment of acute demyelinating diseases on endothelial and cardiac functions. 2017 , 17, 392-397	5
594	The effect of novel simple saffron syrup on fatigue reduction in patients with multiple sclerosis. 2020 , 31,	1
593	New imaging techniques in the diagnosis of multiple sclerosis. 2008 , 2, 1055-65	6
592	Acute Effect of Pore-Forming α -Toxin on Compound Action Potentials of Optic Nerve of Mouse. 2017 , 4,	11
591	The Association of -308 TNF α Polymorphism and multiple sclerosis in Iranian Patients. 2012 , 1,	1
590	Recurrent neuromyelitis optica with diffuse central nervous system involvement: case report. 2004 , 62, 543-6	9
589	[Oligoclonal IgG bands in the cerebrospinal fluid of portuguese patients with multiple sclerosis: negative results indicate benign disease]. 2005 , 63, 375-9	14
588	Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients. 2006 , 64, 51-4	4

587	Isolated oculomotor nerve paresis as the presenting sign of multiple sclerosis. 2008 , 66, 254-5	4
586	Diffusion tensor MR imaging evaluation of the corpus callosum of patients with multiple sclerosis. 2008 , 66, 449-53	17
585	How much radiologically isolated syndrome suggestive of multiple sclerosis is multiple sclerosis?. 2012 , 70, 2-4	3
584	Effects of high-speed power training on muscle strength and power in patients with multiple sclerosis. 2016 , 53, 359-68	17
583	[The results of a randomized open multicenter comparative study on the tolerability and safety of gilenya (fingolimod) in patients with relapsing multiple sclerosis]. 2015 , 115, 45-50	1
582	[Issues of the current terminology in multiple sclerosis]. 2018 , 118, 121-127	2
581	Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs. 2018 , 9, 7758-7762	8
580	Active brain changes after initiating fingolimod therapy in multiple sclerosis patients using individual voxel-based analyses for diffusion tensor imaging. 2016 , 78, 455-463	5
579	ATYPICAL FORMS OF MULTIPLE SCLEROSIS IN THE TOMSK REGION. 2013 , 12, 13-17	1
578	Disease modifying agents for multiple sclerosis. 2010 , 4, 15-24	11
577	Supratentorial multiple sclerosis lesions affect the blink reflex test. 2010 , 4, 92-9	6
576	Predictors of attack severity and duration in multiple sclerosis: a prospective study. 2011 , 5, 75-82	14
575	Multiple Sclerosis and Subsequent Human Immunodeficiency Virus Infection: A Case with the Rare Comorbidity, Focus on Novel Treatment Issues and Review of the Literature. 2017 , 31, 1041-1046	10
574	Web search behavior and information needs of people with multiple sclerosis: focus group study and analysis of online postings. 2014 , 3, e12	37
573	A New App for At-Home Cognitive Training: Description and Pilot Testing on Patients with Multiple Sclerosis. 2015 , 3, e85	43
572	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. 2018 , 7, e15	17
571	Feasibility and toxicity of hematopoietic stem cell transplant in multiple sclerosis. 2017 , 20, 729-738	3
570	VDR and CYP24A1 Expression Analysis in Iranian Relapsing-Relapsing Multiple Sclerosis Patients. 2017 , 19, 352-360	5

569	Cancer risk among patients with multiple sclerosis: A cohort study in Isfahan, Iran. 2017 , 8, 172-177	8
568	Identification of miR-24 and miR-137 as novel candidate multiple sclerosis miRNA biomarkers using multi-staged data analysis protocol. 2017 , 6, 127-140	14
567	[Comparison of detection of brain lesions in multiple sclerosis in magnetic resonance imaging at magnetic field strength of 1.0 and 3.0 Tesla]. 2007 , 54, 115-7	1
566	Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. 2006 , 63, 879-82	22
565	[Correlation between olfactory dysfunction and various clinical parameters in patients with multiple sclerosis]. 2009 , 66, 203-6	3
564	A unique case of a 70-hour decompression sickness latency. 2018 , 69, 350-353	1
563	Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. 2020 , 3,	10
562	Serum Uric Acid Levels in Patients with Relapsing-Remitting Multiple Sclerosis. 2009 , 6,	3
561	Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores. 2010 , 7,	2
560	Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study. 2018 , 55, 15-21	4
559	The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. 2015 , 19, vii-viii, xxv-xxxi, 1-187	41
558	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. 2017 , 21, 1-352	21
557	Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. 2020 , 10,	15
556	Levels of leukocyte oxidative DNA damage (8-OHdG), serum coenzyme Q10 and lipid peroxidation in the formation attacks of patients with multiple sclerosis. 2017 , 9, 601-607	1
555	Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. 2007 , 13, 3638-40	25
554	Relationship between miR-155 and miR-146a polymorphisms and susceptibility to multiple sclerosis in an Egyptian cohort. 2020 , 12, 276-284	4
553	Optical coherence tomography in the diagnosis and management of optic neuritis and multiple sclerosis. 2011 , 42 Suppl, S28-40	20
552	Evoked potential tests in clinical diagnosis. 2013 , 133, 960-5	7

551	Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients. 2020 , 204, 1101-1110	9
550	Neuropsychiatric manifestations of multiple sclerosis. 2008 , 10, 318-24	12
549	Systematic imaging review: Multiple Sclerosis. 2015 , 18, S24-9	16
548	Treatment of multiple sclerosis. 2011 , 14, S65-9	9
547	Validity and Reliability of the Persian Version of the PERception de la Sclérose En Plaques et de ses Pousse'es Questionnaire Evaluating Multiple Sclerosis-related Quality of Life. 2016 , 7, 25	10
546	Assessing the Risk Factors for Multiple Sclerosis in Women of Reproductive Age Suffering the Disease in Isfahan Province. 2016 , 7, 58	9
545	A comprehensive review of amyotrophic lateral sclerosis. 2015 , 6, 171	321
544	Coexistence of Multiple Sclerosis and Brain Tumor: An Uncommon Diagnostic Challenge. 2017 , 6, 101	6
543	Evolving Landscape of Multiple Sclerosis in India: Challenges in the Management. 2018 , 21, 107-115	2
542	Combination of interleukin-10 gene promoter polymorphisms with HLA-DRB1*15 allele is associated with multiple sclerosis. 2017 , 145, 746-752	5
541	Pythagorean Self-Awareness Serves Successfully as a New Cognitive Behavioral-Based Technique in Multiple Sclerosis Physical and Psychosocial Well-Being and Quality of Life. 2016 , 07, 572-583	11
540	Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis. 2016 , 31, 40-5	25
539	Factors That Moderate Activity Limitation and Participation Restriction in People With Multiple Sclerosis. 2015 , 69, 6902260020p1-9	25
538	Association of interleukin-4 polymorphisms with multiple sclerosis in southeastern Iranian patients. 2012 , 32, 127-30	15
537	Auditory Evoked Potential Inconsistency in Sudden Unilateral Hearing Loss with Multiple Sclerosis. 2019 , 15, 160-164	5
536	The Assessment of Sexual Dysfunction in Male Patients with Multiple Sclerosis. 2018 , 55, 349-353	2
535	Specificity of Lower Urinary Tract Symptoms in Neuromyelitis Optica in Comparison With Multiple Sclerosis Patients. 2018 , 22, 185-191	4
534	Optic nerve and spinal cord are the major lesions in each relapse of Japanese multiple sclerosis. 2011 , 2011, 904706	2

533	P300 wave changes in patients with multiple sclerosis. 2013 , 21, 205-7	10
532	Prevalence of Herpes Simplex Virus Infection in Patients With Relapsing-Remitting Multiple Sclerosis: A Case-Control Study in the North of Iran. 2016 , 11,	4
531	A Review of Geoepidemiological Differences of Multiple Sclerosis in Iran and Other Middle East Countries. 2014 , 2,	7
530	Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial. 2015 , 17, e30618	3
529	Functional Genetic Variants of FOXP3 and Risk of Multiple Sclerosis. 2016 , 19,	5
528	The High Prevalence of the Varicella Zoster Virus in Patients With Relapsing-Remitting Multiple Sclerosis: A Case-Control Study in the North of Iran. 2016 , 9, e34158	8
527	Prevalence of Cytomegalovirus in Patients With Multiple Sclerosis: A Case-Control Study in Northern Iran. 2016 , 9, e36582	6
526	Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community. 2011 , 13, 65-74	17
525	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. 2012 , 14, 105-14	16
524	Environmental factors affecting the daily functioning of Jordanian individuals with multiple sclerosis. 2012 , 14, 169-78	2
523	Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis. 2014 , 16, 111-5	4
522	Fear of Falling Is Associated with Recurrent Falls in People with Multiple Sclerosis: A Longitudinal Cohort Study. 2015 , 17, 164-70	29
521	Factors Associated with Employment Status in Individuals with Multiple Sclerosis. 2015 , 17, 284-91	54
520	Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database. 2016 , 18, 154-61	2
519	Fatigue and Comorbidities in Multiple Sclerosis. 2016 , 18, 96-104	27
518	Cultural Adaptation, Validity, and Factor Structure of the Jalowiec Coping Scale in Iranian Women with Multiple Sclerosis: Which Coping Strategies Are Most Common and Effective?. 2017 , 19, 209-216	6
517	Relationship Between Fatigability and Perceived Fatigue Measured Using the Neurological Fatigue Index in People with Multiple Sclerosis. 2017 , 19, 232-239	14
516	Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting. 2017 , 19, 265-273	3

515	A Longitudinal Evaluation of Cognitive Fatigue on a Task of Sustained Attention in Early Relapsing-Remitting Multiple Sclerosis. 2018 , 20, 55-61	17
514	Reliability and Validity of a Danish Version of the Multiple Sclerosis Neuropsychological Screening Questionnaire. 2018 , 20, 49-54	3
513	Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis. 2021 , 23, 8-15	3
512	Clinical presentation and diagnosis of multiple sclerosis. 2020 , 20, 380-383	16
511	Assisting the diagnosis of multiple sclerosis using a set of regional brain volumes: A classification model for patients and healthy controls. 2021 , 26, 100766	0
510	The brainstem in multiple sclerosis: MR identification of tracts and nuclei damage. 2021 , 12, 151	2
509	Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States. 2021 , 13524585211048401	4
508	COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021. 2021 , 103335	0
507	Plantar Basın Dalgası Sinyalleri Kullanarak Erken MS'lilerde Ataksinin Hybrt CNN Modelleri ile Belirlenmesi.	
506	Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan. 2021 , 12, 749406	1
505	Project Y: The search for clues explaining phenotype variability in MS.. 2022 , 57, 103337	0
504	Monocyte to High-Density Lipoprotein Ratio: A Novel Predictive Marker of Disease Severity and Prognosis in Patients With Neuromyelitis Optica Spectrum Disorders. 2021 , 12, 763793	0
503	Radiological Tumor-Like Image in Multiple Sclerosis. 2011 , 19, 104-108	
502	Multiple Sclerosis. 2002 , 211-225	
501	Multiple Sclerosis, Diagnosis. 2003 , 244-253	
500	Pathophysiology and Clinical Features of Multiple Sclerosis. 2003 , 408-410	
499	Perfusion MRI. 2003 , 73-82	
498	Functional MRI. 2003 , 83-97	

497 Pharmacovigilance des vaccins contre l'hépatite B. **2003**, 187, 1489-1500

496 Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. **2003**, 061120065753028

495 Neuroepidemiology: Fundamental Considerations. **2004**, 2-22

494 Functional MRI in Multiple Sclerosis. **2004**, 145-155

493 MRI Visualization of Multiple Sclerosis. **2004**, 763-790

492 Acute Focal Demyelinating Disease mimicking Malignant Brain Tumor : A Case Report. **2004**, 13, 54-59

491 Infektionen des Nervensystems und multiple Sklerose. **2004**, 1689-1703

490 Diffusion-Weighted Imaging of the Normal-Appearing White Matter in Multiple Sclerosis. **2004**, 79-89

489 Evidence for an Early Treatment of Multiple Sclerosis. **2004**, 1-13

488 Genetic Susceptibility and Epidemiology. **2004**, 701-731

487 Multiple Sklerose und verwandte Krankheitsbilder. **2005**, 449-464

1

486 References. **2005**, 251-324

485 Optic Neuropathies and Central Nervous System Disorders. **2005**, 473-505

484 Multiple Sklerose. **2006**, 1105-1137

483 References. **2006**, 811-946

482 Diagnosis and treatment of multiple sclerosis: potential changes in management for clinically isolated episode of optic neuritis. **2006**, 332, 668

481 The impact of living with multiple sclerosis. **2006**, 31-65

480 A case of childhood relapsing/remitting multiple sclerosis and interferon β treatment in a Korean patient. **2007**, 50, 580

479 Manifestations Like Multiple Sclerosis in a Patient with Rheumatoid Arthritis and Sjögren's Syndrome. **2007**, 14, 369

478 Multiple Sclerosis Episodes. **2007**, 335-354

477 Multiple Sclerosis. **2007**, 50, 252

1

476 Multiple Sklerose. **2007**, 1499-1503

475 Use of magnetic resonance imaging in clinical management of multiple sclerosis. **2007**, 761-771

o

474 Vasovistió for Multiple Sclerosis Recognition. **2008**, 199-205

473 Pseudotumorous clinical and neuroimaging manifestation of multiple sclerosis. **2008**, 63, 99-103

472 Episodios de esclerosis múltiple. **2008**, 341-354

471 Multiple sclerose (MS). **2008**, 446-450

470 Neuromyelitis Optica (Devic Syndrome). **2008**, 433-434

469 Multiple Sclerosis. **2008**, 470-482

468 Multiple Sclerosis. **2008**, 719-727

467 Quantitative analysis of hyperintensity rim sign surrounding MS plaque on T1 weighted images. **2008**, 54, 158-165

466 OPTIC NEURITIS 317.28. **2008**, 583-585

465 MULTIPLE SCLEROSIS 340 (Sclerose en Plaques Disseminées, Disseminated Sclerosis). **2008**, 219-221

464 Difficulties in diagnosis of amyotrophic lateral sclerosis in patient with bulbar symptoms - a case report. **2008**, 63, 188-191

463 Copaxone in therapy of remittent disseminated sclerosis patients. **2008**, 7, 104-110

462 Disorders of the Central Nervous System and VEMPs: Detecting Lesions in the Vestibulospinal Pathway. **2009**, 92-97

461 Multiple Sclerosis. **2009**, 933-940

460 Interferon beta for secondary progressive multiple sclerosis.

459 Treatment: minimizing impairments, activity limitations and participation restrictions. **2009**, 127-190

458 9 Multiple sclerose (MS). **2009**, 110-121

457 Significance of Neuro-otologic Examination in the Diagnosis of Multiple Sclerosis. **2009**, 102, 543-551

2

456 Neuroimmune Interactions That Operate In The Development And Progression Of Inflammatory Demyelinating Diseases: Lessons From Pathogenesis Of Multiple Sclerosis. **2009**, 291-318

455 Progressive primary form of multiple sclerosis: clinical and radiological improvement with methylprednisolone in continuous pulsetherapy in one case for 16 years. **2009**, 67, 536-8

454 MRI and the Differential Diagnosis of Dementia. **2009**, 261-272

453 Optic magnetic resonance imaging findings in 41 patients with neuromyelitis optica. **2009**, 29, 921-925

1

452 A Fuzzy Regional-Based Approach for Detecting Cerebrospinal Fluid Regions in Presence of Multiple Sclerosis Lesions. **2010**, 552-561

1

451 Importance of Neurootologic Examination in Diagnosing Multiple Sclerosis with Abnormal Eye Movement. **2010**, 103, 1085-1092

450 Sympt^mes, formes, ^volution. **2010**, 11-20

449 Analysis of the association of allelic variants of apolipoprotein E and interleukin 1 beta genes with multiple sclerosis in ethnic Tatars. **2010**, 44, 350

448 Cognitive and Affective Neuroscience Theories of Cognition and Depression in Multiple Sclerosis and GuillainBarr^' Syndrome. **2010**, 337-353

447 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis. 1

446 Neuroimaging and Cognitive Function in Multiple Sclerosis. **2011**, 355-367

445 Neuroradiologia e sclerosi multipla. **2011**, 33-56

444 Esclerosis m^ltiple. **2011**, 189-e39

443 Multiple Sklerose. **2011**, 1219-1257

442 MS: Clinical Features, Symptom Management, and Diagnosis. **2011**, 89-110

441 Aspetti clinici generali. **2011**, 3-31

440 Pediatric Multiple Sclerosis. **2011**, 157-177

439 Multiple Sclerosis. **2011**, 1233-1252

438 Cannabinoids for multiple sclerosis.

437 Sight-dependent quality of life and ophthalmic findings in a group of Brazilian patients with multiple sclerosis. **2011**, 69, 809-13

436 Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. **2012**, 1-114

435 Neurology. **2012**, 959-999

o

434 Parainfectious and Autoimmune Disorders. **2012**, 3543-3554

433 Krankheiten des Nervensystems. **2012**, 235-260

432 A Case of Tumefactive Multiple Sclerosis Mimicking Primary Intracranial Tumor. **2012**, 21, 625-629

431 Plantar Pressure Assessment: A New Tool for Postural Instability Diagnosis in Multiple Sclerosis. **2012**, 179-204

1

430 Diagnosing Multiple Sclerosis. **2012**, 15-27

1

429 Acquired Disorders Affecting the White Matter. **2012**, 1052-1061

428 Esophageal Disease in Older Patients. 782-813

427 Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies. **2013**, 187-219

426 General Introduction. **2013**, 1-9

425 What Is Disease Progression?. **2013**, 11-30

424 The Diagnosis of Multiple Sclerosis. **2013**, 31-36

423 Neuroimaging in Multiple Sclerosis. **2013**, 43-64

422 Combina  es de T cnicas de Reabilita  o No Paciente Com Esclerose M ltipla (EM). **2012**, 20, 483-484

o

421 Clinico-radiological dissociation in multiple sclerosis: Future prospects. **2013**, 03, 147-153

1

420 Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen. **2013**, 301-315

419 Neutralisierende Antik rper. **2013**, 135-149

418 Multiple Sclerosis. **2013**, 1628-1637

417 Betaferon  MRI-Daten. **2013**, 69-77

416 Kognition. **2013**, 113-125

415 M. **2013**, 646-728

414 Fr ththerapie bei MS. **2013**, 39-51

413 Lesion contrast differences in MRI sequences in multiple sclerosis: Correlation to clinical disability. **2013**, 06, 319-326

412 Betaferon  Klinische Evidenz. **2013**, 53-67

411 Importance of neutralizing antibody positivity in Tur-kish multiple sclerosis patients. **2013**, 05, 1917-1923

410 Cos fa sclerosi multipla. **2013**, 3-10

2

409 Neurogenic Disorders. 272-309

408 Padroniza  o da Msis-29 Para um Centro de Refer ncia em Esclerose M ltipla. **2013**, 21, 237-246

407 Zunehmende Gangst r rung mit Monospastik. **2013**, 24, 38-43

1

406 Multiple Sclerosis. **2014**, 149-166

405 Biomarkers for Phase Switches in Multiple Sclerosis. **2014**, 1-22

404 Tumor necrosis factor-alpha polymorphism and susceptibility to multiple sclerosis in the Iranian population. **2015**, 17, e18247

403 Uso de Rosuvastatina em Esclerose M ltipla. **2007**, 15,

402 Clinical Syndromes Including Smallpox and Measles. 107-125

401 Esclerose M ltipla: duas apresenta  es cl nicas, uma s botaen a!. **2014**, 9, 365-370

1

400 Juxtacortical.

399 Poser Criteria, for Multiple Sclerosis. **2015**, 1-2

398 Optische Koh renztomografie (OCT). **2015**, 177-184

397 Multiple Sklerose. **2015**, 1-12

396 Krankheitsverlauf und Prognose. **2015**, 63-73

1

395 Marker des Liquor cerebrospinalis und des Blutes im  berblick. **2015**, 123-135

394 MS-Dokumentation, MS-Register und MS-Management. **2015**, 447-459

393 [Criteria of ineffectiveness of treatment with first-line therapy: how to use MRI results in decision making?]. **2015**, 115, 75-78

392 Magnetresonanztomografie. **2015**, 137-175

391 Liquor- und Blutuntersuchungen. **2015**, 115-122

390 Blood-Brain Barrier Disruption in Multiple Sclerosis. **2015**, 1-22

- 389 Retrobulbar Optic Neuropathy: From the Neurologist's Approach. **2016**, 345-350 0
- 388 Acquired Inflammatory Diseases of the Optic Nerve: From the Neuro-Ophthalmologist's Approach. **2016**, 361-367
- 387 [Neurological and psychiatric disorders in Behçet's disease]. **2016**, 116, 76-86 1
- 386 The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis. **2016**, 18, e25995 1
- 385 Utility of Myelin Basic Protein as an Early Prognostic Biomarker in Multiple Sclerosis. **2016**, 19,
- 384 Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. **2016**, 34, 290-296 1
- 383 The Effect of IFN- β on Biochemical Factors in Multiple Sclerosis Patients. **2016**, 19,
- 382 Escalation therapy in multiple sclerosis. **2016**, 17, 407-411
- 381 Diagnostic positif de la sclérose en plaques. **2017**, 79-111
- 380 High-Field-Strength MRI (3.0 T or More) in White Matter Diseases. **2017**, 223-237
- 379 [A current view on the MRI diagnosis of multiple sclerosis: an update of 2016 revised MRI criteria]. **2017**, 117, 66-73 1
- 378 A Comparison of Machine Learning Approaches for Classifying Multiple Sclerosis Courses Using MRSI and Brain Segmentations. **2017**, 643-651 2
- 377 [Primary progressive multiple sclerosis: current issues of timely diagnosis]. **2017**, 117, 35-40 1
- 376 Liquordiagnostik. **2017**, 1-32
- 375 A Clinical Case Report of Multiple Sclerosis Treated with Only Hominis Placental Pharmacopuncture. **2017**, 38, 289-300 1
- 374 HLA DRB5*01 Association Survey with Multiple Sclerosis in Khuzestan Province of Iran. **2017**, 19,
- 373 General Introduction: What Is Progressive Multiple Sclerosis?. **2018**, 1-29
- 372 Encyclopedia of Ophthalmology. **2018**, 1408-1408

- 371 EFFECT OF LECETHIN USAGE ON CHANGES OF CYTOKIN LEVELS IN PATIENTS WITH MULTIPLE SCLEROSIS. **2018**, 4, 57
- 370 Liquor- und Blutuntersuchungen. **2018**, 115-122
- 369 Pathologie de la substance blanche. **2018**, 537-594.e14
- 368 Differenzialdiagnose, Sonderformen und Diagnosesicherung. **2018**, 85-114
- 367 McDonald diagnostic criteria for multiple sclerosis.
- 366 Functional Evaluation of Multiple Sclerosis Patients in Khoy (IRAN). **2018**, 11, 37-43 1
- 365 Association Between HLA-A*02 Genotype and Multiple Sclerosis in Khuzestan Province, Iran. **2018**, 10,
- 364 Multipl Skleroz n De k Klinik Tiplerinde ve Farkli Evrelerinde Cd4(+) Cd25(+) Reg  İ tuar T H  Ėre Profili ve Foxp3 Ekspresyonu. **2018**, 40, 7-13 1
- 363 Application of determination of free light chains of immunoglobulins in the diagnosis of multiple sclerosis. **2018**, 19, 53-58
- 362 Vestibular-evoked myogenic potential: an easy neurophysiological tool for evaluating brain stem involvement in multiple sclerosis. **2018**, 34, 144-148 1
- 361 Detection of Active Plaques in Multiple Sclerosis using 3 and 12 Directional Diffusion-weighted Imaging: Comparison with Gadolinium-enhanced MR Imaging. **2020**, 10, 737-744 1
- 360 Multiple Sklerose: Diagnostik. **2019**, 1-13
- 359 Diagnosis of Multiple Sclerosis: 2017 McDonald Diagnostic Criteria. **2018**, 36, 273-279
- 358 Case Reports: Ischemic Strokes in a Young Woman With Manifestations of Multiple Sclerosis. **2018**, 4, 184-189
- 357 Longitudinally persistent cerebrospinal fluid B-cells resist treatment in multiple sclerosis. 0
- 356 Role of Hsp70 in Multiple Sclerosis: An Overview. **2019**, 149-167
- 355 The Role of Fampridine in the Symptomatic Treatment of Gait Impairment in Patients with Multiple Sclerosis. **2019**, 61, 199-207
- 354 Histoire naturelle de la scl rose en plaques. **2019**, 107-135

- 353 Association of Interleukin 13/+110 Gene Polymorphism with Hepatitis B Virus Infection in Golestan Province, Northern Iran. **2019**, In Press,
- 352 Welche Verdachtsdiagnose stellen Sie?. **2019**, 31, 46-49
- 351 Comparison Between T2, STIR and PSIR Sequences, for Detection of Cervical Cord MS Plaques. **2019**, 16, 0
- 350 Multipl Skleroz Hastalarında Metilprednizolon ve İnterferon Tedavisinin Kan Vitamin B12, Folik Asid ve Homosistein D⁺ Seveleri İhterine Etkisi. 325-338
- 349 Clinical Updates and Recent Developments in Neuro-Ophthalmology. **2020**, 201-249
- 348 Clinical Features, Symptom Management, and Diagnosis. **2020**, 89-108
- 347 Propriedades psicométricas da Frontal Assessment Battery na esclerose múltipla. **2019**, 5, 19-37
- 346 Features psychoneurological adaptation in patients with late-onset demyelinating pathology. **2019**, 2019, 25-30
- 345 Liquordiagnostik. **2020**, 213-244
- 344   **2020**, 89-96
- 343 Procedural Learning Improves Cognition in Multiple Sclerosis. **2020**, 74, 913-924 1
- 342 Current evidence on the potential therapeutic applications of transcranial magnetic stimulation in multiple sclerosis: a systematic review of the literature.. **2022**, 37, 199-215 1
- 341 Multimodal Evoked Potentials as Candidate Prognostic and Response Biomarkers in Clinical Trials of Multiple Sclerosis. **2021**, 38, 171-180 3
- 340 Concurrent and Predictive Validity of the Depression Anxiety Stress Scale-21 in Multiple Sclerosis: A Cross-Sectional Study with Controlling the Confounding Factors. **2020**, 22,
- 339 MS Diagnostic Criteria: Moving Ahead or Walking in Place?. **2021**, 0
- 338 Multiple sclerosis diagnostic criteria: From Poser to the 2017 revised McDonald criteria. **2021**, 50, 104089 0
- 337 Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. **2021**, 4
- 336 Multiple Sclerosis. **2020**, 1-35

- 335 Inner Retinal Layer Disease: Multiple Sclerosis.. **2020**, 5, 93-101
- 334 Anatomical Covariance Analysis: Detection of Disrupted Correlation Network Related to Clinical Trait Fatigue in Multiple Sclerosis: A Pilot Study. **2020**, 2020, 1-9 2
- 333 Automatic detection of multiple sclerosis lesions using Mask R-CNN on magnetic resonance scans. **2020**, 14, 4277-4290 2
- 332 Cognitive Fatigue Predicts Cognitive Failure in Multiple Sclerosis Patients and Healthy Controls: A Case-Control Study. **2021**, 36, 908-917 0
- 331 Delayed diagnosis of multiple sclerosis in a low prevalence country. **2021**, 43, 521-527 0
- 330 Rule Extraction in the Assessment of Brain MRI Lesions in Multiple Sclerosis: Preliminary Findings. **2021**, 277-286 2
- 329 Literatur. **2022**, 468-512
- 328 Imaging Biomarkers: Keys to Decision-Making in Stroke. **2020**, 259-296
- 327 Immunmedierte Erkrankungen des Nervensystems. **2020**, 37-87
- 326 Multiple Sklerose: Diagnostik. **2020**, 1085-1097
- 325 Impact of EBV on multiple sclerosis in some of the Iraqi males: Immunological and molecular study. **2020**, 0
- 324 Lack of association between the variant rs10735810 in the VDR gene and the pathogenicity of Multiple Sclerosis in patients of Khuzestan MS Society. **2020**, 42, 91-96
- 323 Gray Matter alterations in MS and CIS: a Coordinate based Meta-analysis and regression.
- 322 Retinal imaging biomarkers of neurodegenerative diseases. **2021**, 1-11 2
- 321 The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. **2021**, 10, 4
- 320 Rituximab for people with multiple sclerosis. **2021**, 11, CD013874 1
- 319 Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study. **2021**, 10, 2
- 318 The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized controlled pilot trial. **2021**, 16, e0258752 0

- 317 Emotional experience is increased and emotion recognition decreased in multiple sclerosis. **2021**, 11, 21885 o
- 316 Neurophysiology. **2007**, 11-20
- 315 Diffusion-Weighted Imaging. **2007**, 65-74
- 314 Functional MRI. **2007**, 85-104
- 313 M. **2005**, 725-843
- 312 Multiple Sklerose und andere neuroimmunologische Erkrankungen des ZNS. **2005**, 1222-1229
- 311 Multiple Sclerosis: Other MR Techniques. **2005**, 225-240
- 310 Acute Disseminated Encephalomyelitis. **2005**, 255-266
- 309 Intracranial Pathology of the Visual Pathway. **2006**, 341-431
- 308 Clinical drug evaluation using imaging readouts: regulatory perspectives. **2005**, 62, 357-84 o
- 307 Multiple Sklerose (Encephalomyelitis disseminata). **2006**, 225-256
- 306 Central and Peripheral Nervous System Diseases. **2006**, 59-74
- 305 Demyelinating Disorders. **2006**, 63-68
- 304 Multiple Sklerose. **2007**, 231-251
- 303 Optic Neuritis and Multiple Sclerosis. **2008**, 3-17
- 302 Multiple Sklerose und andere neuroimmunologische Erkrankungen des ZNS. **2007**, 1372-1380
- 301 Diagnosis of Multiple Sclerosis. **2007**, 133-144
- 300 Infektionen des Nervensystems und multiple Sklerose. **2007**, 1732-1747

- 299 Demyelinating Diseases of the Central Nervous System. **2009**, 1033-1073
- 298 Evidence from biomarkers and surrogate endpoints. **2004**, 1, 323-330
- 297 Imaging of multiple sclerosis: Role in neurotherapeutics. **2005**, 2, 277-303
- 296 Pediatric multiple sclerosis. **2006**, 3, 264-275
- 295 Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis. 0
- 294 rsfMRI Study of Sensimotor Cortex in Multiple Sclerosis (MS) Using Independent Component Analysis (ICA) in GIFT Toolbox with Infomax Algorithm. **2021**, 337-350
- 293 Severe Bilateral Optic Neuritis: A Rare Presentation of Clinically Isolated Syndrome. **2020**, 12, e11135
- 292 Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes. 2
- 291 Neurology in practice: multiple sclerosis. **2001**, 71 Suppl 2, ii1-2
- 290 Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. **2008**, 31, 944-52 52
- 289 Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis. **2007**, 2, 463-8 4
- 288 Early stage and long term treatment of multiple sclerosis with interferon-beta. **2009**, 3, 257-71 8
- 287 Neurological complications of biologic therapy in psoriasis: a review. **2009**, 2, 27-32 13
- 286 Childhood multiple sclerosis and related disorders. **2007**, 22, 11-5 2
- 285 Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke. **2011**, 4, 21-3 8
- 284 Family Analysis of Linkage and Association of HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, RANTES, MMP9 and TIMP1 Gene Polymorphisms with Multiple Sclerosis. **2011**, 3, 85-92
- 283 Multiple sclerosis review. **2012**, 37, 175-84 226
- 282 25-hydroxyvitamin D Concentrations in Patients with Optic Neuritis as a Clinically Isolated Syndrome and Healthy Controls. **2012**, 3, 313-7 10

281	Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study. 2012 , 17, 248-53	9
280	Color blindness among multiple sclerosis patients in Isfahan. 2012 , 17, 254-7	4
279	Restless legs syndrome in Iranian multiple sclerosis patients: a case-control study. 2013 , 4, S189-93	14
278	The association of -475 and -631 interleukin-2 gene polymorphism with multiple sclerosis in Iranian patients. 2013 , 15, 124-9	9
277	Cow's milk allergy in multiple sclerosis patients. 2013 , 18, S62-5	6
276	Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis. 2013 , 20, 32-8	7
275	A new approach to structural integrity assessment based on axial and radial diffusivities. 2012 , 27, 85-90	19
274	Efficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis. 2012 , 11, 70-3	3
273	A preliminary path analysis: Effect of psychopathological symptoms, mental and physical dysfunctions related to quality of life and body mass index on fatigue severity of Iranian patients with multiple sclerosis. 2012 , 11, 96-105	1
272	Frequency distribution of the first clinical symptoms in the Iranian population with multiple sclerosis. 2012 , 11, 118-20	3
271	Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran. 2012 , 11, 87-90	8
270	Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. 2013 , 12, 136-43	17
269	Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack?. 2013 , 18, 617-20	
268	Multiple sclerosis in children. 2013 , 7, 1-10	3
267	Feasibility and Findings from a Novel Working Memory fMRI Paradigm in Multiple Sclerosis. 2013 , 1, 1011	
266	Activities of daily living and lesion position among multiple sclerosis patients by Bayes network. 2013 , 8, 1327-36	0
265	Quality of life in multiple sclerosis (MS) and role of fatigue, depression, anxiety, and stress: A bicenter study from north of Iran. 2014 , 19, 593-9	31
264	Spatial Analysis of Multiple Sclerosis Disease in Tehran Metropolitan Zone, Iran, 2001-2012. 2014 , 43, 621-9	3

263	Association study of four polymorphisms in the interleukin-7 receptor alpha gene with multiple sclerosis in Eastern Iran. 2015 , 18, 593-8	8
262	HLA class I & II alleles in multiple sclerosis patients from Puerto Rico. 2013 , 105, 18-23	4
261	Optic neuritis, the most common initial presenting manifestation of multiple sclerosis in northern Iran. 2015 , 6, 151-5	1
260	Diagnosis and Management of Multiple Sclerosis in Children. 2016 , 10, 13-23	
259	Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran. 2017 , 46, 699-704	38
258	Circulating concentrations of interleukin (IL)-17 in patients with multiple sclerosis: Evaluation of the effects of gender, treatment, disease patterns and IL-23 receptor gene polymorphisms. 2017 , 16, 15-25	11
257	The Optimization of Magnetic Resonance Imaging Pulse Sequences in Order to Better Detection of Multiple Sclerosis Plaques. 2017 , 7, 265-270	0
256	The protective role of TBX21-1514T>C polymorphism in susceptibility to multiple sclerosis. 2018 , 17, 111-116	
255	A Spatio-Temporal Model for Longitudinal Image-on-Image Regression. 2019 , 11, 22-46	1
254	DNMT3B-579G>T (rs1569686G>T) polymorphism and the risk of multiple sclerosis in a subset of Iranian population. 2019 , 18, 70-75	1
253	The Future of Progressive Multiple Sclerosis Therapies. 2020 , 37, S43-S49	1
252	Clinical and radiologic manifestation B-cell mediated autoimmune diseases of central nervous system. 2020 , 9, 28-40	1
251	Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. 2005 , 26, 341-6	106
250	Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. 2005 , 26, 119-27	56
249	Experimental autoimmune encephalomyelitis in the rat spinal cord: lesion detection with high-resolution MR microscopy at 17.6 T. 2005 , 26, 19-25	12
248	Regional lobar atrophy predicts memory impairment in multiple sclerosis. 2005 , 26, 1824-31	69
247	Multiple sclerosis: new insights and trends. 2006 , 27, 954-7	51
246	Diffusion-weighted MR imaging characteristics of an acute strokelike form of multiple sclerosis. 2006 , 27, 1006-8	48

245	Multiple sclerosis and Alzheimer disease through the looking glass of MR imaging. 2005 , 26, 2488-91	6
244	Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. 2005 , 26, 572-7	270
243	Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. 2007 , 28, 267-71	7
242	A diffusion longitudinal MR imaging study in normal-appearing white matter in untreated relapsing-remitting multiple sclerosis. 2007 , 28, 475-8	16
241	Oculomotor Fatigue and Neuropsychological Assessments mirror Multiple Sclerosis Fatigue. 2020 , 13,	
240	Multiple sclerosis: the role of MR imaging. 2006 , 27, 1165-76	111
239	Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord. 2006 , 27, 1189-93	92
238	Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis?. 2006 , 27, 1794-8	59
237	Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis. 2003 , 24, 658-62	11
236	Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. 2006 , 27, 455-61	194
235	Measurement of volumetric lesion load in multiple sclerosis: moving from normal- to dirty-appearing white matter. 2003 , 24, 1929-30	5
234	Ischemia and multiple sclerosis: perfusion MR imaging provides insight into an underexplored pathophysiology. 2005 , 26, 1306-8	2
233	A widespread pattern of cortical activations in patients at presentation with clinically isolated symptoms is associated with evolution to definite multiple sclerosis. 2005 , 26, 1136-9	27
232	Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. 2021 , 12, 199	
231	Association of HLA-DR2-Related Haplotype (HLA-DRB5*01-DRB1*1501-DQB1*0602) in Patients with Multiple Sclerosis in Khuzestan Province. 2021 , 15, 35-46	
230	Antidepressant Effects of a Persian Medicine Remedy on Multiple Sclerosis Patients: A Double-Blinded Randomized Clinical Trial. 2019 , 8, e1212	
229	Autoimmune conditions in the World Trade Center general responder cohort: A nested case-control and standardized incidence ratio analysis. 2021 ,	1
228	Psychometric Properties of the HADS Measure of Anxiety and Depression Among Multiple Sclerosis Patients in Croatia.. 2021 , 12, 794353	2

227	Siponimod for multiple sclerosis. 2021 , 11, CD013647	2
226	Coping Strategies and Their Impact on Quality of Life and Physical Disability of People with Multiple Sclerosis. 2021 , 10,	4
225	The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis.. 2022 , 58, 103395	1
224	Non-Neoplastic Spinal Pathologies. 2022 , 723-733	
223	Validation of the fatigue severity scale in Croatian population of patients with multiple sclerosis disease: Factor structure, internal consistency, and correlates.. 2022 , 58, 103397	0
222	Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics. 2021 ,	0
221	An Automatic Segmentation of T2-FLAIR Multiple Sclerosis Lesions. 2008 ,	32
220	T1/T2-Weighted Ratio in Multiple Sclerosis: A Longitudinal Study With Clinical Associations.	
219	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. 2022 , 13524585211061861	1
218	The central vein sign is present in most infratentorial multiple sclerosis plaques.. 2022 , 58, 103484	0
217	Antidepressant Effects of a Persian Medicine Remedy on Multiple Sclerosis Patients: A Double-Blinded Randomized Clinical Trial. 2019 , 8, e1212	0
216	Oculomotor fatigue and neuropsychological assessments mirror multiple sclerosis fatigue. 2020 , 13,	1
215	Cognitive Event-Related Potentials-The P300 Wave Is a Prognostic Factor of Long-Term Disability Progression in Patients With Multiple Sclerosis. 2020 ,	1
214	Relayed nuclear Overhauser effect weighted (rNOEw) imaging identifies multiple sclerosis. 2021 , 32, 102867	1
213	The effects of static and supervised functional stretching exercises on lower limb spasticity and function in patients with multiple sclerosis: A Randomized Controlled Trial.	
212	Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. 2021 , 12, 199	0
211	Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis.. 2022 ,	0
210	Validation of MRI radiological reports in pediatric MS according to the McDonald 2017 criteria: A Danish nationwide multicenter cohort study.. 2021 , 57, 103443	

- 209 Lesion Volume Quantification Using Two Convolutional Neural Networks in MRIs of Multiple Sclerosis Patients.. **2022**, 12, 1
- 208 Impact of CYBA genotypes on severity and progression of multiple sclerosis.. **2022**,
- 207 The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.. **2022**, 1 0
- 206 Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France.. **2022**, 12, 1001 0
- 205 Handedness and Cognition in Multiple Sclerosis: Potential Indications for Hemispheric Vulnerability.. **2022**,
- 204 Recent Considerations on Gaming Console Based Training for Multiple Sclerosis Rehabilitation.. **2022**, 10, 1
- 203 Postural Control in Relapsing-Remitting Multiple Sclerosis.
- 202 Comparing natural history of early and late onset pediatric multiple sclerosis.. *Annals of Neurology*, **2022**, 9-4 2
- 201 The Neuroimmunology of Multiple Sclerosis: Fictions and Facts.. **2021**, 12, 796378 0
- 200 Peripheral helper T cells in the pathogenesis of multiple sclerosis.. **2022**, 13524585211067696
- 199 The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.. **2022**, 1 0
- 198 Current and future applications of artificial intelligence in multiple sclerosis. **2022**, 107-144 1
- 197 T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations.. **2022**, 34, 102967 0
- 196 A systematic review of self-concept change in multiple sclerosis.. **2022**, 1-40 1
- 195 "Stable" vs. "silent progressive multiple sclerosis": a real-world retrospective clinical imaging Brazilian study.. **2022**,
- 194 Effectiveness of non-pharmacological rehabilitation interventions in pain management in patients with multiple sclerosis: Systematic review and meta-analysis.. **2022**, 0
- 193 A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.. **2022**, 13, 845539 3
- 192 Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity.. **2022**, 10, 0

- 191 Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.. **2022**, 13524585211073761 o
- 190 Muscle Quality of Knee Extensors Based on Several Types of Force in Multiple Sclerosis Patients with Varying Degrees of Disability.. **2022**, 58, o
- 189 Do Hungarian multiple sclerosis care units fulfil international criteria?. **2022**, 17, e0264328 o
- 188 Contrast-enhanced double inversion recovery sequence for patients with multiple sclerosis: feasibility of subtraction images between pre- and post-contrast images.. **2022**, 2841851221080831
- 187 Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells.. **2022**, 1
- 186 Incidence and Prevalence of Multiple Sclerosis in Malmö, Southern Sweden.. **2022**, 2022, 5464370
- 185 Evaluation of the Psychometric Properties of Jebsen Taylor Hand Function Test (JTHFT) in Italian Individuals With Multiple Sclerosis.. **2022**, 13, 847807
- 184 Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study.. **2022**, 12, 4555 o
- 183 Dietary patterns and risk of multiple sclerosis: Results of a double-center case-control study in Iran.. **2022**, 2601060221082379
- 182 Identify the report as a systematic review.. **2022**, 2601060221080240
- 181 Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis.. **2022**, 13, 814734 o
- 180 Association between Apal and Taql polymorphisms of the vitamin D receptor gene and the multiple sclerosis. **2022**, 27, 101584
- 179 Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.. **2021**,
- 178 Intake of Vitamin D in Patients with Multiple Sclerosis in the Valencian Region and Its Possible Relationship with the Pathogenesis of the Disease.. **2021**, 11,
- 177 Role of lipoic acid in multiple sclerosis.. **2021**, 3
- 176 Evaluation of the quality of the care pathway for patients with multiple sclerosis in France: Results of an original study of a cohort of 700 patients. **2021**, 1
- 175 Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?. **2022**, 13, 844873 o
- 174 Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.. **2022**, 13, 146 o

173 Effects of EMG-Controlled Video Games on the Upper Limb Functionality in Patients with Multiple Sclerosis: A Feasibility Study and Development Description.. **2022**, 2022, 3735979

172 Patient-Specific Out-of-Pocket Cost Communication and Remote Financial Navigation in Patients with Multiple Sclerosis: A Randomized Controlled Feasibility Study.. **2022**, 62, 103797

171 White Matter. 283-310

170 MRS in infectious, inflammatory, and demyelinating lesions. 110-130

169 Rehabilitation of dementia. 509-534

168 Disease-modifying therapy for multiple sclerosis in clinical practice. 583-603

167 Data_Sheet_1.docx. **2018**,

166 Table_1.XLSX. **2020**,

165 Table_2.XLSX. **2020**,

164 Table_3.XLSX. **2020**,

163 Table_4.XLSX. **2020**,

162 Table_5.XLSX. **2020**,

161 Image_1.JPEG. **2019**,

160 Table_1.pdf. **2019**,

159 Data_Sheet_1.docx. **2019**,

158 Table_1.docx. **2019**,

157 Presentation_1.pdf. **2019**,

156 Table_1.docx. **2018**,

155 Table_2.docx. **2018**,

154 Data_Sheet_1.PDF. **2019**,

153 Data_Sheet_1.DOC. **2020**,

152 Video_1.mp4. **2020**,

151 Table_1.DOCX. **2020**,

150 Table_1.DOCX. **2020**,

149 Data_Sheet_1.xlsx. **2018**,

148 Oligoclonal bands: An immunological and clinical approach. **2022**,

147 Optic Neuritis. **2022**, 4505-4533

146 Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.. **2022**, 15, 17562864211070449

145 Updates on Pediatric Demyelinating Disorders. **2022**, 231-259

144 Neuropsychiatric Symptoms in Demyelination Disorders.

143 Impact of the covid-19 pandemic on the psychological status and cortisol level of multiple sclerosis patients.. **2022**, 1-24

142 Genetic biomarkers in multiple sclerosis: An umbrella review of meta-analyses of observational studies.. **2022**, 63, 103834

141 Case 115. **2012**, 232-233

140 Ocrelizumab for multiple sclerosis.. **2022**, 5, CD013247

o

139 Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.. **2022**,

o

138 Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. **2022**, 15, 175628642210903

137 Molecular biomarkers in multiple sclerosis. **2022**, 72, 127-148

136 Current and Future Biomarkers in Multiple Sclerosis. **2022**, 23, 5877

1

135 Analytical validation of a multivariate proteomic serum-based assay for disease activity assessments in multiple sclerosis.

0

134 Traitements de fond de la sclérose en plaques. État des lieux et perspectives. **2022**,

133 Les formes atypiques de sclérose en plaques et formes frontales. **2022**,

132 Fampridin Etoksikasyonu: Olgu Sunumu.

131 Exploring Retinal Blood Vessel Diameters as Biomarkers in Multiple Sclerosis. **2022**, 11, 3109

1

130 Improving cervical spinal cord lesion detection in multiple sclerosis using filtered fused proton density-T2 weighted images. **2022**, 11, 205846012211052

129 Incidencia y prevalencia de la esclerosis múltiple en España. Una revisión sistemática. **2022**,

128 History and prospects of multiple sclerosis treatment. **2022**,

127 Correlation of -475 IL-2 Promoter Gene Polymorphisms and the Levels of Serum IL-2 on the Risk of Multiple Sclerosis. **2022**, 11, 83-88

0

126 Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. **2022**, 8, 205521732211049

125 Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.

124 Nintendo Switch Joy-Con Infrared Motion Camera Sensor for Training Manual Dexterity in People with Multiple Sclerosis: A Randomized Controlled Trial. **2022**, 11, 3261

123 The History of Diagnosis and Treatment of MS: a Brief Overview.

122 Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. **2022**, 9, e200004

3

121 The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria.

0

120 Educational Case: Multiple sclerosis. **2022**, 9, 100036

- 119 U-NET Architecture for automatic MS lesions segmentation using MR images. **2022**,
- 118 Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review. 13,
- 117 The Dimensionality of the Multidimensional Fatigue Inventory (MFI-20) Derived From Healthy Adults and Patient Subpopulations: A Challenge for Clinicians. **2022**, 0
- 116 Cellular Cytotoxicity and Multiple Sclerosis.
- 115 Grey matter atrophy in patients with benign multiple sclerosis. 0
- 114 Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. **2022**, 9, e200009 1
- 113 Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia. **2022**, 11, 4081
- 112 Self-employment, sickness absence, and disability pension in multiple sclerosis.
- 111 Reliability of Isometric Muscle Strength Measurement and Its Accuracy Prediction of Maximal Dynamic Force in People with Multiple Sclerosis. **2022**, 58, 948
- 110 Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)E systematic review protocol. **2022**, 11,
- 109 Prediction of Conversion from CIS to Clinically Definite Multiple Sclerosis Using Convolutional Neural Networks. **2022**, 2022, 1-8 0
- 108 Genotyping of ARNTL and CLOCK Circadian Rhythm Gene Polymorphisms in Iranian Patients with Multiple Sclerosis. **2022**, 2, 0
- 107 Maximally Expressed miRNAs of Milk in Cells, Plasma and Lipid Fraction of Human Milk and Antibodies-Abzymes Catalyzing Their Hydrolysis. **2022**, 23, 8102 0
- 106 Cautious optimism for the future of migraine treatment. **2022**, 52, 1112-1114
- 105 Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study. **2022**, 66, 104064 0
- 104 Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting Multiple Sclerosis. **2022**,
- 103 Goal-directed upper limb movement patterns and hand grip forces in multiple sclerosis. **2022**, 8, 205521732211162
- 102 High-resolution HLA class II sequencing of Swedish multiple sclerosis patients.

- 101 Exploring the molecular aspects of glycosylation in MOG antibody disease (MOGAD). **2022**, 23,
- 100 The comorbidity and cognition in multiple sclerosis (CCOMS) neuroimaging protocol: Study rationale, MRI acquisition, and minimal image processing pipelines. 1,
- 99 Diagnosis of Multiple Sclerosis. **2022**, 28, 1006-1024
- 98 Multiple Sclerosis: Enzymatic Cross Site-Specific Recognition and Hydrolysis of H2A Histone by IgGs against H2A, H1, H2B, H3 Histones, Myelin Basic Protein, and DNA. **2022**, 10, 1876 1
- 97 The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis. 13,
- 96 Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles. **2022**, 12,
- 95 Antibody Response to HML -2 May Be Protective in Amyotrophic Lateral Sclerosis. 1
- 94 Factors and strategies affecting motor imagery ability in people with multiple sclerosis: a systematic review. **2022**, 1
- 93 Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy controls. **2022**, 67, 104181 0
- 92 Prevalence of multiple sclerosis in Guangzhou, China: A population-based case-finding prospective study. **2022**, 68, 104151 0
- 91 Cut-off evaluation of intrathecal oligoclonal bands of IgM in relapsing-remitting multiple sclerosis; a retrospective study. **2022**, 68, 104188 0
- 90 Longitudinal changes of deep gray matter shape in multiple sclerosis. **2022**, 35, 103137 0
- 89 Neuroinflammation in Multiple Sclerosis. **2022**, 0
- 88 Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study. **2022**, 27, 67 0
- 87 Multiple sclerosis. **2022**, 81, 173-183 0
- 86 Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. **2022**, 185, 3467-3486.e16 4
- 85 Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. 13, 2
- 84 An algorithm to determine the date when the McDonald criteria are met for the diagnosis of relapsing-remitting multiple sclerosis. **2022**, 0

83	Disability in Multiple Sclerosis is Associated with Vascular Factors: An Ultrasound study.	0
82	Sleep in multiple sclerosis: a systematic review and meta-analysis of polysomnographic findings.	0
81	The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis. Publish Ahead of Print,	0
80	Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. 2022 , 17, e0274565	0
79	Diagnosis and classification of optic neuritis. 2022 ,	3
78	Evaluating brain damage in multiple sclerosis with simultaneous multi-angular-relaxometry of tissue. 2022 , 9, 1514-1527	0
77	The borderland of multiple sclerosis and functional neurological disorder: A call for clinical research and vigilance.	0
76	The Symbol Digit Modalities Test and the Paced Auditory Serial Addition Test Involve More than Processing Speed. 2022 , 104229	1
75	Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. 2022 , 104220	0
74	What are the trends in the treatment of multiple sclerosis in recent studies? A bibliometric analysis with global productivity during 1980-2021. 2022 , 68, 104185	0
73	The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases. 2022 , 10, 2492	0
72	Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans. 2022 , 12, 815	1
71	Multiple Sclerosis: Enzymatic Cross Site-Specific Recognition and Hydrolysis of H3 Histone by IgGs against H3, H1, H2A, H2B, H4 Histones, Myelin Basic Protein, and DNA. 2022 , 10, 2663	1
70	Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis. 2022 ,	0
69	Classification of multiple sclerosis clinical profiles using machine learning and grey matter connectome. 9,	1
68	Studying the Interactions of U24 from HHV-6 in Order to Further Elucidate Its Potential Role in MS. 2022 , 14, 2384	0
67	Trends in the environmental risks associated with earlier onset in multiple sclerosis. 2022 , 104250	2
66	MicroRNAs expression in peripheral blood mononuclear cells of patients with multiple sclerosis propose.	0

- 65 Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis. **2022**, 2022, o
- 64 Contemporary study of multiple sclerosis disability in South East Wales. jnnp-2022-330013 o
- 63 Association between miRNA-145 and miRNA-155 expression in peripheral blood mononuclear cells of patients with multiple sclerosis: a case-control study. **2022**, 22, o
- 62 Evaluating the energy regulatory hormones of nesfatin-1, irisin, adropin and preptin in multiple sclerosis. **2022**, 68, 104221 o
- 61 Foetal Allogeneic Intracerebroventricular Neural Stem Cell Transplantation in People with Secondary Progressive Multiple Sclerosis: A phase I dose-escalation clinical trial. 1
- 60 Long-term dietary acid load is associated with depression in multiple sclerosis, but less evidence was found with fatigue and anxiety. **2022**, 104415 o
- 59 Entz^ bldliche Erkrankungen des zentralen und peripheren Nervensystems [Begutachtung. **2022**, 1-7 o
- 58 Improving the detection of new lesions in multiple sclerosis with a cascaded 3D fully convolutional neural network approach. 16, o
- 57 Incidence and prevalence of multiple sclerosis in Spain: a systematic review. **2022**, o
- 56 Multi-modal retinal scanning to measure retinal thickness and peripheral blood vessels in multiple sclerosis. **2022**, 12, o
- 55 Supplementation with *Crocus sativus* L. (Saffron) against Placebo in Multiple Sclerosis: A Systematic Review and Synthesis without Meta-Analysis of Randomized Controlled Trials. **2022**, 1, 227-241 o
- 54 Disability in multiple sclerosis is associated with vascular factors: An ultrasound study. **2022**, o
- 53 Association between LAG3/CD4 Genes Variants and Risk for Multiple Sclerosis. **2022**, 23, 15244 o
- 52 Efficacy of interoceptive and embodied rehabilitative training protocol in patients with mild multiple sclerosis: A randomized controlled trial. 13, o
- 51 Clinical Neuroimaging in Pediatric Dysimmune Disorders of the Central Nervous System. **2022**, o
- 50 New Contrast Enhancement Method for Multiple Sclerosis Lesion Detection. o
- 49 Psychometrische Pr^ fung des deutschsprachigen Neurologischen Fragebogens zur M^ digkeit bei Multipler Sklerose (NFI-MS-G) bei Rehabilitanden mit Multipler Sklerose. o
- 48 Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference. 10.1212/WNL.0000000000206774 o

47	Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. 135245852211342	o
46	Discriminating Spatialised Speech In Complex Environments In Multiple Sclerosis. 2022 ,	o
45	Criterion validity of muscle strain analyses of skeletal muscle function in patients with multiple sclerosis. 2022 , 104478	o
44	Lesion location across diagnostic regions in multiple sclerosis. 2023 , 37, 103311	o
43	Long Term Misdiagnosis of Neuromyelitis Optica Spectrum Disorder Patients with Multiple Sclerosis.	o
42	The immunomodulatory effects of all-trans retinoic acid and docosahexaenoic acid combination treatment on the expression of IL-2, IL-4, T-bet, and GATA3 genes in PBMCs of multiple sclerosis patients. 1-10	o
41	Review on Diagnosis and Management Approach of Multiple Sclerosis. 2023 , 12, 100-105	o
40	Efficacy of Mindfulness-Based Cognitive Therapy Compared to Diet Modification Alone for Dysphagia in Persons with Multiple Sclerosis.	o
39	Determining the Prognostic Characteristics of People with Multiple Sclerosis with Bowel and Bladder Dysfunction as the Initial Presentation: A Cohort Study. 2023 , 2, 62-67	o
38	Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. 2023 , 58, 102220	o
37	Remote Observational Research for Multiple Sclerosis. 2023 , 10, e200070	o
36	Cortical lesions at diagnosis predict long-term cognitive impairment in multiple sclerosis: a 20-year study.	o
35	An Updated Evaluation of Intrathecal IgG Synthesis Markers in Relation to Oligoclonal Bands. 2023 , 13, 389	o
34	Graph-Based Analysis of Brain Connectivity in Multiple Sclerosis Using Functional MRI: A Systematic Review. 2023 , 13, 246	o
33	Diagnostic and prognostic value of the RUNXOR/RUNX1 axis in multiple sclerosis. 2023 , 178, 106032	1
32	Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management. 2023 , 83, 117-134	o
31	Effectiveness of Ocrelizumab in Primary Progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY).	o
30	Deciphering crucial genes in multiple sclerosis pathogenesis and drug repurposing: A systems biology approach. 2023 , 280, 104890	o

- 29 Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study. **2023**, 12, 1023 ○
- 28 Decreased frequency of regulatory T cells and level of helios gene expression in secondary progressive multiple sclerosis patients: Evidence about the development of multiple sclerosis. **2023**, 116, 109797 ○
- 27 The Efficacy of the Speed of Processing Training Program in Improving Functional Outcome: From Restoration to Generalization. **2023**, ○
- 26 Clinical Validation of a Multi-protein, Serum-based Assay for Disease Activity Assessments in Multiple Sclerosis. ○
- 25 High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. **2023**, 30, 1389-1399 ○
- 24 Cholesterol metabolism: Towards a therapeutic approach for multiple sclerosis. **2023**, 164, 105501 ○
- 23 Imaging of Central Nervous System Demyelinating Disorders. **2023**, 29, 292-323 ○
- 22 Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis. 135245852311514 ○
- 21 Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms. ○
- 20 Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience. **2023**, 72, 104582 ○
- 19 Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. 2200018 ○
- 18 Vitamin D receptor polymorphisms among the Turkish population are associated with multiple sclerosis. **2023**, 25, 41-50 ○
- 17 Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis. 135245852311572 ○
- 16 Inflammatory Activity After Diverse Fertility Treatments. **2023**, 10, e200106 ○
- 15 A highly challenging balance training intervention for people with multiple sclerosis: a feasibility trial. **2023**, 9, ○
- 14 The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey. 14, ○
- 13 Maternal Multiple Sclerosis and Health Outcomes Among the Children: A Systematic Review. Volume 15, 375-389 ○
- 12 Lymphocyte mitochondrial genome integrity is not altered by cladribine. ○

- 11 Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina. 135245852311572 ○
- 10 Multiple Sclerosis and Other Idiopathic Inflammatory-Demyelinating Diseases. **2013**, 909-943 ○
- 9 Multiple Sclerosis Disease Evolution Assessment in Brain MRI Lesions Based on Texture and Multi-Scale Amplitude Modulation-Frequency Modulation (AM-FM) Features. **2023**, 11, 29918-29933 ○
- 8 Stability of sensor-based gait parameters reassessed after a period of one year in people with multiple sclerosis. **2023**, 23, ○
- 7 Comparison of OX40 expression in patients with multiple sclerosis and neuromyelitis optica as an approach to diagnosis. **2023**, 19, ○
- 6 Effects on Corticospinal Tract Homology of Faremus Personalized Neuromodulation Relieving Fatigue in Multiple Sclerosis: A Proof-of-Concept Study. **2023**, 13, 574 ○
- 5 ~~2020-11-20~~ ~~2020-11-20~~ **2023**, 30-31 ○
- 4 The impact of the COVID-19 pandemic on neuropsychiatric and sleep disorders, and quality of life in individuals with neurodegenerative and demyelinating diseases: a systematic review and meta-analysis of observational studies. **2023**, 23, ○
- 3 Validity of an inertial sensor-based system for the assessment of spatio-temporal parameters in people with multiple sclerosis. 14, ○
- 2 A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study. 135245852311677 ○
- 1 The rising role of magnetic resonance imaging biomarkers in diagnosing multiple sclerosis. ○